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 Chapter 1 Introduction and aims of the thesis 
Before any methods for measuring “anesthetic drug effects” can be suggested, one needs to 
define the exact clinical phenomenon to be measured. Therefore, we have to define 
“anesthesia”. 
 
Until today, scientists do not fully understand the neurophysiologic and neuro-anatomical 
mechanisms of the clinical condition called “anesthesia”. However, throughout the history of 
medicine, many methods to deliberately interfere with consciousness have been discovered 
and optimized, on a mainly empirical basis.  Even now, performing anesthesia remains an 
individual pharmacological experiment, during which unexpected individual responses can 
occur. This clinical reality is the result of a large biological variability that characterizes the 
human species. 
 
Currently, the “anesthetic state” is considered to be a combination of three important clinical 
endpoints. The “hypnotic component of anesthesia”, the “analgesic component of 
anesthesia” and “immobility”.(1) To have a better understanding of the complex endpoints 
that we attempt to monitor in this thesis, a more detailed description of these three 
components will be given in chapter 2. 
 
The endpoint of interest for this thesis is “the hypnotic component of anesthesia”.  This 
can be obtained by “hypnotic anesthetic drugs”, such as propofol and inhaled anesthetics. By 
means of these hypnotic drugs, the anesthesiologist aims to obtain “unconsciousness”. 
“Unconsciousness” implies that the patient becomes unaware of his surroundings during the 
surgical procedure. However, the intensity of hypnotic drug effect that is aimed for can be 
variable.  
 
It is often sufficient, in minor procedures, to avoid “memory formation”. The patient remains 
responsive to verbal command, but will not remember anything afterwards. This goal can be 
obtained by using low doses of a hypnotic drug. This anesthetic technique is called 
“sedation” or “conscious sedation”.(2-8) 
 
For major surgery, more profound levels of hypnotic drug effect are necessary, in order to 
avoid any response to verbal command, and to decrease the incidence of “awareness”. 
Awareness is an accidental return of consciousness during surgery, a very traumatic 
experience, resulting in long term morbidity.(9-18) In many publications and in this thesis, we 
will refer to this level of hypnotic drug effect as the “surgical level of hypnotic drug 
effect”.(19,20) 
 
If excessive doses of a hypnotic drug are administered, the patient will be unresponsive as 
required, but the incidence of side effects will increase. Until now, it is not clear whether 
excessive hypnotic drug effects result in a worse long-term outcome, but a recent study by 
Monk et al, has evoked a fierce debate on this potential risk.(21) Determining the risks of 
excessive hypnotic drug effect is one of the research areas of interest in anesthesia. 
Excessive hypnotic drug dosages will also increase the probability of a delayed recovery due 
to accumulation of anesthetic drugs in the fatty tissues of the patient.(22,23) 
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 In order to avoid insufficient, as well as excessive hypnotic drug effect, it is mandatory 
to implement, validate and optimize monitoring devices based on physiological 
parameters, that are a reflection of  the “hypnotic” component of anesthesia.(1,24) 
 
This thesis will focus on one neurophysiologic measure, called the “auditory evoked 
potential” (AEP), as a tool for monitoring the hypnotic component of anesthesia.(25-28) 
 
The auditory evoked potential (AEP) is an electrical wave, extracted from the 
electroencephalogram (EEG), that is evoked by repeated acoustic stimuli (clicks or tone 
bursts) to a normally hearing person.(29,30)  The AEP, measured by means of electrodes on 
the scalp, consists of several positive and negative deflections, which are a reflection of the 
intact acoustic neuro-anatomical pathway.(31) A standardized click stimulus will evoke a 
very constant and homogenous shape of the AEP. (Figure 1) 
 
As the AEP has a tenfold smaller micro voltage compared to the superimposed spontaneous 
EEG, an averaging technique is mandatory for extracting AEP out of the EEG.(27,32,33) A 
commonly used technique is the moving time average (MTA). The MTA is based on the 
averaging of a number of sweeps of the raw EEG. “Sweeps” or “epochs” are small 
periods of EEG registration, ranging between 80 to 125 milliseconds. Due to the repetition of 
the standardized acoustic clicks, epochs containing an AEP wave will have more 
homogenous features, compared to epochs containing EEG without AEP. The averaging of a 
number of epochs, will enhance the homogenous characteristics (amplitude and latency) of 
the AEP. The “random” features of the spontaneous EEG will not be enhanced. This 
technique enables visualization and further analysis of the AEP components. A major 
drawback of this MTA technique is the need for large amounts of epochs, which causes a 
considerable delay in extracting AEP derived information.(27,33,34) 
 
Once AEP is extracted from the raw EEG by means of the MTA, the sub-components are 
analyzed further. AEP has three major components, depending on the latency (= delay of 
appearance) after the auditory click stimulus (Figure 1). The three components are: the 
brainstem auditory evoked potentials (BAEP), the mid-latency auditory evoked potentials 
(MLAEP) and the long latency auditory evoked potentials (LLAEP).(30,35) BAEP are rather 
insensitive for anesthesia drugs. LLAEP disappear even at very low doses of hypnotic 
drugs.(28,36,37) Consequently, MLAEP are best suited for anesthesia purposes. 
 
Thornton et al, and Schwender et al, found that the amplitude of the Pa and Nb curves of 
MLAEP decreases, while the latency increases, in a consistent way with increasing doses of 
hypnotic drugs.(25,26,35,36,38-40) They suggested that by quantifying these changes in the 
main components of the MLAEP wave, a numerical endpoint could be defined that would act 
as a measure for cerebral hypnotic drug effect.(41,42) 
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 Figure 1. Schematic presentation of the Auditory Evoked Potential. The graph is semi-logarithmic, 
meaning that the x-axis is logarithmic and the y-axis is linear. If the acoustic stimulus is given on 
time 0, than the respective waves will be measured on the scalp with a latency (=delay after the 
click) shown on the timescale. BAEP = brainstem auditory evoked potentials (Waves I through VI); 
MLAEP = Mid-Latency auditory evoked potentials (Waves N0 through Nb); LLAEP = Long Latency 
auditory evoked potentials (Waves P1 through N2) 
 
Major drawbacks had to be overcome. The detection and interpretation of the raw MLAEP 
demands special expertise of the observer, as he or she must decide which curves are 
relevant and which are not. The quantification of amplitudes and latencies is subjective, 
making the first application of MLAEP in anesthesia prone for observer’s bias.(43,44) In a 
constantly changing setting of clinical anesthesia, the time delay needed for extracting 
information from the raw MLAEP, was excessively long.(33) Several technological solutions 
have been suggested and tested for bypassing these difficulties. 
 
In a first commercialized device for anesthesia purposes (Audiomedix, Glasgow, Scotland), a 
numerical index, called the AEPex, was implemented and tested for clinical use.(45) With this 
device, the AEP components are extracted by means of the classic moving time average 
technique, using 256 epochs of 144 milliseconds each. This resulted in a 36.9 seconds time 
delay for index calculation during optimal measurement conditions. The AEPex algorithm 
reduced the amplitudes and latencies into one single number, ranging between 100 to 
0.(45,46) In this way, the observer’s bias for MLAEP interpretation is eliminated. AEPex has 
been clinically validated by Kenny et al, but the number of trials remain limited.(47-51) 
Additionally, the commercial success of AEPex was minimal, as more competitive AEP 
derived monitors became available on the market. 
 
More recently, Erik Weber Jensen applied a new mathematical approach for MLAEP 
extraction, called the autoregressive modeling with exogenous input (ARX).19 The ARX 
technology uses a limited amount of epochs for a primary MLAEP extraction, while running a 
classic MTA technique in the background, as a quality control. This technology allows data 
extraction from MLAEP within six seconds.(19,33,34,52-55) The limited delay time was a 
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 major advantage in comparison with the older MTA technology, as demonstrated by Urhonen 
et al.(34) The ARX technology was incorporated in a commercialized MLAEP monitor for 
anesthesia purposes, called the A-Line® auditory evoked potential monitor (Danmeter, 
Odense, Denmark).  It produces a numerical unitless index, called the A-Line® Auditory 
Evoked Potential Index (AAI). This index is calculated using the “area under the 
curve”(AUC) implemented on the fast extracted MLAEP measured between 20 and 79.9 
milliseconds after every click stimulus. By means of this algorithm, AAI reflects the changes 
in raw MLAEP evoked by hypnotic drugs with minimal delay. The scale of AAI ranges 
between 100 and 0. The target for obtaining a surgical level of anesthesia ranges between 
25 and 15.  
 
This thesis is the result of a close cooperation between three participants of a 
consortium. The first participant is Erik Weber Jensen, inventor of the AAI technology and 
driving force for innovating and improving the algorithms. The second participant is Danmeter 
(Odense, Denmark). This medical company provides hardware technology for monitoring AAI 
in human subjects, conform European regulations, and has a commercial interest in AAI 
technology. The third participant is the promoter and the author of this thesis, as 
representatives of the University of Ghent and the department of anesthesia, University 
Hospital Ghent. 
 
The aim of this consortium (and this thesis) is to develop a strategy for validating and 
optimizing the new MLAEP technology, during clinical anesthesia practice and as a 
tool for pharmacological research. Within this consortium, the independent position of the 
researcher must be guaranteed. Therefore, all costs for the studies were covered by 
departmental funding only. Danmeter provided all necessary hardware for performing the 
measurements. The engineering department of Danmeter and Erik Weber Jensen provided 
technical and mathematical support, if requested by the researcher. The methodology of all 
studies, the ownership of the obtained data and the rights for publishing the results are 
completely in the hands of the independent researcher. In return, Danmeter was informed on 
the results before the date of publication in order to allow commercial strategy adaptations, if 
deemed necessary.  
 
Until now, no real standardized methodology is available in the scientific literature for 
“validating” a new monitor of hypnotic drug effect. Consequently, this thesis includes a 
search for an acceptable and reproducible method to compare different measures of 
the “hypnotic component of anesthesia”. As these neurophysiologically derived indices 
use diverse principles and mathematics, our search sometimes resembles a comparison 
between “apple and pear”. Consequently, not much statistical tests are available for 
describing such a dataset. However, by combining pharmacokinetic-pharmacodynamic 
models with neurophysiologic technology, we feel to have succeeded in creating an objective 
and reproducible methodology for evaluating index performances. 
 
In a first publication,(56) we investigated the ability of the AAI to discriminate several 
clinical endpoints of hypnotic drug effect: the “loss of response to name calling”  as described 
by the Observers Assessment of Alertness and Sedation scale (OAAS/S), the “loss of 
eyelash reflex” and the “loss of response to a painful stimulus”. This was done both during a 
mono-administration of propofol, as well as during the combined administration of an 
increment dose of opioids (remifentanil) and propofol.(56) We compared the performance of 
AAI with bispectral index (BIS) (Aspect Medical, Newton, MA, USA), which is an index of 
hypnotic drug effect derived from the raw EEG, and the predicted effect-site concentration of 
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 propofol (CePROP), which is a pharmacological endpoint of hypnotic drug effect. CePROP is a 
prediction of the propofol concentration at the (theoretical) site of drug action, based on 
validated pharmacokinetic-pharmacodynamic models.(57,58) 
 
We found that AAI, BIS and CePROP were equally effective in discriminating the “absence” or 
“presence” of a clinical sign of hypnotic drug effect. AAI, BIS and CePROP were not able to 
accurately predict a response to a painful stimulus. This confirms that AAI, BIS and CePROP 
reflect the “hypnotic component of anesthesia”, rather than the analgesic component of 
anesthesia. The addition of remifentanil to propofol did affect the threshold levels of AAI, BIS 
and CePROP for detection of the respective clinical endpoints, but the specificity and sensitivity 
remained unaltered. 
 
Although these results can be considered as a clinical validation of AAI, the methodology 
chosen has some intrinsic drawbacks. We attempt to validate a continuous parameter (AAI, 
BIS and CePROP) in its ability to discriminate between dichotomous or categorical clinical 
endpoints. “Dichotomous” means that the clinical endpoint can only be “absent” or “present”. 
There is no gradual transition from one condition to the other. Consequently, it can be a very 
challenging task for the observer to determine the exact moment of transition from one 
condition to the other. This drawback introduces a potential observer’s bias in the 
methodology.(59) Moreover, by using dichotomous endpoints only a very limited range of 
anesthetic drug effects is tested.(59) More advanced statistical methods are mandatory to 
better appreciate the subtle differences between hypnotic drug effect monitors.  
 
In a second publication,(60) we introduced a continuously available pharmacological 
endpoint of hypnotic drug effect as a reference for comparing monitoring systems. We 
already used CePROP as a measure (or prediction) for hypnotic drug effect (dependent 
variable). In contrast, this study introduces CePROP as an independent variable. CePROP is a 
prediction of the propofol concentration at the (theoretical) site of drug action. For a hypnotic 
drug, this site of action should be somewhere in the brain. As CePROP is calculated from a 
pharmacokinetic-pharmacodynamic model, developed in a standardized population by 
Schnider et al,(57,58) and clinically validated by Struys et al,(61) we know that CePROP has a 
close relationship with the clinical anesthetic drug effect in the patient. Moreover, the 
technology for CePROP prediction is available to any anesthesiologist, as it is incorporated in 
several commercialized target controlled infusion (TCI) systems. 
 
In this protocol, we performed a standardized propofol induction, while simultaneously 
calculating the corresponding CePROP, using target controlled infusion technology. 
Meanwhile, measurements of AAI, BIS and Spectral Entropy1 (GE Healthcare, Helsinki, 
Finland) were performed. Propofol was continued in such a way that the patient gradually 
evolved from a “fully awake” condition towards very deep anesthesia (detected by burst-
suppression patterns on the EEG). 
 
With this data set, we are able to compare the performance of continuously available 
neurophysiologically derived indices concerning their ability to detect another 
(pharmacologically derived) continuous parameter. We used advanced statistical methods for 
this goal. (Prediction Probability (Pk) analysis, the Individualized Spearmann Rank 
1 Spectral entropy by GE Healthcare (Helsinki, Finland), is a recently commercialized hypnotic drug effect 
monitor, extracted from the spontaneous electroencephalogram. Two indices are calculated by this monitor: the 
state entropy (SE) and the response entropy (RE)
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 Correlation, Non Linear Mixed Effect Modeling, …) This methodology revealed some major 
weaknesses for AAI in comparison to BIS and Spectral entropy. The baseline variability (= 
the difference in AAI values of the awake patient) was unacceptably high. The discriminating 
power of AAI for deep levels of anesthesia was considered to be inadequate.(60) 
 
Based on the results from the first validation, the consortium reflected on potential 
improvements in the AAI algorithm. Erik Weber Jensen developed a new algorithm and 
software package (version 1.6) for calculating an index with higher performance. The new 
index was called AAI1.6 and is implemented in a commercialized monitor, called the AEP 
monitor/2 (Danmeter, Odense, Denmark). This monitor incorporates important adaptations, 
both on the technological level, as on the neurophysiologic measures used for extracting 
information. The AAI1.6 is a “composite index”, combining information from MLAEP, the 
spontaneous EEG and the percentage of burst suppression patterns.  Whenever MLAEP 
quality is low, information on the cerebral hypnotic drug effect is extracted from 
spontaneous electroencephalogram rather than MLAEP. Whenever burst suppression 
patterns appear, indicating very profound hypnotic drug effects, the percentage of burst 
suppression versus normal EEG is the only factor for AAI calculation. This composite index 
could theoretically solve the lack of discriminating power at deep levels of anesthesia, and 
could improve the robustness of information acquisition on cerebral hypnotic drug effect.  
 
For decreasing the baseline variability, the upper scale limit of AAI was decreased from 100 
to 60. Additionally, the AEP monitor/2 is equipped with an acoustic stimulus volume 
controller, using fuzzy logic technology. This volume controller adapts the click stimulus 
intensity according to the measured signal-to-noise ratio, to avoid the potentially interfering 
“startle response”. The “startle response” is an acoustically evoked post auricular muscle 
response, causing a very homogenous electrical interference on the electroencephalogram. 
The startle response has been mentioned as a cause for false high AAI calculations due to 
erroneous signal detection, and could be a cofactor for the high baseline variability found in 
our second study. 
 
In a third publication,(62) we re-evaluated the AAI1.6 by comparing it with the old AAI 
(version 1.5) and BIS, in a comparable protocol as used for the second trial. We applied the 
same advanced statistical methodology, and found that the new AAI1.6 had considerable 
improved baseline variability, although BIS still performed better. The discriminating power 
at deep levels of anesthesia was improved due to the inclusion of 
electroencephalographically derived information next to the MLAEP. The decrease of the 
upper scale limit improved the baseline variability even more. However, our study could not 
exclude a potentially decreased sensitivity during sedation levels of anesthesia. 
 
As an additional clinical validation we investigated the effects of “difficult hypnotic 
molecules” on AAI. Ketamine is a dissociative anesthetic drug, that disrupts the transfer of 
sensory input to the association areas of the brain. The patient still receives sensory input, 
but the brain is not able to organize this data in a comprehensive way. Consequently, the 
patient is “unconscious” to his sensory experiences. Administration of ketamine evokes 
changes on the EEG, often compared with epileptic insults. All monitors based on raw 
EEG, can be distorted by this electroencephalographic effect of ketamine.  
 
In a fourth study,(63) we tested the effects of ketamine during a steady state propofol 
anesthesia, on the first version of AAI, and compared it with BIS.(63) We found that AAI was 
not altered by ketamine. In contrast BIS increased after ketamine. As an additional finding, 
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 an increase in variability of AAI was observed. In some patients, this was accompanied by an 
increased electromyographic activity2. We hypothesized that the increased variability in AAI 
could be (partially) caused by this change in EMG. Additionally, we found in literature, that 
the basic locomotor rythmicity in cats is dependent on the N-Methyl-D-Aspartaat (NMDA) 
receptor. Ketamine is an inhibitor of the NMDA receptor. 
  
In a fifth study,(64) we studied whether a neuro-muscular blocking agent (NMBA) could alter 
the effects of ketamine on the new version of AAI, BIS and spectral entropy.  A NMBA 
(rocuronium), given in sufficiently high dosage, is able to block all electromyographic activity. 
By comparing patients in steady-state propofol anesthesia (control group), with three study 
groups, receiving respectively rocuronium, ketamine or both, we explored the effects of 
electromyographic interferences on the distortion of EEG, evoked by ketamine. We 
concluded that rocuronium did not significantly alter the effects of ketamine in any of the 
tested devices. Consequently, our hypothesis on the interference of ketamine with the 
electromyogram, as stated after the former study, was rejected. 
 
This thesis demonstrates that the use of MLAEP, as a measure of the hypnotic component 
of anesthesia, has improved considerably over the last five years. However, technologic 
improvement is still possible. The use of headphones for eliciting the acoustic stimuli, limits 
the communication capacity between anesthesiologist and patient at the start of the 
induction. A potential solution could be the use of bone conduction. However, this should be 
explored further. 
 
Other practical issues remain. The risk of a very long application of acoustic stimuli is 
insufficiently investigated, which could limit the use of MLAEP on the intensive care. The 
currently commercialized AEP monitor/2 is not available in “module” version, which might 
result in ergonomic problems for the OR. Moreover, the costs for monitoring MLAEP in 
clinical practice remain rather high. Due to such practical considerations, the commercial 
success for the AEP monitor/2 could be hampered compared to spontaneous EEG derived 
indices. Therefore, a new spontaneous electroencephalographic derived index, called the 
Cerebral State Index (CSI), was developed using raw binary files registered with the 
AEPmonitor/2 in our studied population. The CSI algorithm combines “neural networking“ 
and an “ANFIS” mathematical model for index calculation. This new index has abandoned 
the raw MLAEP as a source of information, but aims to have an equal clinical performance 
for measuring the cerebral hypnotic drug effect. 
 
In a sixth trial,(65) we validated CSI, by investigating its performance using a retrospective 
control group of raw data files, extracted from our own studied populations. Moreover, in this 
study we compared the performance of the new CSI algorithm with the composite index AAI 
as a validated pharmacodynamic endpoint. This study is an example of how AAI can be used 
in clinical pharmacological studies as a reflection of cerebral hypnotic drug effect.  
 
Additionally, the new CSI index opens possibilities for simultaneous extraction of MLAEP and 
EEG derived information using identical electrode positions. After further clinical validation, 
this index will allow location specific measurements of simultaneously derived cortical (EEG) 
and subcortical (MLAEP) neurophysiologic  processes. This CSI validation study has won the 
2 A fraction of the electrical activity measured during electroencephalographic registrations, is considered to be 
evoked by muscle activity rather than by cortical brain activity. This fraction in the measured spectrum is called 
“electromyogram”(EMG).
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 “best clinical trial” award 2006 of the Belgian Society of Anesthesia and Resuscitation 
(BSAR). 
 
The technologic evolution described in this thesis, suggests that additional drastic 
improvements for MLAEP monitoring in anesthesia are not expected by the industry. In 
contrast, new indications for using MLAEP in anesthesia are currently under investigation in 
the academic world, preserving future perspectives for MLAEP in anesthesia. 
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 Chapter 2 Basic principles and technical background 
This chapter contains several topics that are relevant for a better comprehension of the 
 
1 The definition and components of anesthesia 
2 Methods for monitoring the hypnotic component of anesthesia 
3 The physiological and anatomical background of AEP measurement 
4 The pharmacological background of commonly used anesthetic drugs, with an 
emphasis on drugs used in our trials 
5 The principles and practice of target controlled infusion (TCI) systems 
6 Specific statistical analyzing methods as used in several trials
methodology used in the six trials presented in this thesis: 
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 2.1 The definition and components of anesthesia 
 
Throughout history, the clinical state of anesthesia has been defined in many ways. First, it 
was defined as a continuum of clinical symptoms resulting from the progressively 
increasing dose of a single drug. This concept appeared valid as long as general practice 
was restricted to the use of one single drug (e.g. ether) for evoking adequate anesthesia. 
Several sequences of clinical signs, related to anesthesia, have been described using this 
concept of a single continuum e.g. by Plombey, Guedel and Artusio.(1-3) 
 
Kissin contributed to the definition of 
anesthesia, by stating that a general 
anesthesia condition could be obtained 
through a wide spectrum of 
pharmacological actions, activated by 
different drugs.(4,5) This conclusion was 
based on the experience that many 
combinations of drugs could result in an 
“adequate anesthesia”. The introduction of 
new drugs allowed the development of a 
“balanced anesthesia” method. In a  
“balanced anesthesia”, all clinical goals of 
anesthesia are managed by separate 
groups of medication: hypnotic drugs for 
obtaining sedation or “unconsciousness”, 
analgesic techniques for relieving pain, and 
neuromuscular blocking agents for immobility. These groups of medication interact with 
each other, resulting in a need for lower dosages and avoidance of side-effects, without 
compromising the quality of anesthesia. This theory is reflected in graphical presentations 
such as “the triangle of anesthesia”, which visualizes the interaction between all clinical 
goals of anesthesia. (Figure 2) However, this triangle appears to be a major simplification 
of a much more complex reality. 
 
Recent improvements in neuro-imaging techniques, drug titration methods and online 
neurophysiologic monitoring, have participated in the creation of a more detailed picture of 
the complex mechanisms of anesthesia. Currently, it has been proven that anesthetics 
have various sites of action, both located at the spinal cord as well as at the level of 
supraspinal cerebral structures.(6,7) Simultaneously, important progress has been made 
on a molecular level, as several receptors have been identified as mediators for anesthesia 
effects.(6,8,9) With these findings in mind, Peter Glass suggested a new concept for 
describing the interaction of hypnotics and opioids, in their ability to obtain “loss of 
consciousness” and “loss of response to a painful stimulus”. He states that both endpoints 
are the result of separate neurophysiologic phenomena, that have to be targeted 
independently by the anesthetic drugs.(10) 
 
General anesthesia is a process requiring a state of unconsciousness (produced primarily 
by the volatile anesthetics and propofol). Simultaneously, these hypnotic drugs have an 
independent effect on the memory formation function, resulting in amnesia.(11) Both the 
effects on consciousness and memory formation are considered to be mediated at the 
Figure 2: The triangle of anesthesia 
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supraspinal level (hippocampus, amygdala, frontal cortex etc…) and are defined as the 
“hypnotic component of anesthesia”. (7,12-17) 
This primary obtained hypnotic drug effect can be affected by all sensory input, such as a 
noxious stimulus, that reaches the higher cerebral centers through the spinal cord.(17,18) A 
noxious stimulus must be inhibited from reaching this supraspinal level, as it will interfere 
with the ongoing hypnotic processes, resulting in a tendency to return to consciousness. 
This effect is called the “arousal response”.(19) One could hypothesize that this arousal 
response reflects some kind of survival mechanism. Although a patient is unconscious for 
the perception of “pain”, his system will detect “harm” and attempts to wake up the patient 
in order to protect the integrity of the body. All mechanisms that aim to inhibit the effects of 
a noxious stimulus, are combined in the “analgesic component of anesthesia”.(10) In 
general, this is achieved by the administration of opioids, or by the application of a 
locoregional analgesic technique. 
A problem for this definition of anesthesia is the inadequate description of  “response to a 
painful stimulus”.(10)  A painful stimulus can result in various clinical responses, ranging 
from “an activation of the autonomous nervous system without movement”, over “an 
inadequate movement”, or “an adequate redrawal reflex”. All these potential “responses” 
use different neurophysiologic pathways, and should be explainable within an “ideal” 
definition of anesthesia. As “immobility” remains an important necessity for performing 
surgery in an adequate way, the definition of anesthesia should preferentially include 
“immobility” as an endpoint. Therefore, Ted Eger has suggested an alternative approach for 
defining anesthesia.(20) He states that the clinically relevant goals of anesthesia are limited 
to “amnesia” and “immobility”. In this view, all other cerebral drug effects, such as “the 
inhibition of the autonomic stress response”, “unconsciousness” and “relaxation” are side 
effects and not essential for “general anesthetic drugs”. This definition relies on the 
historical reality that “immobility” operationally has been used as an endpoint for anesthetic 
potency, as described by the  “minimal alveolar concentration” (MAC) (21) One MAC is the 
minimal concentration of an inhaled anesthetic in the lung alveolus, that is required in a 
group of study subjects, to prevent movement in 50% of this population, after receiving a 
standard noxious stimulus. Therefore, the anesthetic potency is commonly described as a 
function of movement. The approach of Ted Eger is also based on the finding that all 
“general anesthetics” are able to target “amnesia” and “immobility” in a reversible way, in 
contrast to the “side effects”, that are not consistently present for all commonly used 
anesthetics. (20) 
Although substantial differences can be found between the approach of Peter Glass versus 
Ted Eger, they both describe a differential effect of anesthetics at two separate levels, the 
spinal cord (response to painful stimulus versus movement) and the supraspinal areas of 
the brain (unconsciousness and amnesia). Both views discriminate between “analgesic” 
versus “hypnotic” components of anesthesia. The measurements studied in this thesis aim 
to quantify the hypnotic components of anesthesia. 
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 2.1.1 The hypnotic component of anesthesia 
The endpoint of interest for this thesis is “the hypnotic component of anesthesia”. It can be 
obtained by the administration of a “hypnotic anesthetic drug”, such as propofol, 
sevoflurane, etc…. By means of these hypnotic drugs, the anesthesiologist aims to obtain a 
predefined level of “unconsciousness” (sedation) and “amnesia” (loss of explicit memory 
formation). Both endpoints are separate phenomena, based on different neurophysiologic 
pathways.(11,22) Hypnotic drugs have a distinct effect on both, although the intensity and 
dose-effect relationship can be variable between molecules.(23,24)  
 
Several studies have shown that during sedation, other forms of memory formation can 
remain present on a subconscious level.(25) This unconscious process of data 
management is often referred to as “implicit memory formation”. It can be detected by 
means of specific postoperative questionnaires. These tests explore the potential changes 
in behavior after an exposure to a stimulus that was not recalled by the patient. This 
stimulus can be either a “list of words” or a “story” that was told during “apparently” 
adequate anesthesia conditions. Although “implicit memory formation” might be considered 
as a fraction of the “hypnotic component of anesthesia”, it is currently not established if 
implicit memory formation has any importance for the outcome of anesthesia.(26,27) 
 
The fundamental cerebral mechanisms of both “consciousness” and “memory formation” 
are insufficiently understood.(28) In the setting of anesthesia, “unconsciousness” implies 
that the patient loses all cognition, in such a way that he becomes unaware of his 
surroundings during a surgical procedure. Although one might argue that “consciousness” 
versus “unconsciousness” is a phenomenon that is either “present” or “absent”, more 
gradual changes have been described, ranging between “fully awake and responsive” to 
“unresponsive to any (verbal or sensory) stimulus”.(29,30) These gradations of levels of 
consciousness have been described for both pharmacological induced conditions, such as 
anesthesia, as well as for pathological conditions (Coma).(31,32) 
 
In clinical practice, the anesthesiologist targets a predefined level of hypnotic drug effect, 
depending on the intensity of the surgical procedure. In minor procedures, it is sufficient to 
avoid “memory formation”. Although the patient will have amnesia for what happened, he 
remains responsive to verbal command (reflecting a maintained consciousness at the time 
of the command). Generally, the subjective experience of the patient is one of having been 
asleep throughout the duration of the procedure. This anesthetic technique is called 
“sedation” or “conscious sedation”.(33-39)  
 
For major surgery, more profound levels of hypnotic drug effect are needed, in order to 
avoid any response of the patient to verbal command and to decrease the incidence of 
“awareness”. Awareness is an accidental return of consciousness during surgery, a very 
traumatic experience, resulting in long term morbidity for some patients.(40-43) Most cases 
of “awareness” are linked to a human or technical error resulting in insufficient 
administration of hypnotic drugs.(44) Some anesthetic techniques or specific surgical 
procedures are characterized by an increased risk for awareness.(45) However, the 
incidence of awareness (0.1% to 0.2%) appears to be comparable in every region of the 
world, independent of the local differences in applied anesthesia techniques.(27,43,45)   
The problem of “awareness” has become more important due to the introduction of neuro-
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muscular blocking agents (NMBA) in anesthesia practice. The NMBA abolish the ability of a 
patient to make a voluntary movement, thereby masking an important endpoint for 
inadequate anesthesia. Consequently, an accidental return of consciousness might get 
unnoticed by the anesthesiologist, unless an alternative method for quantifying the level of 
hypnotic drug effect is available. The level of hypnotic drug effect needed for major surgery, 
is referred to as the “surgical level of hypnotic drug effect”.(46,47) 
If excessive doses of a hypnotic drug are administered, the patient will remain unresponsive 
as required, but the incidence of side effects will increase.  Establishing the risks of 
excessive hypnotic drug effect is one of the research areas of interest in anesthesia. The 
side effects can result in hemodynamic or respiratory instability, but additionally, studies are 
performed to evaluate the effects of anesthetic drugs on the progression of dementia or the 
incidence of subtle neuropsychological changes due to anesthesia effects.(48-52)  Until now, 
it is not indisputably proven that excessive hypnotic drug effect results in a worse long-term 
outcome, although a study by Monk et al, has evoked a fierce debate on this potential 
risk.(53) From a pharmacological point of view, excessive hypnotic drug dosages will 
increase the probability for a delayed recovery due to accumulation of anesthetic drugs in the 
fatty tissues of the patient.(54,55) The application of a monitor for hypnotic drug effect would 
allow optimal hypnotic drug titration, adapted to the individual response of the patient.(56) 
2.1.2 The analgesic component of anesthesia
The “analgesic component of anesthesia” aims to protect the patient against the deleterious 
effects of pain. A patient that receives a sufficiently large dose of hypnotic drugs, will not 
experience pain in a conscious way. However, the human body reacts on any painful 
stimulus with either a reflex movement, an inflammatory or humoral stress response or 
both.(57-61) The reflex movement can  interfere with ongoing surgical procedures, whereas  
the stress response is correlated with a higher incidence of postoperative 
morbidity.(57,60,61) These deleterious effects of a noxious stimulus can be avoided by the 
intravenous administration of strong analgesic drugs, such as remifentanil, sufentanil or 
fentanyl, or by a locoregional anesthesia technique. Locoregional techniques use local 
anesthetics, such as lidocaine or bupivacaine, to block sensory input to the brain at the level 
of the spinal cord or at the site of the surgical procedure. The site of action of intravenously 
administered analgesic drugs is located at receptors of the spinal cord, the brain and almost 
every tissue of the human body. 
It has been questioned if one can use the word “pain” when a patient is unconscious. “Pain” 
implies the presence of some kind of subjective interpretation of the sensory input. By 
definition one needs to be conscious to allow a subjective interpretation. Therefore,  more 
recently, the “analgesic component of anesthesia has also been described as a balance 
between “nociception versus antinociception”. Nociception describes the ability of the spinal 
system to process sensory (noxious) information to the supraspinal areas. Antinociception 
describes the level of inhibition on this process, which correlates strongly to the level of 
analgesic drug effect.(62) 
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2.1.3  Interaction between the hypnotic and analgesic component 
When a hypnotic drug is given to a patient, he will lose consciousness once an individually 
determined drug concentration has been reached at the site of drug action. Although the 
exact mechanism of action for hypnotic drugs is generally unknown, the site of action 
certainly is located within the higher brain structures. In anesthesia practice, it is well known 
that the administration of an opioid,  given before the hypnotic drug, will result in a need for a 
lower dose of hypnotics to obtain the same clinical finding of “loss of consciousness”. This 
macroscopic fenotypical expression of an interaction between opioids and hypnotics is used 
on a daily basis by anesthesiologists to obtain “balanced” anesthesia. 
Consequently, if we aim to obtain a predefined anesthetic effect, such as “loss of response to 
intubation”, several drug choices will be effective. A high dose of opioids combined with a 
small dose of hypnotics, is equally effective for  obtaining unresponsiveness, compared to a 
high dose of hypnotics and a low dose of opioids.(63) The appropriate choice in clinical 
practice will be determined by the experience of the anesthesiologist, the condition of the 
patient and the expected side-effects of, opioids and hypnotics respectively. 
Although opioids are not considered to have “real” hypnotic effects, the administration of a 
massive dose of opioids can provoke a state of unresponsiveness, which is clinically 
indistinguishable from anesthesia evoked by hypnotic drugs. Apparently, the shift in 
balance between “nociception and antinociception”, evoked by large quantities of opioids 
on a subcortical level, inhibits all sensory input to the higher brain structures. Consequently, 
a natural tendency towards “decreased concentration capacity” and “sleepiness” sets 
in.(64) Moreover, in this condition the patient will not respond to moderate or even severe 
painful stimuli either. However, once a sensory stimulus is sufficiently powerful to exceed 
the blocking capacity of the analgesic action, the patient might return to consciousness 
immediately. This phenomenon confirms the limited direct hypnotic effects of opioids and it 
has been suggested as a cause for the higher incidence of awareness in anesthesia for 
cardiac surgery, where high doses of opioids were commonly combined with low doses of 
hypnotics.(65)  
Whether this clinical interaction is evoked by pharmacokinetic or rather by 
pharmacodynamic mechanisms is subject of specifically designed interaction studies. (63) 
However, a thorough discussion of the currently available interaction models between 
opioids and hypnotics is considered not relevant for this thesis as our studies mainly focus 
on the macroscopic clinical expression of a limited amount of combinations of respectively 
analgesic and hypnotic drug concentrations. 
2.1.4 Immobility 
The third endpoint for obtaining an adequate surgical level of anesthesia is “immobility”. As 
mentioned before, involuntary reflex movements can occur as a response to pain, but also 
voluntary movements might occur during periods of insufficient hypnotic drug effect. These 
movements can be potentially harmful during delicate surgery. Other reasons to advocate 
“immobility” are: the need for a smooth intubation of the patients’ trachea, avoiding 
excessive muscle tone during abdominal surgery, avoiding hiccups or coughs during 
delicate neurosurgical or liver procedures etc…  
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When we consider “immobility” as an endpoint of adequate anesthesia, it should be 
evaluated as the result of a spinal process. Therefore, it can only be evaluated in a valid 
way when neuro-muscular blocking agents (NMBA) are not in use. NMBA block the 
muscarine receptors at the neuromuscular junction, resulting in an inability of acetylcholine 
to bind to the receptor. Acetylcholine is a neurotransmitter that is released by the motor-
neurons, whenever an action potential reaches the neuromuscular endplate. Therefore, if 
NMBA are administered, the neuronal stimulus is not transmitted towards the muscles, 
rendering the patient immobile, even if the brain voluntarily commands the muscles to 
move. The introduction of NMBA, has enabled the anesthesiologist to decrease the amount 
of hypnotic and analgesic drugs, while guaranteeing immobility, in a “balanced 
anesthesia”.(4,5) But on the other hand  the elimination of a voluntary movement implies 
that an important clinical sign of insufficient hypnotic drug effect becomes undetectable. 
This condition renders the patient more susceptible for “awareness” during surgery.(40) 
The introduction of NMBA in anesthesia practice increases the need for an objective 
quantification of the hypnotic component of anesthesia, as all clinical signs of insufficient 
hypnotic drug effect are abolished by NMBA.  
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2.2 Methods for monitoring the hypnotic component of anesthesia
Why do anesthesiologists want to measure consciousness and the level of cerebral 
hypnotic drug effect? The most obvious reason is to avoid awareness. Additionally, better 
individualized drug titration might decrease the incidence of movement, prevent 
hemodynamic, respiratory or adrenergic disturbances during surgery, minimize drug dosing 
for obtaining a rapid recovery from anesthesia, shorten post anesthesia care unit stay and 
eventually, minimize costs.  
What are the characteristics of a “perfect” measure of hypnotic drug effect? It should deliver 
information on the changes in the patient’s state in a continuous way. The measure of 
hypnotic drug effect should have a gradual (monotonic) correlation with the clinical 
transition from awake to deeply anesthetized. It should have a strong correlation with the 
respective effect-site concentrations of hypnotic drugs. It should have a comparable 
response when equipotent doses of different hypnotic drugs are given. The measurement 
should only minimally suffer from interfering external factors, such as the electromyogram, 
the electro-cardiogram, electrocoagulation, mechanical interferences (e.g. hot air blankets) 
or drugs without hypnotic effect such as neuro-muscular blocking agents (NMBA). 
Ultimately, monitors should be able to detect the hypnotic effect of “atypical” hypnotic drugs 
such as ketamine, Xenon or Nitrous Oxide.  
Various measures are used to detect the level of hypnotic drug effect on a clinical basis. 
They are based on the description of a response to a verbal or tactile stimulus. The clinical 
endpoints are used in daily practice, due to their simplicity. But one might criticize the 
objectivity and reproducibility. They only reflect a limited fraction of the sequences found 
during the transition from fully awake to completely unresponsive. Moreover, the sequence 
of “appearance” or “disappearance” can differ between individuals and depends on the 
choice of anesthetic drugs. Consequently, the correlation between many clinical signs and 
the actual mechanism of “loss of consciousness” can be questioned. Additionally, as the 
measurements depend on the stimulus given by the observer, the timing and frequency of 
measurement is critical.  
Clinical scales of hypnotic drug effect have been developed, such as the Observer’s 
Assessment of Alertness and Sedation Scale (OAA/S). These are sequences of 
progressively more intense stimuli, allowing a categorical description of the level of 
hypnotic drug effect. Much of the previously mentioned drawbacks of solitary clinical 
measures remain, but the suggested clinical scales are the best available alternative for 
clinical description of the hypnotic component of anesthesia. 
The neurophysiological and anatomical mechanisms of “consciousness” are insufficiently 
understood. As it is currently not possible to measure “consciousness” in a direct way, 
several “surrogate” measures of consciousness, based on changes in the spontaneous or 
evoked electroencephalogram (EEG), are increasingly available in clinical practice for 
quantifying the cerebral hypnotic drug effects. Currently, validations of these 
neurophysiologic indices are often limited to vague descriptions of the correlation between 
one clinical endpoint and the studied index.  We demonstrate in this thesis that this 
approach is inadequate for detecting subtle differences between monitors. We propose to 
implement more standardized study procedures to validate monitors of cerebral hypnotic 
drug effect.  
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 2.2.1 Clinical measures 
2.2.1.1 Loss of memory formation or Amnesia 
Memory formation can be inhibited at very low levels of hypnotic drug effect. Several levels 
of memory formation have been described during anesthesia: “explicit memory formation”, 
“implicit memory formation” and “implicit learning”. Currently, it is impossible to test memory 
formation in a direct way during anesthesia. It can only be tested in a post hoc setting. 
 
“Awareness” is mainly used for defining “unintentional” return of consciousness during 
anesthesia, which is independent of the memory formation function. In contrast, “explicit 
memory formation” implies both return of consciousness and a sustained memory 
formation of the event. Explicit memory formation also applies to sedation conditions at 
intensive care, where the occurrence of memory formation is not always “undesired”. 
Explicit memory formation always indicates that awareness was present, but lack of explicit 
memory gives no clear indication about whether or not awareness occurred. 
 
Awareness can be tested by standardized questionnaires, to test if the patient has 
remembered anything during anesthesia. But there have been reports of explicit memory 
formation, the onset of which can be delayed by days, or even weeks. Therefore, any 
“awareness” testing should be repeated at several time intervals after anesthesia to 
increase sensitivity. 
 
During anesthesia, some sensory (mainly auditory) processing can occur at an 
unconscious level. “Implicit memory formation” can be detected using specific 
postoperative psychoanalytical tests. A certain level of unconscious learning has also been 
reported during anesthesia.(25) At this time it is not established if implicit memory formation 
is harmful when it occurs during anesthesia.(66-68)  
2.2.1.2  Loss of response to name calling 
The anesthetist repeats the patients name at a constant time interval until the patient does 
not respond anymore. The response should be discussed with the patient in advance, 
before any hypnotic drug is given. The response of the patient should be simple and logic 
(e.g. answer “yes”). Calling the patient’s name has the advantage that people tend to 
instinctively focus attention. 
 
Several drawbacks can provoke “false negative” registrations. “Loss of response to name 
calling” is not feasible in patients with an important hearing deficiency. A patient might hear 
his name, but due to the hypnotic effect, does not care to answer anymore. Response can 
be delayed due to the speech being sluggish and slow. “Amnesia” may occur before “loss 
of consciousness”. Consequently, the patient might have forgotten the adequate response, 
although the name is adequately heard. These problems can be minimized (but not 
excluded) by agreeing on a logic and spontaneous answer (such as “yes”). The test is only 
possible in conditions without any NMBA effect. At the end of a procedure, residual NMBA 
effects must be excluded first. Many publications using this measure do not provide 
sufficient details on the exact procedure of data registration,thus decreasing the 
reproducibility of study results. 
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 2.2.1.3 Loss of response to verbal command 
This measure is very similar to “loss of response to name calling”. In this case the stimulus 
is a request to do a simple task (“Squeeze my hand twice?”) or to answer a question 
(“What is your date of birth?”). It tests not merely the return of consciousness, but also the 
ability to deliver adequate responses. Generally, this is considered to be a higher cortical 
function. Consequently, this measure tests a lower level of hypnotic drug effect, compared 
to “the response to name calling” method. The response should be adequate and readily 
given, to be considered “positive”. Comparable problems can occur as with “the response 
to name calling”. The task must be carefully defined or agreed, to avoid including 
phenomena appearing by coincidence. For instance, when one asks to squeeze the hand 
only once, it is difficult to categorize a slight movement of the fingers. 
 
“Asking a question” includes some degree of memory formation testing. It can only be 
performed in non intubated patients. Moreover, the question must be comprehensible for 
the patient, and the answer must be well known by the patient. 
2.2.1.4 Loss of response to eyelash reflex 
The eyelash reflex is an involuntary blinking reflex of the eyelid whenever the eyelashes 
are touched. In contrast to the former clinical measures, this measure needs a tactile 
stimulation. As the sensory input of tactile stimulations can be inhibited by opioids, the loss 
of eyelash reflex can disappear either before or after the loss of response to name calling, 
depending on the balance between hypnotics and opioids. The correlation between this test 
and the “loss or return of consciousness” is not established at all. However, this test is used 
by many clinicians to evaluate hypnotic drug effect in daily practice. 
 
Recently, automatic electromyographic registrations of the eyelash reflex have been tested 
in order to obtain a more objective approach for measuring the hypnotic component of 
anesthesia.(69,70) 
2.2.1.5 Loss of response to a painful stimulus 
The use of a painful stimulus enables a further categorizing of the level of consciousness, 
after detection of unresponsiveness to a normally spoken voice. A general drawback of 
these methods is the diverse neurophysiologic pathways used for the sensory input of 
tactile stimuli versus the auditory pathway of the spoken voice. Therefore, the use of 
opioids must be considered whenever interpreting these clinical signs of hypnotic drug 
effect. 
2.2.1.5.1 Trapezius and index finger squeeze 
A variety of painful stimuli have been used as a measure of anesthetic drug effect.  This 
ranges from a mild shaking of the shoulder, to squeezing the index finger or squeezing the 
trapezius muscle. The latter is included in the “Observers assessment of alertness and 
sedation” (OAA/S) scale, which will be discussed in more detail. One might question the 
reproducibility of such painful stimuli, as the pain intensity might differ between observers. 
Additionally, the clinical value of a painfull stimulus is limited as no objective measure of 
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 pain intensity is available. Consequently, no clear correlation is known between the “low 
intensity” stimulations and the response on laryngoscopy, intubation or incision. In some 
studies, it is not clearly defined what response can be considered a positive  response. 
When a “response to a painful stimulus” is used as a measurement of hypnotic effect, one 
could argue that reflex movement is not a very accurate response. It rather indicates 
insufficient analgesic effect. However, as the differentiation between voluntary and reflex 
movements is difficult to determine, any response is mostly considered as “positive 
response”. 
2.2.1.5.2 Standard incision on forearm 
One of the oldest population based measures of anesthetic potency, the “minimal alveolar 
concentration” (MAC) has been determined using a standardized incision on the 
forearm.(71) One MAC is the percentage of an inhalational anesthetic in the alveolar gas 
mixture that is able to inhibit movement in 50% of the population after a standardized 
incision of the forearm. MAC allows comparison between several inhalational anesthetics in 
equipotent conditions. 
 
From a modern neurophysiologic point of view this measure is rather arbitrary as it 
combines both hypnotic and analgesic endpoints of anesthesia. No distinction is made 
between responses performed as a voluntary act or rather as a reflex movement, although 
these findings represent entirely different neurophysiologic pathways. Most inhalational 
anesthetics have both hypnotic and analgesic capacity, which can additionally obscure 
comparisons between intravenous and inhalational anesthetics. Due to all these 
drawbacks, MAC may be considered a less appropriate method for quantifying the hypnotic 
component of anesthesia when using the most recent definition of anesthesia. MAC does 
not enable an adequate differentiation between the “hypnotic” versus “analgesic” 
components of anesthesia. 
 
The MAC principle is used in daily practice and is very well validated for all kind of 
endpoints. Therefore, it will remain necessary to compare new proposals for quantifying the 
level of hypnotic drug effect with this “traditional” approach.  
2.2.1.5.3 Tetanic stimulation 
It is not convenient to use a standardized incision at the forearm of patients, just for clinical 
research goals, when this is not intended for the planned surgery. Therefore, other 
approaches are being suggested to enable “harmless” painful stimulation in a standardized 
way. By means of a neurostimulator, validated for measuring the intensity of the NMBA 
activity, we can deliver a standardized electrical current with predefined characteristics and 
fixed time duration. A tetanic stimulation, given at the level of the nervus medianus, 
provokes a painful sustained contraction of the flexor muscles of the hand. The advantages 
of this method are:  it is harmless to the patient, the intensity of the stimulation is 
comparable between patients and multiple researchers will deliver a comparable 
stimulation. A disadvantage is that it has not yet been validated in comparison with the 
classic “incision of the forearm” or other painfull stimuli.  
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 2.2.1.5.4 Laryngoscopy, intubation, laryngeal mask placement 
Painful stimuli are able to categorize the level of hypnotic drug effect in many different 
endpoints. However, the clinical importance of these stimuli is debatable. In practice, it is 
much more interesting to evaluate the chance of response to laryngoscopy, the intubation 
of the trachea or the placement of a laryngeal mask. Such endpoints have much more 
direct implications for daily practice, as they are often the first noxious stimulation during 
the procedure. Therefore, the response to these stimuli may indicate if anesthesia is 
sufficient to allow further surgery. For instance, the response on laryngoscopy (as 
measured by bispectral index) has been suggested as a good predictor for response to 
intubation, during propofol and remifentanil anesthesia.(72) Laryngoscopy has also been 
used as a painful stimulus for developing the interaction model between propofol and 
remifentanil by Bouillon et al.(63) 
 
A disadvantage of this method is the high intensity of pain provoked by these stimuli. 
Therefore, this method evaluates rather deep ranges of anesthetic depth. Less painfull 
methods will remain mandatory for quantifying lower levels of hypnotic drug effect. 
2.2.1.6 The Observer’s Assessment of Alertness and Sedation Scale (OAA/S) 
To standardize the clinical signs of hypnotic drug onset and offset, the Observer’s 
Assessment of Alertness and Sedation Scale has been developed.(73) (table 1) The 
original scale, as described by Chesnik et al, included measures of responsiveness, facial 
expression, the quality of speech and some features of the pupil. The responsiveness 
score ranged from category 5 to 1, as it mainly aimed to describe the hypnotic clinical 
effects of benzodiazepines.(73) In order to adapt this scale to anesthesia conditions, a 
Modified OAA/S scale has been suggested.(74) (table 2) It includes category 0, which is 
the “disappearance of response to a painful stimulus”, as this is an important endpoint for 
general anesthesia goals. The modified OAA/S scale does focus more on the hypnotic 
responsiveness during the induction and recovery of anesthesia. It is easily determined and 
can be tested repeatedly with short intervals.  
 
However, the accuracy of the OAA/S scale is still dependent on the frequency and intervals 
of measurement. Also, the tactile stimuli of the OAA/S score are rather related to the spinal 
action of hypnotics than to cerebral actions. Due to the interaction between opioids and 
hypnotics the sequence of responses to the OAA/S scale may be distorted. In some 
patients it is found that several steps in the scale are skipped without gradual transition. 
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 This score was developed for evaluating the sedation level of intensive care patients.(75-
77) It is a categorical scale ranging from 1 (excitation) over 2 (quiet and oriented) to 6 (no 
response to any verbal stimuli). In contrast to the OAA/S scale, the RAMSAY score 
describes the consciousness state in more subjective terms, with a less clear description of 
the stimuli that should be given in order to get a positive response. The disappearance of 
response to a painful stimulus is also not included as an endpoint. Generally it aims to 
quantify less profound levels of anesthetic drug effect compared to the OAA/S scale. 
Table 3: The Ramsay Score 
2.2.1.7 The Ramsay score 
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 2.2.2 Electrophysiological measures 
Due to the limitations of the clinical findings of anesthetic drug effect, a search for more 
continuously available measures of the hypnotic component of anesthesia is needed. 
Measures obtained from the spontaneous and the evoked EEG have been explored as a 
“surrogate measure of the hypnotic component of anesthesia”. 
The spontaneous electrical activity of the brain cortex can be measured using non invasive 
electrodes attached to several locations of the patients’ head. An internationally accepted 
grid system is available to aid consistent electrode placement.(78) This measurement has 
been developed for many diagnostic applications in neurology.(79-81) The first experiments 
of the use of EEG to monitor the anesthetized patient were performed some 55 years 
ago.(82-86) Meanwhile, great advances have been made on signal processing techniques, 
improving the clinical robustness of electroencephalographic measurements. 
 
Particularly, in the operation room, there are many electrical interfering devices. Most of the 
external interference radiates a 50 Hz line frequency to the patient, a common voltage 
mode that has much higher intensity compared to the measured EEG. Differential 
amplifiers are able to minimize this line frequency noise, but additionally, a bandpassfilter is 
necessary to remove unwanted frequency components that do not contain relevant 
information. For intraoperative monitoring, a bandpassfilter between 0.5 and 30 Hz is often 
used.(19)  
The traditional representation of the EEG is a strip chart containing 8 to 32 channels 
displayed as voltage versus time. Conventional chart speed is 30 mm/s and a typical 
vertical scale is 100µV/cm. As the EEG is a complex registration, standardized analyzing 
methods are needed for describing the alterations in EEG, evoked by drugs or pathological 
conditions. 
 
Interpretation of the EEG is classically performed by extensive cross-channel comparisons, 
combining pattern recognition technology and semiquantitative measures of height and 
frequency of the wave components. The electroencephalographic frequency ranges have 
been arbitrary divided into four subranges or frequency bands: alpha (8-12 Hz), beta (13-30 
Hz), theta (4-7 Hz) and delta (0.5-3 Hz). 
 
Three classes of intravenously administered anesthetic drugs can be defined according to 
different effects on the spontaneous EEG: hypnotics (thiopental and propofol), opioids 
(fentanyl, sufentanil, alfentanil, remifentanil) and benzodiazepines (midazolam, diazepam). 
For instance, propofol changes the EEG from a low-voltage, high-frequency awake signal, 
over an initial activation (excitation) signal, with increased frequency and voltage features, 
to a progressive high-amplitude low-frequency signal. Eventually, at very deep levels of 
propofol effect, “burst suppression” patterns occur. “Burst suppression” is a registration of 
complete electrical silence, interrupted by short periods of high frequency waves.(87-89) In 
contrast, increasing opioids concentrations cause a progressive increase in high-amplitude 
2.2.2.1 Spontaneous electroencephalogram
2.2.2.1.1 Classic  electroencephalogram analysis 
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 low frequency patterns in the delta band (0.5-3Hz). These changes only become apparent 
once “unconsciousness” is achieved. This implies that rather high doses of opioids are 
needed for evoking clear changes on the EEG. Benzodiazepines cause increases in the 
EEG voltage with specific activation in the beta range (13-30 Hz). 
 
The application of computer processing of the spontaneous EEG aims at compressing the 
massive amount of information, into a more compact parameter, that can be interpreted by 
an anesthetist, without specific expertise on EEG. Special care must be taken that this 
compact “parameter” provides all relevant information from the changes in the raw EEG. As 
the most apparent changes in EEG during anesthesia are located into the frontal leads, the 
montage of electrodes in anesthesia related monitors are generally limited to the frontal 
region.(19) 
2.2.2.1.2 The power spectrum analysis 
The transition from raw EEG detection into a single numerical trend needs several 
steps:(90) 
 
1 Amplification and filtering of the electrical biosignal  
2 Digitization of the amplified signal into a discrete numerical time series of a 
predefined interval 
3 Dividing the time series into segments by grouping, according to the algorithm 
of the monitor. The algorithm can be based on two major principles: time 
domain analysis versus frequency domain analysis. 
 
The “time domain analysis” evaluates the alterations of one variable in the EEG over time.  
An example of clinical importance is the quantification of the “burst suppression” patterns in 
most currently available monitors. Burst suppression is quantified as a ratio based on the 
percentage of “electrical silence” versus “high frequency bursts” detected during a 
predefined time period, ranging between 20 to 60 seconds. Other measures, based on 
“time domain analysis” have been described in literature for quantifying the 
electroencephalographic changes, but none of these are currently applied in clinical 
practice.(91) 
 
“Frequency domain analysis” or “spectral analysis” is based on the theorem stating that any 
function in time can be described as a superposition of sinus waves of different 
frequencies.(90) Hence, additional information can be extracted compared to time domain 
analysis. Analyzing the frequency domain depicts the separate frequency bands versus 
their respective amplitudes (expressed in voltage) or versus their power (voltage2). The 
“power” part is the most interesting, as it represents how strong a specific frequency band 
contributes to the total EEG. This transformation from the “time domain” registration to a 
“power spectrum analysis” is called the “Fourier transformation”. This is a basic step in the 
majority of modern algorithms used for EEG quantification. 
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Figure 3: Basic characteristics of a sine wave, 
characterized by frequency f, amplitude A and  
phase ș 
 
The Fourier transformation transforms the raw EEG, characterized by a summation of sinus 
waves, into a mathematical description of every available frequency, by its corresponding 
amplitude A and phase ș.  Some authors claim that the “phase” contains no additional 
information on electroencephalographic behavior.(92) Hence, “phase” data are discarded in 
classic EEG analysis. 
 
The theoretical concept used for “power spectrum analysis” is based on ideally obtained 
samples with infinite duration. In reality, we have to determine the power spectrum from a 
finite segment of a few seconds. This implies the occurrence of a measurement error. 
Hence, one has to apply an extrapolating technique on the finite sample for making a 
prediction of the “probable” spectrum, when the sample would have lasted for an “infinite” 
time. The two most common techniques for doing so are: “the fast Fourier transformation 
(FFT)” and the “maximum entropy”. The FFT repeats the measured sample identically to 
infinity, whereas the maximum entropy uses a way of extrapolation, that maximizes the 
entropy of the total signal.(90)  
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 2.2.2.1.3 Single descriptors of the power spectrum 
To parameterize the changes in power spectrum associated with anesthesia and hypnotic 
drug administration, many single descriptors of the power spectrum have been suggested 
and tested in clinical practice: 
 
 
1 The total power: the area under the power spectrum curve (Figure 4) 
2 Absolute power: the area under the power spectrum curve for one specific 
frequency band 
3 Relative power: the ratio between the area under the power spectrum curve 
for one specific frequency band versus the total power 
4 The spectral edge frequency 95% (SEF95%): the upper frequency 
correspondent to 95% of the total power (Figure 4) 
5 Median frequency (MF): the upper frequency correspondent to the median 
value of the total power (Figure 4) 
6 Delta Power or Peak power: the frequency correspondent to the highest 
power. (Figure 4) 
 
 
 
Figure 4: Presentation of a theoretical power spectrum analysis of the spontaneous 
electroencephalogram. MF = Median Frequency, SEF 95% = spectral edge 
frequency 95%, EEG = electroencephalogram 
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 Various studies have been performed using these single descriptors in anesthesia as a 
measure of the hypnotic component of anesthesia.(88,93-97) As not all parameters appear 
equally sensitive for monitoring several hypnotic drugs the SEF95% and MF are probably 
best suited for anesthetic purposes. As we do not further explore these classic parameters 
in this thesis, we refer to the specialized literature, for additional information on threshold 
values and general performance of SEF95% and MF.(87,95-101)  
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 2.2.2.1.4 Bispectral index 
The power spectrum analysis assumes that the distribution of the analyzed data is 
Gaussian, that the frequency distribution behaves according to a first order linear model 
within the EEG and that data are stationary, which means that they will remain within 
certain predefined limits over time. In reality, biologic systems exhibit significant non-linear 
complexities that do not meet these assumptions.(53) Moreover, the elimination of phase 
information, has been questioned. Therefore, new signal processing algorithms have been 
developed, capable of tracking non-linear as well as linear changes in spontaneous EEG. 
 
The “bispectral index” (BIS) (Aspect Medical System, Newton, MA, USA) combines the 
widely used Fast Fourier Transformation with an additional, second order (quadratic) 
analyzing model for the EEG, called bispectral analysis. This implies the quantification of 
the phase coupling (= bicoherence) between two frequencies and the corresponding 
harmonic. The extent of coupling can vary between 0% (if no harmonic is present) to 100% 
(if a harmonic is generated during the entire epoch). 
 
As demonstrated in figure 5, two very different complex waveforms, reflecting two different 
clinical conditions can result in identical power spectra. The additional bispectral analysis is 
able to differentiate between both conditions. 
 
Figure 5: Two different complex waves (left panel) can result in identical power 
spectrum analysis (middle panel). The bispectral analysis (right panel) is able to 
differenciate between both conditions due to the inclusion of phase.  
(from: Sebel PS, et al: EEG bispectrum predicts movement during thiopental/ 
isoflurane anesthesia. J Clin Monit 1995, 11, 83-91.) 
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 The BIS, as incorporated in a commercialized device called BIS XP® (Aspect medical, 
Newton, MA, USA), is developed by identifying the key features of the EEG, measured in a 
large database of patients, receiving one or more of the most commonly used hypnotic 
drugs. The key features are defined by combining bispectral analysis and classic power 
spectrum analysis. Several electroencephalographic features were identified as strongly 
correlated to a specific level of clinical hypnotic drug effect. By means of multivariate 
statistical models, an optimal combination of features was defined in order to describe the 
full spectrum of cerebral hypnotic drug effect. The database of empirically derived 
electroencephalographic registrations was eventually transformed to a linear dimensionless 
scale, ranging between 0 and 100. (Figure 6) 
 
The awake patient will have a BIS between 100 and 95. BIS values between 80 and 60 are 
compatible with “sedation”. Between 60 and 40, the ideal “surgical level of anesthesia” is 
obtained, whereas values under 40 indicate excessive drug effect. BIS has a burst 
suppression detection algorithm, shown on screen as a percentage called the “suppression 
ratio” (SR). Every SR higher than zero reflects intensive inhibition of all cortical electrical 
activity, which is not necessary for adequate anesthesia. 
 
 
 
The result of this technology is an index that reflects alterations in the cortical electrical 
activity, closely correlated to the typical changes found in an anaesthetized population. 
However, other states of the brain, accompanied with an increased amplitude and 
Figure 6: Guidelines of BIS ranges as included in the user guide of BIS XP® 
(Aspect Medical, MA, USA), toestemming Paul Manberg (cfr. Prof. Struys) 
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 decreased frequency pattern of the EEG, will be reflected by BIS. Therefore, BIS can be 
reduced during natural sleep or during ischemic conditions of the brain. 
 
Bispectral Index has been studied in more than 1000 publications, both for clinical 
applications as for pharmacological research.(27) Moreover, Bispectral Index is the only 
neurophysiologic measure that has gathered some evidence, as a monitor for reducing 
awareness in a high risk population for awareness.(43,45) Bispectral index was introduced 
as an anesthesia device for monitoring anesthetic drug effect,  but currently, BIS has also 
been investigated as a monitor for brain ischemia,(27) for titration of sedation on intensive 
care,(102) for pediatric purposes,(38,103-105) and for differential diagnosis in coma 
patients.(106) 
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 2.2.2.1.5 Spectral Entropy 
Entropy is a concept first introduced in thermodynamics to indicate the amount of 
irregularity in molecular movements at a certain temperature. This concept has been 
adapted for applications in signal processing technology, as it allows quantification of the 
amount of irregularity within the signal. The EEG can be considered as a complex signal 
that evolves from a very irregular pattern towards a more regular slow frequency wave as 
hypnotic drug effect sets in. (Figure 7) 
 
Recently, different entropy concepts have been applied to describe the “amount of order” in 
the EEG.(107-109) One of these, Shannon entropy, has been shown to be a useful 
measure of anesthetic drug effect.(108) Shannon entropy measures the predictability of 
future amplitude values of the EEG based on the probability distribution of amplitude values 
already observed in the signal. Unfortunately, Shannon entropy as described is not 
normalized to the total power of the EEG. Therefore, its absolute value may vary between 
individuals because of interindividual differences in signal strength, precluding routine 
clinical use. 
 
To overcome these shortcomings, spectral entropy has been developed. The spectral 
entropy is obtained by applying the Shannon entropy concept to the power distribution of 
the Fourier-transformed electroencephalographic signal, which has been normalized to unit 
power. Spectral entropy permits separation of the contributions from different frequency 
ranges. For example, using spectral entropy, one can separate the high-frequency 
contribution above 32 Hz, (which is likely electromyographic) or from the low-frequency 
contribution below 32 Hz (which is likely encephalographic). (Figure 8) The detailed 
spectral entropy algorithm is published elsewhere.(110) 
Entropy is high 
Wide spread 
of 
frequencies 
Few 
relevant 
frequencies 
Entropy is low 
Figure 7: Concept of entropy as adapted to the irregularity of the EEG. When the 
raw EEG consists out of a wide spread of sinus waves with different frequencies, 
the entropy will be high. During anesthesia, the raw signal contains a smaller 
range of frequencies, resulting in low entropy. 
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Spectral Entropy has become commercially availably (M-ENTROPY module; GE 
Healthcare, Helsinki, Finland). In this device, two spectral entropy indicators are 
considered, state entropy (SE), calculated over the frequency range (0.8–32 Hz) that is 
likely dominated by the EEG, and response entropy (RE), calculated over the frequency 
range (0.8–47 Hz) that includes both the EEG and electromyogram (EMG). Sudden 
appearance of the electromyographic signal data often indicates that the patient is 
responding to some external stimulus, such as a painful stimulus, i.e., nociception, due to 
some surgical event.(111,112) Such a response may result in arousal if the level of 
analgesia is insufficient. In theory, in the nonparalyzed patient’s EMG can provide a rapid 
indication of impending arousal. 
The M-Entropy module has a scale ranging between 100 and 0. When no neuromuscular 
blocking agents are used, the RE is always a little higher than the SE.  The awake patient 
will have SE and RE values between 100 and 90. For sedation, SE and RE values between 
80 and 60 are targeted. A surgical level of anesthesia is obtained between values of 60 to 
40. Below 40, the level of hypnotic drug effect is excessive. These thresholds are equal to 
the BIS thresholds. This is probably a commercially inspired intention rather than a 
coincidence. 
2.2.2.1.6 Other indices based on electroencephalogram 
Increasing numbers of new algorithms are explored in literature. The most important are: 
the narcotrend,(113-117) the patient state index,(118,119) SNAP(120-125) and the 
cerebral state index.(126,127) Some of these are incorporated in commercialized devices, 
others are only developed for academic purposes. Although some interesting alternatives 
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for BIS and Spectral Entropy are available, it appears that most of these indices encounter 
comparable limitations compared to BIS and Spectral Entropy. One could question if these 
indices add anything but complexity to the already complicated interpretation of monitoring 
cerebral hypnotic drug effect. On the other hand, a vivid competition on the market avoids 
monopolization and decreases costs. Therefore, it remains mandatory to explore new 
algorithms and hardware solutions for improving the performance of 
electroencephalographic measures of the hypnotic component of anesthesia. 
2.2.2.2 Evoked electroencephalogram 
As the level of consciousness can be determined clinically, by evaluating the response to 
verbal stimuli, it appears logic that measuring the neurophysiologic response to auditory 
stimuli could reveal additional information on the cerebral hypnotic drug effect. Moreover, 
the neuroanatomical description of the auditory pathway is restricted to a well known 
number of neuronal synapses. In contrast, the interpretation from the spontaneous activity 
of many millions of cortical neurons, representing many disparate subpopulations, is much 
more complex. Therefore, it might eventually be feasible to link the behavior of an evoked 
response during anesthesia, with a direct receptor activity located on the specific pathway. 
Whether this potential advantage has any validity, remains to be seen. 
Chronologically speaking, most of the effects of hypnotic drugs found on evoked responses 
were discovered empirically, and only then it was taken in consideration to use them as 
measures of cerebral drug effect. As this thesis mainly focuses on the quantification of the 
hypnotic component of anesthesia, we will restrict this discussion to auditory evoked 
potentials monitoring. Other evoked potentials, such as somatosensory evoked potentials 
(SSEP) or visual evoked potentials (VEP) are out of the scope of this thesis. 
2.2.2.2.1 The Auditory Evoked potentials (AEP)1
2.2.2.2.1.1 Definition, components, anesthetic effects 
The AEP is defined as the passage of electrical activity from the cochlea to the cortex, 
which produces a waveform consisting of 11 waves in the EEG. These can be divided into 
three parts: brainstem auditory-evoked potential (BAEP), middle-latency auditory-evoked 
potential (MLAEP), and long-latency auditory-evoked potential (LLAEP). These parts 
indicate the sites in the brain from which the various waves are believed to originate. 
(Figure 1) 
The BAEP is represented by the Roman numerals I–VI and extends from 0 to 10 ms after 
the stimulus. These waves represent the process of stimulus transduction in the brainstem: 
acoustic nerve (I), cochlear nucleus (II), superior olivary complex (III), ventral nucleus of the 
lateral lemniscus and preolivary region (IV), inferior colliculus (V), and medial geniculate 
body (VI).(9,128,129) The early cortical or middle-latency auditory-evoked potentials, 
marked by the waves N0, P0, Na, Pa, and Nb, are thought to originate from the medial 
geniculate body and the primary auditory cortex.(130) These waves occur from 10 to 
1 Modified from  “Jensen EW, Martinez P, Litvan H, Vereecke HE, Rodriguez B, Struys MM: Chapter 33: Recent 
Advances In Composite AEP/EEG Indices For Estimating Hypnotic Depth During General Anesthesia,
Akay/Handbook Of Neural Engineering, 2007 Edited by Akay M, Wiley-IEEE Press, 2007, pp 535-553 
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100 ms after the stimulus. The third part, more than 100 ms after the stimulus, called 
LLAEP, reflects the neural activity of the frontal cortex and association areas. 
Factors known to affect the BAEP are the age and sex of the subject; the rate, amplitude, 
and polarity of the stimulus; the filter settings used; and the dose of certain administered 
anesthetic agents and other drugs. Original studies have shown that the BAEP peaks 
change during anesthesia with volatile agents(131-135) but not during anesthesia 
maintained with intravenous agents.(136-140) The LLAEP show great intra- and 
interindividual variations because these signals, are heavily influenced by the hypnotic drug 
effect and the subject’s individual emotional state and alertness.(141,142) The MLAEP, on 
the other hand, show graded changes in their latencies and amplitudes for a variety of 
anesthetic agents and less intra- and interindividual variations than LLAEP. (138-140)  
Therefore, MLAEP have been widely examined as a measure of depth of anesthesia. 
Apart from anesthetic applications, the AEP is clinically useful in detecting and localizing 
lesions in the auditory pathway and in the investigation of hearing loss in infants and in 
other non-communicative subjects. The AEP is present in the first days of life. In the infant, 
the latencies of the peaks are prolonged and the amplitudes diminished. With advancing 
age, the peaks will evolve toward latencies and amplitudes found in a normal adult. There 
is good evidence that the AEP is useful in the evaluation of the state of maturation in 
newborn infants.(143) 
The first evoked potential measurement systems were based on the superposition of ink-
written or photographic traces, and electronic or digital averagers were applied to AEP-
averaging processes. The signal-to-noise ratio (SNR) of AEP is often very poor. Hence 
they are more difficult to extract than, for example, visual-evoked potentials. This is a 
problem, especially in the operating theatre, due to the use of other electric equipment 
producing vast amounts of noise. Modern instrumentation amplifiers with a high common-
mode rejection ratio (CMRR) can overcome the problems of a moderate level of electrical 
noise; however, the noise arising from electrical surgery (diathermy), which produces a 
strong electrical field, renders AEP monitoring impossible. 
Research applying MLAEP for monitoring depth of anesthesia was initiated in the beginning 
of the 1980s.(131,132) Since then a vast number of papers have been published in this 
field of interest.(131-140) Generally, with increasing doses of a hypnotic drug, the 
amplitude (latency) of the main MLAEP components (Na, Pa and Nb) decrease (increase) 
in a dose dependent way. (Figure 9) 
The absolute changes in MLAEP are not very reproducible as there are big interindividual 
differences of response to anesthetics.  Combining results of several studies, one can 
conclude that thiopental, propofol, etomidate, enflurane, and isoflurane all show a dose–
response suppression of the MLAEP, whereas receptor-specific agents such as 
midazolam, diazepam, and flunitrazepam have very little effect on the 
MLAEP.(131,137,144-146) The additive interaction between isoflurane and nitrous oxide 
(N2O) was also not detected by MLAEP.(147) 
Schwender et al. also correlated end-tidal concentrations of desflurane with changes in 
various peaks of the MLAEP. A tendency towards increased latency of Pa, P1, and Nb 
waves and decreased Na/Pa amplitude was noticed when the end-tidal concentration of 
desflurane was increased; however, it was not statistically significant.(148) The study also 
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showed that the latency of peak V of the BAEP changed very little through the entire period 
of anesthesia. It was concluded that only end-expiratory concentration greater than 4.5% 
significantly suppress the different MLAEP components. 
A variant of MLAEP monitoring is the 40-Hz auditory steady-state response (ASSR) 
described by Plourde.(149,150) The ASSR is elicited with a stimulus frequency of 
approximately 40 Hz. This high stimulus frequency causes overlapping of the responses to 
the successive stimuli. Both inhalational agents and intravenously administered drugs 
cause a profound attenuation of the amplitude of the 40-Hz ASSR. The author concludes 
that the 40-Hz ASSR depends on the level of consciousness; however, further validation is 
needed.(149,150) 
Figure 9: Gradual changes in 
amplitude and latency of the 
major components of mid-latency 
auditory evoked potentials. The 
doses are just an example, as 
large interindividual differences in 
MLAEP response exist. 
(Extracted from ref 1 footnote p. 40) 
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 2.2.2.2.1.2 Extraction methods of AEP 
As the AEP has a tenfold smaller microvoltage compared to the superimposed 
spontaneous EEG, an averaging technique is mandatory for extracting AEP out of the 
EEG.(151-153) The most common averaging technique, called Moving Time Average 
(MTA), is based on the averaging of a number of sweeps of the raw EEG. “Sweeps” are 
small periods of electroencephalographic registration, ranging between 80 to 125 
milliseconds, also called epochs. Due to the repetition of the standardized acoustic clicks, 
epochs containing an AEP wave will have more homogenous features, compared to 
epochs containing EEG without AEP. The averaging of a number of epochs, will enhance 
the homogenous characteristics (amplitude and latency) of the AEP. The variable features 
of the spontaneous EEG will not be enhanced. This technique enables visualization and 
further analysis of the MLAEP components. A major  drawback for MTA is the need for 
large amounts of epochs, which causes a considerable delay for extracting MLAEP derived 
information.(152-154) 
 
The interpretation of the raw MLAEP wave demands special expertise of the observer, as 
he must decide which curves are relevant and which are not. Moreover, the quantification 
of amplitudes and latencies is subjective, making this technique prone for observers 
bias.(155,156) In a constantly changing setting of clinical anesthesia, the time delay caused 
by the classic MTA extraction technique, was excessively long.(153) 
 
Throughout the last two decades a number of methods have been explored in order to 
facilitate a single-sweep or a few-sweeps extraction of the MLAEP. The main focus of this 
technical section is to review some of these methods with particular emphasis on the 
autoregressive model with exogenous input (ARX model), as this technique is the main 
topic of this thesis. The performance of the ARX approach is examined extensively in 
clinical applications, whereas other methods for single-sweep analysis are only briefly 
described. This section is important as it demonstrates that, in future, the delay for 
receiving information of MLAEP can be reduced below 6 seconds, if this would appear 
necessary. 
2.2.2.2.1.2.1 Wavelets 
Wavelets have found use in a number of signal processing applications in biomedical 
engineering. The wavelet transformation (WT) is a signal decomposition into a set of basic 
mathematical functions, called wavelets. Bartnik et al.(157) applied the WT to the AEP and 
concluded that an AEP from a single sweep could be extracted even though the AEP and 
the EEG are in the same frequency range. 
 
However, the signal-to noise ratio of the AEP could be improved by allowing some 
preaveraging (which increases the delay again). WT has been successfully applied to 
visual-evoked potentials (VEP) by Geva et al.(158) Recently Kochs et al.(159) have applied 
WT in clinical studies for AEP extraction. WT is a promising tool for single-sweep analysis 
of evoked potentials that should be explored further.  
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 2.2.2.2.1.2.2 Optimal Vector Quantization 
Haig et al.(160) suggest the use of global optimal vector quantization to classify single-trial 
event-related responses (such as AEP). It was concluded that this method facilitates a 
more detailed analysis as compared with MTA. This method has not yet been applied in 
clinical applications.  
2.2.2.2.1.2.3 Maximum Length Sequences 
In 1982 Eysholdt and Schreiner reported on the use of m-pulse sequences (also called 
maximum length sequences) to extract the BAEP from the ongoing 
electroencephalographic activity.(161) In theory, this is also applicable on MLAEP. The 
method allows a faster stimulus rate compared with that allowed by moving time averaging 
and therefore decreases the processing time necessary to extract the AEP. The method 
was further refined by Shi and Hecox.(162) Drawback is a potential change in the AEP 
morphology due to the increased stimulus rates. An examination of the effects of increased 
stimulus rate has been performed by Don et al.(163)  
2.2.2.2.1.2.4 
The autoregressive model is a mathematical model enabling fast extraction of information 
on signal morphology, without decreasing the output quality. It differentiates the AEP 
morphology within a much shorter time, compared to the classic MTA, as it only uses 15 to 
18 sweeps containing both EEG and MLAEP (Figure 10). Additionally, an “exogenous 
input” is applied to the model. The exogenous input is a -high quality, long delay- AEP 
extraction, produced by averaging the latest 256 sweeps, used as a feedback controller for 
the fast extracted calculations. This quality control has a delay comparable to the classic 
MTA. 
 
ARX has already been applied in neurophysiological monitoring. The application of ARX 
models to visual evoked potentials (VEP) was originally described by Cerutti(164,165) and 
later by Liberati and Cerutti(166) and applied by Magni.(167) As the signal-to-noise ratio 
(SNR) of the VEP is considerably larger than that of the auditory evoked potential (AEP), 
single-sweep analysis was possible. In contrast, for AEP extraction, a preaverage of 15–50 
sweeps improves the SNR before applying the ARX model.(168) 
  
The ARX model has been implemented in a commercialized fast extracting AEP monitor, 
called A-Line® (Danmeter, Odense, Denmark). The output of the device is called the A-
Line® Auditory Evoked Potential Index or A-Line® ARX Index (AAI). AAI is calculated using 
an “area under the curve” algorithm, implemented on the fast extracted MLAEP wave, 
measured within the latency range between 20 and 79.9 milliseconds after click stimulus. 
Figure 10 describes the signal processing from the raw registration until the actual output of 
the AAI.(168,169)  
 
The AAI is projected on a unitless scale, ranging between 100 and 0. All values above 60 
are considered to be compatible with the awake patient. Values between 40 and 25 are 
compatible with the sedation range. The surgical level of anesthesia correlates with AAI 
values between 25 and 15. Below 15, the hypnotic drug effect is considered excessive.  
Autoregressive model with exogenous Input (ARX) 
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In this algorithm, an estimation of the signal-to-noise ratio (SNR) is critical to guarantee 
adequate detection of the AEP signal, due to the decreased number of sweeps.(153) The 
SNR algorithm quantifies the amount of “desired” signal versus the amount of “undesired” 
background noise. Currently, the decision to define “signal” versus “noise” for AEP 
measurement, is based on the assessment of a number of sweeps, or epochs, obtained in 
two different ways. For defining “signal”, the epochs are obtained synchronously with every 
click stimulus. These epochs do contain AEP at a constant latency. Subtracting or 
averaging of these synchronous epochs will enhance the peak amplitudes of the AEP. This 
is called the synchronous average. For defining “noise”, the epochs are obtained in a 
random, asynchronous way with the click stimulus. These sweeps lack the homogenous 
features of the synchronous epochs. Subtracting or averaging of the asynchronous epochs 
will not enhance peak amplitudes. This is called the asynchronous average. The SNR is the 
ratio between the maximum amplitude of the synchronous average, versus the maximum 
amplitude of the asynchronous average.(153)  
 
A closed-loop control system, using a proportional–integral–differential (PID) controller, is 
applied to control the SNR of the averaging processes. A desired SNR is defined between 
1.4 and 4, and reflects the adequate AEP extraction range. The controller acts on the 
averaging process in the following manner: If the estimated SNR of the extracted AEP is 
low (less than the desired SNR of 1.4), the number of averages is increased in order to 
improve the SNR. This has the disadvantage of reducing the system’s ability to track fast 
changes on the AEP. In contrast, if the estimated SNR is higher than desired, the number 
of averages of the averaging process is reduced to improve the detection of fast changes 
of the AEP. This control system balances the quality of the extraction with the speed of 
the averages. 
 
The “take away” message of this section is, that the A-Line® guarantees optimal 
information extracted from MLAEP, at all times. However, during conditions with low 
signal-to-noise ratio, the guarantee in quality decreases the speed for detecting sudden 
changes in the MLAEP. 
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Figure 10: Schematic presentation of the signal processing algorithm in the 
A-Line® monitor. After amplification of the raw signals and digitalization by an 
A/D converter, a first artifact rejection is performed using a bandpassfilter with 
upper limit of 900 Hz. All segments, not defined as artifact, are further 
analyzed within a frequency range of 16 to 100Hz. This window is averaged 
using a moving time average of 15 sweeps (MTA15), resulting in a fast 
extracting output. Simultaneously, the “exogenous input” is calculated using 
moving time average over 256 sweeps (MTA256). These are the input values 
for the autoregressive model with exogenous input (ARX). If the output 
applies to the model, AAI is shown on screen, if not it is rejected. If necessary, 
the MTA15 will increase the number of sweeps according to the signal-to-noise 
controller. 
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 2.3 Anesthetic drugs used in our study protocols 
2.3.1 Hypnotics 
Propofol (di-isopropyl-phenol) is one of the commonly used hypnotic drugs for anesthesia 
applications, producing a dose dependent inhibition of consciousness. It is used for 
intravenous induction and maintenance of anesthesia, both in adults and children. As it has 
no analgesic activity, propofol is generally combined with a strong intravenous analgesic or 
a locoregional analgesic technique. The main reason for its widespread use is the 
interesting pharmacokinetic and pharmacodynamic characteristics. It is a rapidly 
redistributed and eliminated hypnotic drug, allowing to decrease recovery time after long 
times of drug administration, compared to barbiturates or benzodiazepines.(170-175) 
Therefore, it is also applied as a sedative drug for intensive care patients, who often need 
hypnotics over several days. 
 
The present formulation is a 1% oil in water emulsion containing 10% soybean oil, 1.2% 
egg phosphatide and 2.25% glycerol. Propofol has a pKa of 10.76 and an octanol/water 
partition coefficient of 5000. Due to the lipids, propofol has a typical white color. A 
disadvantage of the emulsion is that a large proportion of patients experience a pain at the 
site of injection, probably due to a direct venous irritation, that is difficult to treat. Other 
important side effects are hypotension due to vasodilatation of the arteries, temporary 
respiratory depression after bolus injection, postoperative nausea and vomiting, and tonic-
clonic convulsions at induction. 
Pharmacokinetics-pharmacodynamics: 
Propofol is 97-98% bound to the plasma proteins and is highly lipid soluble. Consequently, 
after a single bolus injection, propofol is quickly redistributed in the body with a primary half 
life, ranging between 1.8 to 8.3 minutes. The liver is the primary metabolizer, by 
conjugating propofol at a metabolism rate of 1.5 to 2 L/min. The beta elimination half time 
ranges between 34 and 64 minutes. Inactive metabolites are cleared by the kidneys. 
 
Several pharmacokinetic-pharmacodynamic models have been described for propofol in 
order to develop adequate target controlled infusion (TCI) systems, and allow better drug 
titration compared to a single bolus, repeated boli, or a bolus followed by a continuous 
infusion. This TCI technology, and the available models will be discussed in more detail in a 
later section.(176-179) 
 
Clinical anesthesia is obtained with plasma concentrations between 4 and 6 µg/ml, when 
nitrous oxide or an analgesic drug is associated. However, a large population variability is 
seen both on pharmacokinetic and pharmacodynamic levels. Concentrations between 1.64-
6.38 µg/ml have been found in volunteers at the point of loss of consciousness, and 
concentrations of 1.0-2.19 µg/ml when consciousness returned.(180) 
2.3.1.1 Propofol (Diprivan®, AstraZeneca)
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 2.3.1.2 Ketamine (Ketalar®, Pfizer) 
Ketamine (2-(O-Chlorophenyl)-2-(methylamino) cyclohexanon chloorhydrate)) is a fast 
acting, non barbiturate hypnotic anesthetic, with a unique “dissociative” effect on the 
cerebral function. Mediated by a strong N-methyl D-Aspartate (NMDA) receptor inhibition, 
the transfer of sensory input to the corresponding association areas is disrupted, causing a 
clinical effect of unconsciousness, catalepsy, amnesia, and strong analgesic effects. 
 
An important advantage of ketamine is that it preserves cardiovascular and respiratory 
stability. Blood pressure and heart frequency are increased due to an adrenergic activation, 
and spontaneous ventilation is maintained. This is why not medically trained soldiers could 
use this drug in the Vietnam war, as an intramuscular anesthetic, for painless evacuation of 
injured colleagues. Ketamine is often called the “battle field drug”. In anesthesia practice, 
ketamine is used as an adjuvans to potentiate other hypnotic drugs or as a low dose 
infusion for decreasing the postoperative need of opioids.(181-184) 
 
Disadvantages are the frequent hallucinations, of a very frightening nature (near death 
experiences, nightmares, delirium). Therefore, the use of ketamine should be avoided 
without combining a benzodiazepine or other hypnotic drug for evoking amnesia of the bad 
experience. Bronchospasme and apnoe have been reported after intravenous bolus doses, 
nausea and vomiting, increased muscle tone with tonic clonic convulsions and increased 
intracranial and intraocular pressure. This latter excludes the use of ketamine for 
ophthalmic and neurosurgical procedures.  
Pharmacokinetics-pharmacodynamics: 
After a single bolus of ketamine of 2.5 mg/kg, peak plasma concentrations are 2 µg/ml. The 
distribution phase ranges between 7 and 17 minutes and elimination takes 130 to 186 
minutes. Elimination is performed primarily by the liver, where N-demethylation results in 
cyclohexanon. After hydroxylation, the metabolites become water soluble and are excreted 
in urine. Metabolite 1 (norketamine) has a tenfold decreased activity than ketamine but it 
has a very long elimination halftime of 4 hours. Metabolite 2 (dehydronorketamine) has no 
hypnotic effect. The elimination halftime is 7 hours. Ketamine is minimally bound to 
proteins. 
 
The unique effect on cerebral function is reflected in the EEG.(44) The dissociation 
between cortex and subcortical structures results in a disruption of the coordinated cortical 
subunits activity. The resulting electrical activity has been compared to “epileptiform” 
changes in EEG. Most derived indices of hypnotic drug effect, based on EEG, lose 
sensitivity when ketamine is associated, as the cortical alterations often result in a false 
increase of  index calculation.(185) 
 
Ketamine has no effect on the raw MLAEP as shown by Schwender et al.(186,187) The 
effects of ketamine on the recently developed MLAEP derived indices are a subject of this 
thesis, and are discussed in more detail. 
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 2.3.2 Analgesics 
2.3.2.1 Remifentanil (Ultiva®, GSK) 
Remifentanil (figure 11) is a strong analgesic opioid, from the group of phenylpiperidines, 
used for analgesia during general anesthesia, and for sedation of mechanically ventilated 
patients on intensive care. 
As a µ-opioid receptor agonist, all known effects and side effects of other opioids are 
present. The desired effect is the strong analgesia. Side effects are: cardiovascular 
inhibition with hypotension and bradycardia, respiratory inhibition and apnoe, muscular 
rigidity, nausea and vomiting, constipation and pruritus.(188,189) The risk for addiction is 
debatable, due to the unique pharmacokinetic characteristics. A more complex problem is 
the suggested phenomenon of the acute tolerance against the effects of remifentanil, that 
has been suspected after long administration times and at high doses.(190-196) However, 
it has not been fully untangled if this problem has major clinical implications. 
Pharmacokinetics-pharmacodynamics: 
Remifentanil has a unique pharmacokinetic profile within the group of opioids.(189) As the 
structure is an ester, the elimination is based on a constant metabolization by non-specific 
esterases. These are available in large quantities in blood and almost all tissues. 
Therefore, the elimination is independent of liver- or kidney function. Moreover, the 
elimination is ultra rapid, as the elimination half time ranges between 3 and 10 minutes. 
Due to the lack of any accumulating effect, the half time remains constant, independent of 
the duration of drug administration. 
 
Figure 11: The molecular structure of remifentanil.
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 This ultra rapid offset time, implies that remifentanil can only be given in a continuous 
infusion or by TCI. Whenever the infusion is stopped, all effects of the opioid disappear 
within a very short time. This allows very predictable recovery conditions, but it also 
demands a change in anesthesia practice for postoperative pain relief. With intermediate or 
long acting opioids, much of the immediate post operative pain is avoided by residual 
opioid effect. For remifentanil, no residual analgesia can be expected. Therefore, the 
postoperative pain therapy must be commenced before and during the anesthetic 
procedure, to avoid the “valley of no analgesia” at the end of surgery. 
2.3.3 Neuro-muscular blocking agents (NMBA) 
2.3.3.1 Rocuronium (Esmeron®, Organon) 
Rocuronium is a non depolarizing neuromuscular blocking agent (NMBA) of the group of 
aminosteroids. All NMBA’s provoke a complete paralysis of the patient, due to a 
competitive binding with the cholinergic nicotine receptors at the level of the neuromuscular 
endplate. Rocuronium is used as adjuvans in anesthesia for improving the intubation of the 
patients’ trachea during routine and emergency procedures and for maintaining immobility 
throughout the surgical procedure. 
Pharmacokinetics-pharmacodynamics: 
The most impressive feature of rocuronium is a rapid onset time. At a dose of 0.6 and 0.9 
mg/kg,  rocuronium is able to completely block the nicotine receptors within 1 min and 45 
seconds respectively.(197,198) The clinical duration of rocuronium is dependent of the 
dose given. For 0.45 mg/kg to 1.2 mg/kg, the duration of action is respectively, 22 and 73 
compartment open model. The rapid distribution half-life is 1 to 2 minutes and the slower 
distribution half-life is 14 to 18 minutes. Rocuronium is approximately 30% bound to human 
plasma proteins. 
 
Studies of distribution, metabolism, and excretion in cats and dogs indicate that rocuronium 
is eliminated primarily by the liver. But an important fraction (between 20 to 40%) is 
excreted by the kidneys. In general, patients undergoing cadaver kidney transplant have a 
small reduction in clearance which is offset by a corresponding increase in distribution 
volume, such that the net effect is an unchanged plasma half-life. Patients suffering from 
liver cirrhosis have a marked increase in their volume of distribution resulting in a plasma 
half-life approximately twice that of patients with normal hepatic function.   
 
A NMBA has no hypnotic effects. Consequently, NMBA should not evoke any alteration in 
the EEG that resembles hypnotic drug effect. However, the frontal muscles located 
between the cerebral cortex and the electrodes that measure the EEG can produce 
interfering electrical activity. This is defined as the electromyogram (EMG). The frequency 
ranges of EMG exceed those of spontaneous EEG. Therefore, noise filters have been 
developed to avoid excessive interference of EMG on the EEG registration. Although the 
noise filter technology of electroencephalographers has improved considerably, it appears 
that an important fraction of the measured electrical activity remains EMG dependent. This 
EMG signal can be inhibited by NMBA. Consequently, NMBA has an influence on the 
minutes. Following intravenous administration of rocuronium, plasma levels follow a three 
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 power spectrum calculations of EEG and can provoke a change in the output of both 
bispectral index, spectral entropy and the first version of the A-Line® ARX Index.(199-201)
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2.4 The principles and practice of target controlled infusion (TCI) systems 
2.4.1 Theoretical concept 
Target Controlled Infusion (TCI) is a computer generated administration of intravenous 
agents, whereby the user does not set an infusion rate in ml/h or µg/kg/min, but rather sets 
a desired (target) plasma (or effect-site) concentration for the drug.(202) The user enters 
some demographic data of the patient into the computer that compares the variables of the 
patient with those of a previously studied patient population. By combining the individual 
demographic data with the pharmacological data obtained from the studied (modeled) 
population, the computer will make a prediction of the ideal infusion speed, in order to 
reach and maintain the requested plasma (or effect-site) concentration with as little error 
and delay as possible.  
2.4.2 Plasma and effect-site concentration  
Pharmacology describes the relation between drug dose and drug effect. This relationship 
is depicted in two separate phases.  
Pharmacokinetics (PK) describe the time course of a drug concentration in the body after 
administration of a drug dose. Depending on the route of administration and the 
physicochemical properties of the drug, we can distinguish an absorption phase, followed 
by (re)distribution and elimination (by metabolization or excretion).  
Pharmacodynamics (PD) describes the relationship between the drug concentration (as 
described by PK) and the actual drug effect. PD represents a sequence of molecular 
processes eventually resulting in the clinical effect of the drug. The first step is the 
interaction between the drug and a receptor in the biophase. The biophase is the direct 
environment of the receptor at the site of drug action. The interaction at the biophase 
results in a process called “effectuation”. This could be, for instance, the formation of a 
second messenger, the inhibition of an enzyme or the physicochemical change in an ion 
channel. These cellular processes ultimately result in a clinical response, called the “drug 
effect”.
In a human population, large variability can be found in the clinical response to 
administration of a drug. At the level of PK, common reasons for this large variability are: 
differences in body composition, organ function and state of disease. At the level of PD, 
different responses between individuals can result from variations in receptor density and 
sensitivity, structural receptor disorders within organs or neurotransmitter pathways. 
TCI systems aim to optimize drug administration by using a pharmacokinetic-
pharmacodynamic (PKPD) population model, extracted from studies that investigate the 
behavior of drug-concentrations and drug-effects in a standardized population of patients. 
These PKPD models are mathematical simplifications of the complexity of the human body, 
enabling to calculate (or predict) the probable concentrations and drug effects in an 
individual patient, after drug administration. 
For intravenously administered hypnotic and analgesic drugs, PK are generally described 
by a three compartmental model (Figure 12). The main determinants of this model are: the 
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 three volumes of distribution (central compartment (V1), rapidly equilibrating (V2) and slowly 
equilibrating (V3) compartments) and the clearances (systemic clearance (k10) versus rapid 
(k12) and slow (k13) inter- compartmental clearances). When a dose of drug is administered 
intravenously, it immediately disperses into the central compartment, resulting in a “central 
compartment concentration”. This central compartment concentration is also called “the 
plasma concentration”, although the theoretically defined central compartment has little 
to do with the real “plasma volume”. Rather, it is a reflection of the “mean” drug 
concentration behavior in the population. Initially, a fast distribution to the rapid and slowly 
equilibrating compartments sets in, resulting in a steep decrease of central drug 
concentrations. Once the rapid equilibrating compartment is in equilibrium with the central 
compartment, the central drug concentrations will decrease with a more moderate rate. 
Finally, when all three compartments are in equilibrium, the drop in central compartment 
concentrations has a log linear shape. This terminal phase is also called the “elimination 
phase”, as the main mechanism for the final descent is based on the excretion of drug from 
the body. 
 
The volumes and equilibration constants of the three-compartmental PK model can be 
estimated, by administering a bolus dose of drugs in a standardized population. Thereafter, 
blood samples are drawn at different points in time, and the change in drug concentration 
over time is plotted. By means of advanced population modeling statistics (e.g. NONMEM), 
the optimal values of the PK model variables can be estimated. The estimate that fits the 
measured data samples best, without allowing excessive complexity in the models, is 
considered for further validation. Ideally, the final PK model should be validated 
prospectively, before conclusions on clinical applicability can be drawn. 
 
For hypnotics and opioids, the site of action is not the plasma. As such, a theoretical effect-
site compartment has been added to the PK model, which represents the site of drug 
action. (Figure 12) The effect-site volume is considered to be negligible. Consequently, it 
has no impact on the PK behavior of the drug. However, the effect-site compartment does 
have a drug concentration, called the effect-site concentration. The behavior of the 
effect-site concentration over time is determined by the equilibration constant “ke0”, which 
describes the rate of definitive drug elimination out of the effect-site. The total amount of 
drug eliminated from the effect-site is negligible, and is not considered to return to the 
central compartment.  
 
As the effect-site is a theoretical concept, the effect-site concentration can not be measured 
directly. However, this theoretical drug concentration is closely related to the actual clinical 
drug effect. Therefore, continuous surrogate measures of hypnotic drug effect, such as 
EEG and MLAEP derived indices, are excellent tools for making assumptions on the 
behavior of the effect-site concentration in the population. Consequently, neurophysiologic 
monitoring has become closely entangled with TCI technology. A continuous search for 
convenient neurophysiologic endpoints of hypnotic drug effect remains mandatory to 
optimize future TCI models. 
 
TCI technology currently allows us to target both plasma- and effect-site concentrations 
with acceptable accuracy.(203) Moreover, once a desired effect is obtained, TCI enables to 
maintain this effect over an unlimited amount of time (in “pseudo” steady-state anesthetic 
conditions). The condition is called “Pseudo”, as the TCI evoked steady state is only based 
on a population prediction, not on an actual individual measurement of drug concentrations 
in the patient. 
53
  
Nevertheless, TCI technology is commonly available to all anesthesiologists and therefore, 
allows a close approximation of “real” steady state anesthesia. By using the most recent TCI 
models in our protocols, we aim for a high reproducibility of our results. It also allows a better 
comparison between anesthetic conditions in our patients, and eventually between the 
monitors tested. 
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Figure 12: Schematic presentation of the three compartmental PKPD model 
enlarged with an effect-site compartment.  
“I” is the injection of a dose of a drug that immediately disperses towards three 
compartments, according to the balance between “distribution volume” and 
“equilibration constants”. V1,V2,V3 ,Ve are the respective distribution volumes of 
compartment 1(central), 2 (rapidly equilibrating), 3 (slowly equilibrating) and the 
effect-site. All k values are the equilibration constants that eventually will define 
the changing concentration in the central (plasma) compartment over time. The 
elimination constant, that reflects the final excretion of drug out of the system, is 
k10. 
 
The behavior of the effect-site concentration is only determined by the ke0, 
which reflects the speed of drug elimination out of the effect-site. The amount of 
drug, eliminated from the effect-site compartment, is not returning to the central 
compartment, but is definitely excreted. As the amount of drug lost by this route 
is considerably smaller, compared to the total elimination, this error is 
considered to be acceptable. 
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2.4.3 The models for remifentanil and propofol 
All PKPD models used in this study are based on the three compartmental model, enlarged 
with an effect-site compartment. (Figure 12) 
2.4.3.1 Marsh, Schnider, ke0 and time to peak effect
For propofol, the first model used in clinical practice, was a three compartmental 
pharmacokinetic model defined by Marsh et al.(177,204) The Marsh model uses only 
weight as covariate between patients. Originally, no pharmacodynamic information was 
included for model building. Therefore, one could only target the plasma concentration. 
Schuttler et al calculated a ke0 of 0.26 min-1 for propofol from a separate population and 
combined this with Marsh pharmacokinetics. This combined PKPD model was 
commercialized in a TCI pump called Diprifusor (Cardinal Health, Alaris, Ohio, Il, USA). It 
was only intended for applications using propofol of the brand Diprivan® (AstraZeneca, 
Loughborough, Leicestershire, United Kingdom). 
Schnider et al, showed that age had a significant effect on the distribution volume and the 
clearance of the rapidly equilibrating compartment, in a population of 24 adult patients with 
a large age difference (21 to 81 years).(178,179) This resulted in a more rapid increase of 
propofol concentrations in the central compartment at the beginning of the infusion, and a 
more rapid decrease at the end of the drug administration, compared to the Marsh model.  
With these findings, Schnider et al, created a new PKPD model including age, weight and 
lean body mass as a covariate for predicting plasma concentration. Both PK and PD data 
were obtained from the same patient population. The pharmacodynamic measurements 
were performed with a surrogate EEG derived index, called semilinear canonical 
correlation. The ke0 of the Schnider model is 0.456 min-1.
Minto et al described an alternative approach for calculating ke0, based on the observation 
of the time to peak effect.(205) After a bolus injection of propofol, a time delay is observed 
until maximum clinical hypnotic effect is obtained. At that point the theoretical plasma and 
effect-site concentration are at equilibrium. This “time to peak effect” allows to depict the 
initial increasing slope of the effect-site concentrations, resulting in the prediction of an 
individualized ke0. Minto et al. showed that “time to peak” for propofol was 1.6 minutes. 
When using Schnider pharmacokinetics, this method results in a mean ke0 of 0.357 min-1.
The Schnider model with time to peak effect algorithm is commercially available in several 
open TCI systems. Recently, the “time to peak effect” method has been implemented on 
the Marsh model, resulting in a Modified Marsh model.(205)
Whenever TCI administration was needed for the studies in this thesis, we preferred to use 
the Schnider model, with the time to peak effect algorithm of Minto for ke0 prediction. At the 
time of study inclusions, this choice was rather arbitrary, as no solid proof was available 
that this model was superior for describing the clinical hypnotic drug effect. Still, we had 
several arguments to favor this option. 
1) The Schnider TCI model is available for all anesthesiologists as it has been implemented 
in commercialized infusion pumps. Consequently, our results have both scientific and 
clinical value. 
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2) The Schnider model has been developed using the “semilinear canonical correlation” as 
a pharmacodynamic  endpoint. This is an independent EEG derived parameter as it is not 
included in the pharmacodynamic measures that we aimed to compare in our studies. If we 
had used a PKPD model that was developed with one of the neurophysiological measures 
under investigation, it could have caused an intrinsic advantage for that specific measure, 
resulting in a better correlation with CePROP. By using the Schnider model, the chance for 
an intrinsic bias for one of the indices under investigation remains limited.  
     
3) For the studies in steady-state conditions (Study 1, 4 and 5) the potential error in the 
PKPD model will have little influence on our conclusions as we focus on the differences in 
neurophysiological response between several predicted steady-state concentrations of 
propofol, in a “step up” procedure. If the model under- or overestimates CePROP at step one, 
it will probably result in a comparable under- or overestimation of CePROP at step two and 
three. In contrast, the difference in drug effect between steps remains equally informative.  
4) For the studies in non steady-state conditions (Study 2,3 and 6), more dramatic errors 
between the predicted CePROP and the actual hypnotic drug effect may occur, especially 
during the first minutes of drug administration. For this problem, one should distinguish 
between the errors on a pharmacokinetic level versus those on a  pharmacodynamic level. 
On a pharmacodynamic level, the Schnider model was validated as an acceptable 
descriptor of hypnotic drug effect, using BIS as a reflection of the cerebral hypnotic drug 
effect.(176) 
On the pharmacokinetic level, a recent article of Prof. M. Struys provides some arguments 
to prefer the Schnider pharmacokinetics with the time to peak effect algorithm, as the 
resulting ke0 better approximates the time course of drug effect during non steady state 
conditions.(206,207) As this information was not yet  available at the time of performing our 
studies, our decision was fully based on the other arguments listed here.  
5) Finally, we preferred to use the Schnider model as it was the only available model at the 
time of study inclusions,  that combined pharmacokinetic and pharmacodynamic data from 
one single population sample. In contrast, the Marsh model had been developed combining 
PK data from one sample, with PD data from a second sample of the population. The 
approach of implementing a ke0, obtained in one study, on a PK model derived from a 
different sample of patients can result in poor predictability of the final model, as shown by 
Gentry et al for thiopental, (208) and Wakeling et al. for propofol. (209)  
As an illustration we listed all parameters for the currently available propofol PKPD models: 
Model Marsh et al.,(204) : Vc = 0.228 * weight (litres * kg). k10 = 0.119/min. k12 = 
0.112/min. k13 = 0.0419/min. k21 = 0.055/min. k31 = 0.0033/min. k41 = 0.26/min. 
Modified Model Marsh et al.,(204): Vc = 0.228 * weight (litres * kg). k10 = 0.119/min. k12 
= 0.112/min. k13 = 0.0419/min. k21 = 0.055/min. k31 = 0.0033/min. k41 for tPeak = 1.6 
min.(205) 
Model Schnider et al.,: Vc = 4.27. V2 = 18.9-0.391 * (age-53). V3 = 238. cl1 = 1.89 + 
0.0456 * (weight-77) - 0.0681 * (lbm-59) + 0.0264 * (height-177). cl2 = 1.29 - 0.024 * (age-
53). cl3 = 0.836. k41 for tPeak = 1.6 min.(179,205)
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2.4.3.2 Minto 
For remifentanil, Minto et al. have developed a PKPD model, including weight, length, age 
and lean body mass as covariates.(205,210,211) In agreement with the short acting 
pharmacological profile, this model is characterized by a small central volume of distribution 
(around 25L) and a large elimination clearance (about 3L/min). The influence of lean body 
mass is more important than weight as such. This is reflected in the clinical experience with 
remifentanil. If remifentanil is given to the obese patient, using a traditional pump, the 
anesthetist should calculate the dose rather with “lean body mass” in stead of using “total 
body weight”. 
The model parameters for remifentanil are summarized here:(210) 
A = (age-40). L = (lbm-55)  
Vc = 5.1 - 0.0201 * A + 0.072 * L 
Cl1 = 2.6 - 0.0162 * A + 0.0191 * L 
V2 = 9.82 - 0.0811 * A + 0.108 * L 
Cl2 = 2.05 - 0.0301 * A 
V3 = 5.42 
Cl3 = 0.076 - 0.00113 * A 
k41 = 0.595 - 0.007 * A 
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2.5 Statistical methodology 
Although statistical methods used in this thesis are explained in the respective “methods 
and materials” sections of the publications, two advanced analyzing techniques will be 
discussed more in depth, as they are not widely known by many researchers. 
2.5.1 Prediction probability (PK)
A recurrent problem in the datasets presented in this thesis is the need for a measure of 
accuracy for different dependent variables (= indices of cerebral hypnotic drug effect, using 
different units and scales) to predict the same ordinal independent variable (=observed 
anesthetic drug effect). In the setting of this thesis, a candidate anesthetic depth indicator is 
judged against a "gold standard" endpoint of hypnotic drug effect. As explained before, the 
clinical endpoints of anesthetic effect are either dichotomous, when evaluating the 
response to a single stimulus, or polytomous at best, when evaluating the response to a 
sequence of gradually more intense stimuli. Additionally, the “golden standard” might be a 
drug effect-site concentration too. 
Warren Smith suggested the use of prediction probability (PK) as an objective measure of 
accuracy for comparing monitors of hypnotic drug effect.(212,213) PK  is a rescaled version 
derived from Kim’s dy.x measure of association that generalizes non-parametric receiver 
operating characteristic (ROC) area for a polytomous ordinal variable. The original output of 
Kim’s measure of association ranged between 1 and -1, reflecting a direct or reverse 
correlation in the behavior between variables. In contrast, PK ranges between 0 and 1. If PK
has a value of 1, it means that the indicator predicts the observed anesthetic depth 
perfectly. If  PK has a value of 0.5, it means that the indicator predicts no better than a 
50:50 chance. PK was developed to avoid the negative values of Kim’s measure of 
association. These are not valid in the setting of neurophysiologic monitoring, as we expect 
the index to evolve in a monotonous way, when the anesthetic state is intensified. 
According to Warren Smith, PK avoids many shortcomings of other measures. For example, 
as a nonparametric measure, PK is independent of scale units and does not require 
knowledge of underlying distributions or efforts to linearize or to otherwise transform scales. 
Furthermore, PK can be computed for any degree of coarseness or fineness of the scales 
for anesthetic depth indicator value and observed anesthetic depth. Consequently, PK fully 
uses the available data without imposing additional arbitrary constraints, such as the 
dichotomization of either scale. And finally, PK can be used to perform both grouped- and 
paired-data statistical comparisons of anesthetic depth indicator performance.(212,213) An 
important shortfall of PK is that data must be gathered via the same response-to-stimulus 
test procedure and over the same distribution of anesthetic depths. Therefore, PK results 
can not be compared between studies using different independent variables. Additionally, 
very high PK results can be obtained easily when endpoints are chosen wide apart in the 
clinical spectrum of hypnotic drug effect. For example, the PK for an anesthetic depth 
indicator that has to predict “the awake patient” at one hand, versus the “unresponsive 
patient to a painful stimulus” at the other hand, will probably be 1. Such a result does not 
allow a subtle comparison between measures. Therefore, apart from the analyzing 
technique chosen, the methodology for data acquisition is equally important when 
evaluating the clinical use of monitors. 
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The algorithm for PK calculation has been distributed freely by Warren Smith as an “Excel®” 
macro, which has become widespread in the world of pharmacological and 
neurophysiologic research centres.   
2.5.2 Non Linear Mixed Effects Modeling (NONMEM) 
Non Linear Mixed Effect Modeling (NONMEM) is a computer program that originally has 
been developed by Stuart Beal and Lewis Sheiner at the University of San Francisco 
(UCSF), California. It is currently distributed by “Globomax”, a subdivision of “Icon’s 
development solutions” (Ellicott City, MD, USA). It has been developed to allow “non-linear 
mixed effects modeling” on a dataset, as an advanced alternative for the classic “naive 
pooled approach” or the intermediate “two stage approach” for population data analysis. 
Due to the background of both inventors, the program is currently mainly applied in 
pharmacokinetic and pharmacodynamic model building. However, in theory, any dataset in 
which the underlying relationship can be expressed as a mathematical model can be 
investigated by NONMEM. 
A limited amount of competitive software is currently available for mixed effect modeling, 
but NONMEM appears to have become the “standard” for phase 1 and 2 pharmacological 
research. It is an important analyzing method for drug approval procedures as defined by 
the Food and Drug Administration in the USA. 
What are mixed effects? And what makes them so important that they are included in the 
programs’ name? To answer this question, some background information is mandatory. 
The result of any scientific experiment can be characterized as arising from a fundamental 
relationship. The purpose of the experiment is usually to deduce this underlying 
relationship. This is called the “structural model”. It is in fact a mathematical equation that 
relates the input (the dependent variable) to the output (the independent variable). In a 
population of individuals, the structural model includes certain “fixed effects”. Fixed effects 
are features that you can determine or measure in the individuals, such as weight, height, 
gender etc… The fixed effects help the model account for how individuals vary within the 
population. Hypothetically, if we know all “fixed effects” that determine the variability 
between individuals we should be able to construct a mathematical equation that perfectly 
predicts the outcome of an identical experiment in any individual.  
However, in any scientific experiment, there are also “random effects”. They are called 
“random” because they can not be predicted in any way. One kind of random effect is the 
unexplained differences between individuals. This is caused by the natural reality of 
“biological variability”, which can not be considered as noise in the dataset as it will never 
be possible to avoid it. A second random effect is caused by residual error in the 
measurement. This is noise in the dataset that can theoretically be minimized by improved 
measurement methods. Although both versions of random effects can not be predicted, 
they arise from a distribution that is, in theory, identifiable by exploring the dataset. The 
MEM in NONMEM stands for “mixed effects modeling”. That means that NONMEM enables 
to estimate both “fixed effects” (e.g. how do weight and age affect pharmacokinetics?), and 
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 two versions of “random effects”: the intra-individual variability (noise) versus the 
interindividual variability (biological variability). These random effects can not be predicted 
in advance (they are random!). But we can use NONMEM to estimate the magnitude 
(variance) of the random effects. (e.g. “How much variability is there in the measurements, 
once the fixed effects are accounted for?” or “How much does clearance in the population 
vary, once the fixed effects are accounted for?”) For variance estimation, NONMEM 
typically considers the “random” distributions to be normal, with a mean of 0.  
In this thesis, we used NONMEM to explore the pharmacodynamic relationship between 
several neurophysiologically derived indices of cerebral hypnotic drug effect (= dependent 
variable) with the calculated effect-site concentration of propofol (= independent variable). 
This relationship classically is described by a sigmoidal Emax model. This model is 
determined by four variables. The baseline effect (E0), the maximum effect (Emax), the 
effective dose compatible with 50% of the maximum effect (ED50) and the slope of the 
sigmoidal curve. We used NONMEM to estimate the typical values for these four variables. 
Additionally, we quantified the intra- and interindividual variability, by estimating the 
respective variances for these random effects. Finally, NONMEM provides a tool (called 
“the objective function”) that allows us to compare several estimated models on the same 
dataset, in order to determine the most optimal parameter estimation.  Greatly simplified, 
the “objective function” should be minimized, as it reflects the mathematical process that 
aims to minimize the -2 log likelihood of the fit of the model to the observed dataset. We 
used this method in our studies to find the optimal set of parameters for describing a 
sigmoidal Emax model within our dataset.  
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 3.1.1 Introduction 
An adequate monitor of hypnotic drug effect is able to discriminate between the presence 
and absence of clinical signs of hypnotic drug effect. The validation for AAI in propofol mono-
anesthesia conditions was already published by Struys et al.(1) Other authors however 
indicated that during combined administration of opioids and hypnotics, the threshold 
compatible with the “point of loss of consciousness” shifted to higher values for BIS and AAI, 
whereas it decreased for CePROP#. Consequently, questions were raised if this shift in 
threshold was accompanied by a decreased sensitivity or predictive value of these indices to 
detect progressively increasing levels of hypnotic drug effect.(2-4) 
 
Therefore, we investigated the ability of the AAI to discriminate several clinical endpoints of 
hypnotic drug effect in pseudo-steady state anesthesia, both during mono-anesthesia with 
propofol, as during combined remifentanil-propofol administration. The independent clinical 
endpoints were defined as:  the “loss of response to name calling” as described by a 
transition from level 3 to 2 on the OAA/S scale, the “loss of eyelash reflex” and the “loss of 
response to a painful stimulus”.(5) We compared the performance of AAI to detect these 
clinical endpoints with BIS and CePROP. The quality of this study results from the TCI 
“pseudo” steady state conditions, maintained during clinical measurements. Moreover, by 
comparing three groups with different doses of remifentanil, a potential impact of the 
potentiating interaction between remifentanil and propofol, on the detection sensitivity of the 
tested monitors could be explored. 
 
A second reason for the high value of our study is the specific choice for advanced statistical 
analysis of the dataset. We used prediction probability (PK) analysis, Probit analysis and 
thorough sensitivity/specificity analysis. PK analysis is developed by Smith et al to allow 
comparison between dependent variables with different units of measure, in their ability to 
detect multiple (polytomous) independent variables.(6,7) This methodology is explained more 
in depth, both in the “statistical analysis” section of the manuscript (p804), as in chapter 2 of 
this thesis. 
 
In an appendix, we used an ordinal logistic regression model to prove that the prediction 
probability for detection of the OAA/S scale improves by combining neurophysiologic 
measures (BIS or AAI) with pharmacologic predictions (CePROP and CeREMI), as compared to 
the solitary measurement of  these independent variables. This additional result proves that 
combining AAI or BIS with TCI technology is worthwhile, as this approach results in an 
improved anesthetic drug titration.  
 
#
 CePROP = the predicted effect-site concentration of propofol, as calculated by the PKPD model of Schnider 
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Ability of the Bispectral Index, Autoregressive Modelling
with Exogenous Input–derived Auditory Evoked Potentials,
and Predicted Propofol Concentrations to Measure Patient
Responsiveness during Anesthesia with Propofol and
Remifentanil
Michel M. R. F. Struys, M.D., Ph.D.,* Hugo Vereecke, M.D.,† Annelies Moerman, M.D.,†
Erik Weber Jensen, M.Sc., Ph.D.,‡ David Verhaeghen, M.D.,§ Nicolaas De Neve, M.D.,§ Frank J. E. Dumortier, M.D.,
Eric P. Mortier, M.D., D.Sc.#
Background: This study was conducted to compare the per-
formance accuracy of the independent variables Bispectral In-
dex (BIS), A-Line ARX index (AAI), and predicted propofol ef-
fect-site concentration (CePROP) to measure the dependent
variables of loss of responses to different stimulation deﬁned as
loss of response to verbal command (LORverbal), eyelash reﬂex
(LORlash), and noxious stimulus (LORnoxious) during stepwise
increased levels of propofol infusion with and without
remifentanil.
Methods: Forty-ﬁve patients were randomly allocated to one
of three groups (0, 2, and 4 ng/ml remifentanil) to receive
graded CePROP and predicted effect compartment controlled
remifentanil (CeREMI). At every step, the ability to respond to
verbal command using the Observer’s Assessment of Alertness/
Sedation Scale (OAA/S), eyelash reﬂex, and electrical tetanic nox-
ious stimulus were compared against BIS, AAI, and CePROP. Pre-
diction probability and sensitivity/speciﬁcity were calculated.
Results: Increasing CeREMI increased BIS and AAI values at
LORverbal and LORlash and decreased CePROP. Similar ﬁndings
were found for LORnoxious. The overall prediction probability to
measure the hypnotic component of anesthesia remained accu-
rate in the three groups for BIS, AAI, and CePROP. Combined
information from CePROP, CeREMI, and BIS or AAI increased
the overall prediction probability for predicting the OAA/S scale
and LORlash. Less accuracy to LORnoxious was found in all inde-
pendent variables.
Conclusions: Although BIS, AAI, and CePROP were inﬂuenced
by remifentanil during propofol administration, their ability to
detect OAA/S and LORlash remained accurate. Improved perfor-
mance is obtained when BIS and AAI are measured in conjunc-
tion with drug targeted effect-site concentrations. Remifentanil
decreases the ability of these independent variables to detect
LORnoxious.
BOTH electroencephalography- and midlatency auditory
evoked potential (MLAEP)–derived variables have been
proposed as measures of the hypnotic state during anes-
thesia.1 For the electroencephalography, the Bispectral
Index (BIS) incorporated in the A-2000 BIS® monitor
(Aspect Medical Systems, Inc., Newton, MA) has been
proven to have a high sensitivity and speciﬁcity to mea-
sure anesthetic drug effect, compared with other pro-
cessed electroencephalographic variables.2–4 Previously,
MLAEP has been used by various investigators to study
anesthetic depth.5 Recently, Jensen et al.6,7 developed a
new method for extracting the MLAEP from the electro-
encephalographic signal by using an autoregressive
model with an exogenous input (ARX) adaptive model.
This method allows extraction of the MLAEP signal
within 15–25 sweeps of 110 milliseconds’ duration each,
resulting in only a 6- to 15-s response delay time. A new
monitoring variable, called the A-Line ARX index (AAI),
is then calculated from this fast extracted MLAEP wave.
This new technology is incorporated in a recently com-
mercialized system called A-Line® (Danmeter A/S,
Odense, Denmark). Recently, Struys et al.8 compared
the accuracy of both BIS and AAI for measuring loss of
responses to different stimulation deﬁned as loss of ver-
bal command (LORverbal), loss of eyelash reﬂex (LORlash),
and loss of response to noxious stimulus (LORnoxious)
during steady state propofol administration. We found
that BIS, AAI, and predicted effect-site concentration of
propofol (CePROP) revealed a similar level of infor-
mation on LORverbal and LORlash but did not predict
LORnoxious. Also, AAI has recently been shown to reliably
assess the level of consciousness during propofol,8,9
sevoﬂurane,10 and midazolam11 anesthesia. The BIS cor-
related better to propofol plasma concentrations than
AAI, but AAI correlated better than BIS to the clinical
signs during recovery from propofol anesthesia.11
In previous work done with the AAI, propofol was
administered solely. Although a clear pharmacodynamic
interaction between remifentanil and propofol has been
described,12 controversy still exists on the inﬂuence of
opiates on the accuracy of both BIS and MLAEP to mea-
sure loss of response to different stimulation.13–16 Dur-
ing remifentanil monoinfusion, AAI measured changes in
patients’ level of arousal better than BIS.17 However, in
this study, a different electrode position was used,
where the AEP was recorded between a frontal () and
an occipital electrode (). It is possible that a change in
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montage such as this could lead to signiﬁcantly different
results compared with those from the current study.
A fundamental question is whether the electroenceph-
alograph- or AEP-derived variables can be used to opti-
mize drug delivery. A ﬁrst step to answer this question is
to examine the performance and accuracy of these mon-
itors under various conditions and to compare them
with the accuracy and usefulness of on-line calculated
drug effect-site concentration. A secondary question is
how opiates affect these performance parameters. This
study was conducted to assess the performance accu-
racy of the AAI to reﬂect the hypnotic component of
anesthesia and to measure loss of responses to different
stimulation deﬁned as LORverbal, LORlash, and LORnoxious
during stepwise increased levels of propofol infusion
with and without remifentanil. The performance of AAI
was compared with that of BIS and CePROP.
Materials and Methods
After Institutional Ethics Committee (Ghent University
Hospital, Gent, Belgium) approval, informed consent
was obtained from 45 female patients with American
Society of Anesthesiologists class I, aged 18–60 yr, who
were scheduled to undergo ambulatory gynecologic sur-
gery. Exclusion criteria included weight less than 70% or
more than 130% of ideal body weight, neurologic disor-
der, and recent use of psychoactive medication, includ-
ing alcohol. They were randomly allocated to one of the
three groups. In all groups, patients received a “stair-
case” computer-controlled infusion of propofol targeting
the effect compartment. Initially, an effect-site concen-
tration of 1.5 g/ml was targeted in the group without
remifentanil, and 1 g/ml was targeted in the two other
groups; this was increased every 4 min by 0.5 g/ml
until loss of response to all relevant clinical measures of
anesthetic depth was observed. In the 0 ng/ml remifen-
tanil group, no remifentanil was given. In the 2 ng/ml
and 4 ng/ml remifentanil groups, an effect compartment
controlled infusion of remifentanil was started 4 min
before the start of propofol. Calculated remifentanil ef-
fect-site concentrations (CeREMI) of 2 and 4 ng/ml were
targeted, respectively.
Propofol and remifentanil were administered via a
computer-assisted continuous infusion device to a target
effect-site concentration (RUGLOOP**) using a three-
compartment model enlarged with an effect-site com-
partment. For propofol, the pharmacokinetic–dynamic
model previously published by Schnider et al.18,19 was
used. For remifentanil, the pharmacokinetic–dynamic
model previously published by Minto et al.20,21 was
used. CePROP was computed to yield a time-to-peak
effect22 of 1.6 min after bolus injection, as also published
by Schnider et al.18,19 and clinically conﬁrmed by Struys
et al.23 For remifentanil, a t1/2ke0 of 1.020619 min was
applied as published by Minto et al.20,21 Propofol and
remifentanil infusion were administered using a Frese-
nius Modular DPS Infusion Pump connected to a Frese-
nius Base A (Fresenius Vial Infusion Systems, Brézins,
France). RUGLOOP steers the pump at infusion rates
between 0 and 1,200 ml/h via an RS-232 interface. By
using this infusion technique, we were able to obtain a
steady state condition for both propofol and remifentanil
at every target level after 4 min of infusion. Hereby,
steady state is deﬁned as the equilibration between the
calculated plasma and effect-site concentration of the
drug. Remifentanil and propofol were infused via a large
left forearm vein. Every patient received approximately
200 ml crystalloid ﬂuid during the study period. No ﬂuid
load was given before induction. No patient received
preanesthetic medication. No other drugs were given.
All patients maintained spontaneous ventilation via a
facemask delivering 6 l/min O2.
Heart rate and noninvasive blood pressure, oxygen
saturation measured by pulse oximetry (SpO2), and cap-
nography were recorded at 1-min intervals using an AS3
monitor (Datex, Helsinki, Finland). BIS (version 3.4) was
derived from the frontal electroencephalogram (At-Fpzt)
and calculated by the A-2000 BIS® monitor using a BIS-
Sensor® (Aspect Medical Systems, Inc.). The smoothen-
ing time of the BIS® monitor was set at 15 s. The AAI
from the MLAEP was calculated using the A-Line® mon-
itor. The MLAEPs were elicited with a bilateral click
stimulus of 70 dB in intensity and 2 ms in duration. Three
electrodes (A-Line AEP electrodes; Danmeter A/S) were
positioned at the mid forehead (), left forehead (refer-
ence), and left mastoid (). The extraction of the MLAEP
using a short moving time average technique together
with an ARX model and the calculations of the AAI are
described elsewhere.8
Ten seconds before each increase in CePROP (after 4
min of infusion at the speciﬁc target effect-site concen-
tration), the independent variables of response (BIS, AAI,
and CePROP) were recorded. Immediately after that,
patient responsiveness to different stimuli was tested
using the dependent variables eyelash reﬂex, Observer’s
** RUGLOOP, written by Tom De Smet, M.Sc. (Medical Engineer, DEMED
Engineering, Temse, Belgium), and Michel M. R. F. Struys, M.D., Ph.D. (Professor
of Anesthesia, Ghent University, Gent, Belgium). More information available at
http://www.anesthesia-uzgent.be.
Table 1. Responsiveness Scores of the Modiﬁed Observer’s
Assessment of Alertness/Sedation Scale24
Score Responsiveness
5 Responds readily to name spoken in normal tone
4 Lethargic response to name spoken in normal tone
3 Responds only after name is called loudly and/or
repeatedly
2 Responds only after mild prodding or shaking
1 Responds only after painful trapezius squeeze
0 No response after painful trapezius squeeze
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Assessment of Alertness/Sedation Scale (OAA/S24; table
1), and response to electrical tetanus (at 100 Hz and
50 mA for 2 s; applied to the volar forearm level) assess-
ments, in that order. Verbal stimulation proceeded nox-
ious stimulus. Patients were considered responsive to
verbal stimulus if their OAA/S value was 3, 4, or 5 and
were considered unresponsive to verbal command at
OAA/S values of 0, 1, and 2. Transition between a re-
sponsive and an unresponsive state was deﬁned as loss
of response to verbal command (LORverbal). Loss of re-
sponse of eyelash reﬂex was deﬁned as LORlash. Patients
were considered responsive to noxious stimulus if they
responded to the tetanic electrical stimulation, regard-
less of whether they responded to trapezius squeeze
during the OAA/S assessment. Loss of response to tetanic
stimulus was deﬁned as LORnoxious.
Both BIS and AAI indices were also logged automati-
cally. RUGLOOP digitally recorded the BIS index every
10 s, and the A-Line monitor recorded AAI index values
nominally every 6 s. The time marks of both systems
were synchronized with the manual timing for stimulus
and manually recorded events to within 1 s.
Statistical Analysis
The signiﬁcance level was set at 5% unless otherwise
reported. The ability of the independent variables (BIS,
AAI, and CePROP) to detect the level of OAA/S, LORlash,
and LORnoxious was evaluated using prediction probabil-
ity (PK), which compares the performance of indepen-
dent variables with different units of measure, as devel-
oped by Smith et al.25,26 Consider a variable such as BIS
or AAI and a “deﬁnitive standard” measure of anesthetic
depth such as the multilevel OAA/S score or the two-
level responsiveness (yes/no) to eyelash reﬂex or nox-
ious stimulus. Then, a PK of 1 for the BIS or AAI variable
would mean that BIS or AAI always increases (decreases)
as the anesthesia gets lighter (deeper) according to the
deﬁnitive standard depth measure. Such an independent
variable can perfectly measure anesthetic depth. Alter-
natively, a PK value of 0.5 would mean that the indepen-
dent variable is useless for measuring anesthetic depth.
For the OAA/S score, a PK was computed for all OAA/S
levels combined. Similarly, PK values for LORlash and
LORnoxious were determined. The jackknife method was
used to compute the SE of the estimate, based on the
assumption that all assessments were independent.25,26
A Student t test with Bonferroni correction was used to
evaluate whether the PK for one variable was different
from another one. Signiﬁcance level was set at 0.0167.
Prediction probability was calculated using a custom
spreadsheet macro, PKMACRO, developed by Smith et
al.25,26 The PK value was calculated for each indepen-
dent variable in each group. A PK analysis for each
independent variable with the three groups pooled was
performed.
To study whether the combined information from BIS
and AAI together with the drug effect-site concentrations
offers more accurate information than the independent
variables alone, two new composite variables have been
designed based on the combined information from BIS
CePROP  CeREMI and AAI  CePROP  CeREMI, and
a PK analysis was performed on both composite vari-
ables. The OAA/S score was used as clinical comparator.
The PK on the combined information was calculated
using ordinal logistic regression, as described in the
Appendix.
The power on the PK values was calculated using a t
statistic deﬁned as the difference considered of clinical
importance divided by the SE of the difference between
two independent variables. Assuming a PK difference of
0.05 as being of signiﬁcant with an SE of 0.02, 15 pa-
tients should be included to ﬁnd signiﬁcant differences
with P  0.025 (Bonferroni correction for two t tests).
Previous assumption were based on previous results of
the AAI and other AEP-independent variables.27
By applying Probit analyses, the effective concentra-
tion or index at which 50% (ED50) and 95% (ED95) of the
patients reached LORverbal, LORlash, and LORnoxious were
calculated for all independent variables. For all indepen-
dent variables, ED50 and ED95 values were compared
between groups using one-way analysis of variance sta-
tistics. If signiﬁcant, an unpaired two-sided Student t test
with Bonferroni correction was used (P  0.0167).
We calculated cutoff (threshold) values for the ability
of the BIS, AAI, and CePROP to detect LORverbal, LORlash,
and LORnoxious in each group. For these calculations, we
used “positive” to denote a test result that suggested
responsiveness and “negative” to denote a test result that
suggested nonresponsiveness. We assumed that in-
creases in the BIS and AAI and a decrease in CePROP
corresponded to an increased likelihood of responsive-
ness. We computed sensitivity as the proportion of re-
sponsive patients with positive test results (value higher
than cutoff value for BIS and AAI and lower than cutoff
value for CePROP). Similarly, we computed speciﬁcity as
the proportion of nonresponsive patients with negative
test results (value lower than cutoff value for BIS and AAI
and higher than cutoff value for CePROP). We computed
the cutoff values for each independent variable and spec-
iﬁcity at a level of 100% sensitivity and at which the sum
of sensitivity and speciﬁcity were highest. The same
sensitivity/speciﬁcity analyses were performed for com-
posite variables.
Results
The demographics (mean  SD) of the 45 female
patients in the three groups are shown in table 2. No
signiﬁcant demographic differences were found be-
tween groups.
Figures 1A and B show the behavior of BIS and AAI
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versus CePROP and CeREMI. The correlation coefﬁcient
between BIS and the drug effect-site concentrations (r
0.92) was signiﬁcantly higher than for AAI (r  0.82). In
all groups, a stepwise increase in CePROP resulted in a
monotonic decrease in the OAA/S score. BIS and AAI
decreased in all groups with decreasing OAA/S scores, as
shown in ﬁgure 2.
Figures 3A–C show the behavior of BIS, AAI, and
CePROP at LORlash. For all independent variables, a sig-
niﬁcant decrease of the variable values between the
responsive and unresponsive state was observed in all
groups. The BIS, AAI, and CePROP values at LORnoxious
are plotted in ﬁgures 3D–F. In all groups, all independent
variables changed signiﬁcantly.
By applying Probit analyses, the effective BIS, AAI, or
CePROP at which 50% (ED50) and 95% (ED95) of the
patients produced a LORverbal, LORlash, and LORnoxious
were calculated and are shown in table 3. For all three
groups, the probability curves for the observations at
LORverbal, LORlash, and LORnoxious are shown in ﬁgures
4A–C for BIS, in ﬁgures 4D–F for AAI, and in ﬁgures
5A–C for CePROP.
The ability of the BIS, AAI, and CePROP to predict the
level of the OAA/S, LORlash, and LORnoxious as presented
by the PK values is shown in table 4. Overall, similar
performances were found for BIS, AAI, and CePROP. A
PK analysis for each independent variable with the three
groups pooled revealed similar ability to detect both the
Table 2. Antropometry
0 ng/ml
Remifentanil
2 ng/ml
Remifentanil
4 ng/ml
Remifentanil
Age, yr 33  5 33  5 34  4
Weight, kg 63  10 66  11 65  9
Height, cm 167  6 168  6 167  6
Fig. 1. Nonlinear regression analysis from the raw data from all
groups (0, 2, and 4 ng/ml remifentanil effect-site concentration
[Ce]) at different propofol effect-site concentrations. (A) Corre-
lation with the Bispectral Index (BIS); (B) correlation with the
A-Line ARX index (AAI).
Fig. 2. Raw data at every Observer’s Assessment of Alertness/
Sedation Scale (OAA/S) score for Bispectral Index (BIS; A), A-
Line ARX index (AAI; B), and propofol effect-site concentration
(Ce; C). Data from the 0 ng/ml remifentanil (Remi) group are
presented as black circles, data from the 2 ng/ml remifentanil
group as white circles, and data from the 4 ng/ml remifentanil
group as black triangles.
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OAA/S levels and LORlash. In contrast, the overall ability
for detection of LORnoxious was lower when pooling the
groups together.
By calculating the t statistic, we found that this study
including 15 patients for each group had the power to
determine signiﬁcant differences between independent
variables to predict OAA/S larger than 0.052, which is in
accordance with our initial assumption that only differ-
ences larger than 0.05 would be considered signiﬁcantly
different.
The PK values to detect the OAA/S level using the
combinations of input variables were better compared
to the PK values of pooled data for BIS, AAI, and CePROP
alone. For the composite index using the combination
BIS  CePROP  CeREMI, the PK value was 0.91 (SE 
0.01), and for the composite index using the combina-
tion AAI  CePROP  CeREMI, it was 0.93 (SE  0.01)
to detect the OAA/S level.
We also performed more in-depth sensitivity/speciﬁc-
ity analysis. Within the three groups, table 5 shows the
cutoff values for each independent variable at which the
sum of the sensitivity and speciﬁcity was the highest,
representing the independent variable value where the
Fig. 3. (A–C) Raw data for (no) response
to eyelash reﬂex for Bispectral Index
(BIS), A-Line ARX index (AAI), and propo-
fol effect-site concentration (Ce). (D–F)
Raw data for (no) response to noxious
stimulus for BIS, AAI, and propofol effect-
site concentration. *P < 0.05 for each
group between the responsive and non-
responsive states. Data from the 0 ng/ml
remifentanil (Remi) group are presented
as black circles, data from the 2 ng/ml
remifentanil group as white circles, and
data from the 4 ng/ml remifentanil group
as black triangles.
Table 3. ED50 (95% CI)/ED95 Values of BIS, AAI, and EC50 (95%
CI)/EC95 Propofol for All Groups at LORverbal, LORlash, and
LORnoxious
Group I: 0 ng/ml
Remifentanil
Group II: 2 ng/ml
Remifentanil
Group III: 4 ng/ml
Remifentanil
LORverbal
AAI 26 (25–28)/20*§ 33 (31–34)/18*§ 40 (39–42)/25*§
BIS 61 (60–62)/55*§ 66 (65–68)/58*§ 77 (75–78)/65*§
CePROP 2.9 (2.7–3.1)/3.8* 2.4 (2.2–2.6)/3.1* 2.0 (1.8–2.2)/2.7*
LORlash
AAI 34 (33–36)/21†‡ 56 (55–58)/44†‡ 56 (54–58)/32†‡
BIS 67 (65–68)/55*‡ 80 (79–82)/66*‡ 84 (82–85)/71*‡
CePROP 2.8 (2.5–3.0)/3.4† 1.8 (1.7–2.0)/2.6† 1.7 (1.6–1.9)/2.5†
LORnoxious
AAI 16 (15–17)/11*‡ 42 (40–44)/23*‡ 55 (53–57)/27*‡
BIS 41 (40–43)/29*‡ 72 (70–73)/56*‡ 85 (84–87)/68*‡
CePROP 4.1 (3.8–4.4)/6.6*# 1.8 (1.4–2.1)/3.8*# 1.3 (1.1–1.5)/3.3*#
* P  0.0167 for ED50 levels between all groups. † P  0.0167 for ED50
levels between group I vs. II and I vs. III. ‡ P  0.0167 for ED95 levels
between all group. § P  0.0167 for ED95 levels between group I vs. III and
II vs. III.  P  0.0167 for ED95 levels between group I vs. III. # P  0.0167
for ED95 levels between group I vs. II and I vs. III.
AAI  A-Line ARX index; BIS  Bispectral Index; CePROP  calculated
propofol effect-site concentration; LORlash  loss of eyelash reﬂex;
LORnoxious  loss of response to electrical tetanic stimulus; LORverbal 
loss of response to verbal command.
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overall “errors” are minimized.28 Table 6 shows the dif-
ferent cutoff values and their speciﬁcity at level of 100%
sensitivity. When using the combined information of BIS
or AAI together with CePROP and CeREMI, the sensitiv-
ity/speciﬁcity proﬁles were more accurate. For both
combinations, the best sensitivity-versus-speciﬁcity com-
binations were found at 100% sensitivity for 82%
speciﬁcity.
Table 7 shows at which average OAA/S score at
LORlash and LORnoxious occurred in each of the three
groups. The OAA/S is an ordinal scale, but it was con-
sidered continuous to be able calculate an average of
OAA/S score with a decimal value.
Discussion
This study was conducted to compare the perfor-
mance accuracy of the independent variables BIS, AAI,
and CePROP to measure anesthetic depth and how opi-
ates quantitatively inﬂuence this information. Therefore,
we observed the inﬂuence of remifentanil on the accu-
racy of the AAI, a new index calculated from the MLAEP,
to reﬂect the hypnotic component of anesthesia (mea-
sured by the different levels of the OAA/S) and to mea-
sure loss of responses to different stimulation deﬁned as
LORverbal, LORlash, and LORnoxious during stepwise in-
creased levels of propofol infusion with and without
remifentanil. The performance of AAI was compared
with that of BIS and CePROP.
In previous work, our group concluded that, during
propofol anesthesia (without opiates) under steady state
conditions, BIS, AAI, and CePROP were accurate inde-
pendent variables to measure the hypnotic component
of anesthesia and loss of responsiveness to different
stimuli. Hemodynamic variables did not perform accu-
rately enough to measure the hypnotic–anesthetic status
of the patient. BIS correlated best with CePROP, fol-
lowed by the AAI. Hemodynamics did not correlate
well.8 To study the hypnotic component of anesthesia,
two clinical measures (also called dependent variables)
were used. We selected the OAA/S score because it
provides a good correlation with a clinical reﬂection of
the hypnotic component of anesthesia and has been
Fig. 4. Probability of loss of response to verbal commend (LOR-
verbal), eyelash reﬂex (LORlash) and a tetanic electrical stimulus
(LORnoxious) as a function of Bispectral Index (BIS) and A-Line
ARX index (AAI). Data from the 0 ng/ml remifentanil (Remi)
group are presented as a solid line, data from the 2 ng/ml
remifentanil group as a dotted line, and data from the 4 ng/ml
remifentanil group as a dashed line.
Fig. 5. Probability of loss of response to verbal commend
(LORverbal), eyelash reﬂex (LORlash), and a tetanic electrical
stimulus (LORnoxious) as a function of the propofol effect-site
concentration (Ce). Data from the 0 ng/ml remifentanil (Remi)
group are presented as a solid line, data from the 2 ng/ml
remifentanil group as a dotted line, and data from the 4 ng/ml
remifentanil group as a dashed line.
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tested prospectively.29 Also, loss of eyelash reﬂex was
used because it is a simple binary variable and commonly
applied by anesthesiologists in clinical practice to detect
loss of consciousness.14
In all groups, a stepwise increase in CePROP resulted
in a monotonic decrease in BIS and AAI as shown in
ﬁgure 1. Similar to our previous work using propofol
alone,8 the correlation between BIS and the combined
drug effect-site concentrations was higher than for the
AAI. In all groups, a monotonic decrease in both BIS and
AAI was observed at decreasing OAA/S levels as shown
in ﬁgure 2. Similar ﬁndings were found for LORlash, as
seen in ﬁgures 3A–C.
LORverbal and LORlash were reached at higher indepen-
dent variable values in a dose-dependent manner when
adding remifentanil. This can be concluded from the
Probit analyses shown in ﬁgure 4 and the extracted ED50
and ED95 as seen in table 3. Although some differences
between groups for the ED50 and ED95 did not reach the
level of signiﬁcance, a clear trend could be observed.
Our results are in contrast with the ﬁndings from Iselin-
Chaves et al.,30 who reported no signiﬁcant inﬂuence of
opiates on the BIS and MLAEP to detect the probability
of loss of consciousness and lack of recall by using the
OAA/S score. However, they used lower concentrations
of opiates (50 and 100 ng/ml alfentanil; potency ratio
alfentanil:remifentanil around 40:1). Recently, Mi et al.14
also found that when applying fentanyl pretreatment
during propofol administration, the hypnotic endpoints
were achieved at higher BIS values. The addition of
remifentanil potentiates the effect of propofol. LORverbal
and LORlash were detected at lower CePROP in the 2 and
4 ng/ml remifentanil groups compared to the 0 ng/ml
remifentanil group, as shown in ﬁgure 5. Also, EC50 and
EC95 propofol decreased signiﬁcantly or tended to de-
crease in a remifentanil dose-dependent matter, as also
described previously by others.31
A possible bias might have been caused by the inﬂu-
ence of opiates on the clinical dependent variables. Both
Table 6. Cutoff Values (Speciﬁcity) at Level of 100% Sensitivity
0 ng/ml
Remifentanil
2 ng/ml
Remifentanil
4 ng/ml
Remifentanil
LORverbal
AAI 19 (58%) 15 (5%) 26 (41%)
BIS 53 (58%) 61 (52%) 65 (55%)
CePROP 4.0 (39%) 3.5 (14%) 3.0 (23%)
LORlash
AAI 23 (63%) 38 (59%) 27 (37%)
BIS 53 (46%) 68 (65%) 70 (53%)
CePROP 3.5 (63%) 3.0 (32%) 2.5 (53%)
LORnoxious
AAI 13 (14%)* 15 (7%) 26 (27%)
BIS 29 (7%) 57 (21%) 65 (27%)
CePROP 7.0 (7%) 3.5 (21%) 3.0 (13%)
* At the 98% sensitivity level.
AAI  A-Line ARX index; BIS  Bispectral Index; CePROP  calculated
propofol effect-site concentration; LORlash  loss of eyelash reﬂex;
LORnoxious  loss of response to electrical tetanic stimulus; LORverbal  loss
of response to verbal command.
Table 4. Prediction Probability (PK) Described as Mean (SE) for Each Independent Variable (BIS, AAI, and CePROP) Using OAA/S,
LORlash, and LORnoxious
0 ng/ml Remifentanil 2 ng/ml Remifentanil 4 ng/ml Remifentanil Pooled Data
OAA/S
AAI 0.88 (0.02) 0.87 (0.02) 0.88 (0.02) 0.87 (0.01)
BIS 0.93 (0.01) 0.90 (0.02) 0.88 (0.02) 0.90 (0.01)
CePROP 0.92 (0.02) 0.92 (0.03) 0.92 (0.02) 0.90 (0.01)
LORlash
AAI 0.94 (0.02) 0.96 (0.02) 0.87 (0.04) 0.94 (0.01)
BIS 0.96 (0.02) 0.92 (0.03) 0.94 (0.04) 0.95 (0.01)
CePROP 0.94 (0.02) 0.95 (0.02) 0.94 (0.02) 0.93 (0.01)
LORnoxious
AAI 0.87 (0.04)* 0.86 (0.04)* 0.81 (0.05)* 0.72 (0.03)
BIS 0.88 (0.05)* 0.86 (0.05) 0.86 (0.04)* 0.75 (0.03)
CePROP 0.83 (0.06) 0.86 (0.04)* 0.87 (0.04)* 0.72 (0.03)
* P  0.05 compared to pooled data PK.
AAI  A-Line ARX index; BIS  Bispectral Index; CePROP  calculated propofol effect-site concentration; OAA/S  Observer’s Assessment of Alertness/
Sedation Scale; LORlash  loss of eyelash reﬂex; LORnoxious  loss of response to electrical tetanic stimulus.
Table 5. Cutoff Values (Sensitivity [%]–Speciﬁcity [%]; Sum of
Sensitivity  Speciﬁcity [%]) at Maximum Level of
Sensitivity  Speciﬁcity whereby Sensitivity > Speciﬁcity
0 ng/ml
Remifentanil
2 ng/ml
Remifentanil
4 ng/ml
Remifentanil
LORverbal
AAI 29 (91–91; 182) 42 (82–81; 163) 41 (93–86; 179)
BIS 61 (99–94; 193) 64 (95–76; 171) 79 (85–82; 167)
CePROP 3.5 (99–76; 175) 3.0 (98–57; 155) 2.5 (96–64; 160)
LORlash
AAI 34 (90–88); 178) 47 (96–82; 178) 47 (96–77; 173)
BIS 67 (90–88; 178) 75 (89–85; 174) 84 (89–87; 176)
CePROP 3.0 (92–85; 177) 2.5 (98–68; 166) 2.0 (87–83; 170)
LORnoxious
AAI 20 (76–64; 140) 40 (92–71; 163) 59 (84–67; 151)
BIS 44 (84–71; 155) 75 (76–71; 147) 90 (77–73; 150)
CePROP 4.0 (80–71; 151) 2.5 (88–50; 138) 2.5 (95–40; 135)
AAI  A-Line ARX index; BIS  Bispectral Index; CePROP  calculated
propofol effect-site concentration; LORlash  loss of eyelash reﬂex;
LORnoxious  loss of response to electrical tetanic stimulus; LORverbal  loss
of response to verbal command.
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OAA/S (from level 2 to 0) and eyelash reﬂex use tactile
stimuli, which might have been lost earlier when adding
remifentanil. To demonstrate this, the averaged OAA/S
scores at LORlash and LORnoxious were calculated and are
shown in table 7. LORlash results showed some increase.
A clear increase in the OAA/S value is observed when
remifentanil is added. In the 2 and 4 ng/ml remi-
fentanil groups, several patients were still responsive at
LORnoxious. This resulted in larger transitions when the
transition between the response and the unresponsive
state, for example, from OAA/S 3 to OAA/S 0 without
passing through OAA/S levels 2 or 1, causing an increase
in averages. This ﬁnding obviously conﬁrms that
remifentanil blocks the response to pain, without caus-
ing LORverbal and LORlash, but proves also that it might be
difﬁcult to quantify the dependence of the electronic
independent variables such as BIS and AAI to opiates
because the deﬁnitive standard to which they were com-
pared changed its behavior through the groups. This fact
highlights that care should be taken when validating loss
of response to different stimuli by using OAA/S score or
eyelash reﬂex when opioids are administered. However,
because no better validated clinical scoring techniques
exist at this moment, we have to accept this possible
bias.
Skepticism still exists in the literature regarding the
accuracy of cerebrally derived parameters to measure
anesthetic depth when adding opiates. Several articles
suggested a weaker correlation between BIS and
CePROP in the presence of opiates.14,32,33 Although they
state that this might reveal the importance of an analge-
sic component on the efﬁcacy of depth-of-anesthesia
electronic monitors, these studies did not apply speciﬁc
statistical techniques such as prediction probability25 or
speciﬁcity/sensitivity calculations.1 Also, one should
clearly differentiate the phenomenon of the inﬂuence of
opiates on the changes in cutoff values for LORverbal,
LORlash, and LORnoxious and the overall change in accu-
racy of these anesthetic depth independent variables
when adding opiates.
The prediction probability, PK, provides a good alter-
native to investigate the overall relative performance of
the different independent variables to measure the hyp-
notic component of anesthesia and loss of responsive-
ness to different stimuli.25 For BIS, Lysakowski et al.34
found no decrease in PK when adding clinical dosages of
fentanyl, alfentanil, remifentanil, or sufentanil versus pla-
cebo during propofol administration. Iselin-Chaves et
al.16 studied the inﬂuence of different dosages of alfen-
tanil on the accuracy of both BIS and nonprocessed
MLAEP during propofol administration and found no
differences in PK between groups. In their study, BIS
performed better than MLAEP. In our study, as indicated
in table 4, the performance results indicate that both BIS
and AAI are reliable independent variables for assessing
the level of OAA/S and LORlash and did not decrease by
the addition of remifentanil. Before being able to con-
clude that the ability to measure the hypnotic compo-
nent remained intact, a PK analysis with the three groups
pooled was needed. As seen in table 4, the PK remained
similar to the group-based PK for both OAA/S and LOR-
lash, indicating an overall equal accuracy of the indepen-
dent variables with and without the addition of opiates.
At the level of signiﬁcance used in our study, BIS and
AAI were found to be comparable in performance to the
estimated steady state propofol concentration, CePROP.
When drug effect-site concentrations are known, one
might argue that it only make sense to measure BIS or
AAI if the combined information offers more accuracy in
measuring depth of anesthesia than a single measure
alone. Vice versa, it might be asked whether drug effect-
site concentrations offer additional information for the
clinician when BIS or AAI is used. However, it must be
stated that electroencephalographic and MLAEP moni-
tors can be attached to the patient at any random time,
whereas calculation of drug effect-site concentration re-
quires knowledge of the complete administration his-
tory. As none of the independent variables in the present
study gave a PK larger than 0.9, when pooling the data
from the three groups into one, it could be interesting to
explore whether a new independent variable deﬁned as
a composite of the electronic independent variables and
the anesthetics concentrations would produce a larger
PK when predicting the OAA/S. Therefore, we calculated
the PK value for the combined information from both
BIS CePROP CeREMI and AAI CePROP CeREMI
using ordinal logistic regression to develop a predicted
OAA/S score (see Appendix). For both combinations,
the overall prediction probability for predicting the lev-
els of OAA/S increased (or tended to increase) compared
to the pooled PK data.
Because the PK concept was developed to generalize
nonparametric receiver operating characteristic curves
area to polytomous ordinal patient state,26 we thought it
was interesting to observe some speciﬁc sensitivity/spec-
iﬁcity characteristics for BIS, AAI, and CePROP. Statisti-
cally speaking, the most frequently applied combined
sensitivity/speciﬁcity lies at the elbow of the receiver
operating characteristic curve, where the sum of both
sensitivity and speciﬁcity is the highest.28 However, as
deﬁned by J. Drummond35 recently, a depth of anesthe-
Table 7. Averaged OAA/S Score at LORlash and LORnoxious
Group
OAA/S Level
at LORlash
OAA/S Level
at LORnoxious
0 ng/ml Remifentanil 3.6 0.87
2 ng/ml Remifentanil 4.2 3.4
4 ng/ml Remifentanil 4.1 4.0
* Average of 15 patients.
LORlash  loss of eyelash reﬂex; LORnoxious  loss of response to electrical
tetanic stimulus; OAA/S  Observer’s Assessment of Alertness/Sedation
scale.
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sia–independent variable should have, at a minimum, a
100% sensitivity (no false negatives) if what the clini-
cians seek is a speciﬁc numeric threshold (cutoff value)
that can be interpreted to mean “not aware.” Therefore,
we observed the inﬂuence of remifentanil on the cutoff
value for LORverbal and LORlash and the corresponding
sensitivity/speciﬁcity proﬁles for BIS, AAI, and CePROP
at the two important points of the receiver operating
characteristic curves: (1) highest sum of sensitivity and
speciﬁcity and (2) level of 100% sensitivity. For both BIS
and AAI, the cutoff values at LORverbal and LORlash re-
vealing the highest sum of sensitivity/speciﬁcity clearly
increased in a dose-dependent manner during remifen-
tanil addition. However, the changes in the values of the
highest sum were minimal and similar between the dif-
ferent anesthetic depth–independent variables, as ob-
served in table 5. This means that the addition of
remifentanil did not decrease the overall sensitivity/spec-
iﬁcity proﬁles of the tested independent variables when
observing the cutoff value at the level of maximum
combined sensitivity and speciﬁcity. As shown in table 6,
the cutoff values detecting LORverbal and LORlash at the
100% sensitivity level were inﬂuenced by the addition of
remifentanil. For BIS, a trend toward higher cutoff values
at the 100% sensitivity level was observed at LORverbal
and LORlash. For AAI, the cutoff value only increased
in the 4 ng/ml remifentanil group when observing
LORverbal and slightly increased between the 0 and
2 ng/ml remifentanil groups, between the 0 and 4 ng/ml
remifentanil groups, and when observing LORlash. The
CePROP cutoff values decreased at this 100% sensitivity
level when adding remifentanil. For all independent vari-
ables, the inﬂuence of remifentanil on the speciﬁcity at a
level of 100% sensitivity was calculated. For the AAI, a
clear decrease in speciﬁcity was observed in the 2 ng/ml
remifentanil group when observing LORverbal, and a de-
crease between the 2 and 4 ng/ml remifentanil groups
was seen when observing LORlash. This might be caused
by the severity of the used statistical criterion, where
one outlier might cause a dramatic decrease in speciﬁc-
ity at the 100% sensitivity level. No decrease in speciﬁc-
ity was observed between groups for BIS when observ-
ing LORverbal and LORlash. Inconsistencies are found in
the data for CePROP when comparing the speciﬁcity
results obtained by LORverbal with these obtained by
using LORlash. Better sensitivity/speciﬁcity proﬁles were
obtained when the information from drug concentra-
tions and BIS or AAI were used together.
This study also tested the inﬂuence of opiates on the
performance of the independent variables to predict
LORnoxious. The supramaximal tetanic stimulus used in
this study was previously used by others as a substitute
for conventional forms of stimulation in humans.36 In
previous work, when only using propofol without opi-
ates, we observed that measures from the cerebral
cortex such as BIS and AAI were poor predictors for
LORnoxious.
8 The overall accuracy for LORnoxious tended
to be lower for all independent variables compared with
their hypnotic prediction accuracy. The PK values were
lower, however, because of the larger SE, not statistically
signiﬁcant at the level of signiﬁcance used in our study.
Sensitivity/speciﬁcity proﬁles for all independent vari-
ables in the three groups were calculated at the two
classic points. As seen in table 5, the values of the
highest sum of sensitivity and speciﬁcity to LORnoxious
were lower compared with the values for the detection
of LORverbal and LORlash. Also, the cutoff values at the
point of highest sensitivity/speciﬁcity were clearly inﬂu-
enced by the addition of remifentanil in a dose-depen-
dent manner. At the level of 100% sensitivity to detect
LORnoxious, a very low speciﬁcity and a clear inﬂuence of
remifentanil on the cutoff values was observed (table 6).
A strong interaction between propofol and remifen-
tanil is observed at the ED50 and ED95 levels when
studying the analgesic component of this interaction at
LORnoxious, as plotted in ﬁgure 5 and table 3. This inter-
action is more pronounced than the hypnotic interaction
between remifentanil and propofol, resulting in the fact
that in this “staircase study,” patients in the 2 and 4
ng/ml remifentanil groups might reach LORnoxious before
reaching LORverbal and LORlash, as shown in table 7.
Similar ﬁndings were observed for fentanyl and propofol
by Smith et al.37 and by Katoh et al.38 for fentanyl and
sevoﬂurane.
In conclusion, we found that although BIS, AAI, and
CePROP were increased by remifentanil during propofol
administration, their ability to detect OAA/S and LORlash
remained accurate. Improved performance is obtained
when BIS and AAI are measured in conjunction with
drug effect-site concentrations. Remifentanil decreases
the ability of these independent variables to detect
LORnoxious.
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Appendix: Deﬁnition of an OAA/S Predictor
Based on Combinations of AAI/BIS, Propofol,
and Remifentanil Effect Concentrations
Methods
Two composite indexes were deﬁned to study whether the com-
bined information BIS  CePROP  CeREMI or AAI  CePROP 
CeREMI offers more accuracy in loss of response to hypnotic stimuli
than a single measure alone (BIS, AAI, CeREMI, and CePROP). The
composite index was deﬁned as an OAA/S predictor based on com-
bined information from the data set BIS  CePROP  CeREMI or
AAI  CePROP  CeREMI. The method of choice for designing a
composite index was the ordinal logistic regression. The ordinal logis-
tic regression has the advantage, as compared with multiple linear
regression, that the output variable is ordinal. An ordinal variable is a
categorical variable that has three or more levels of natural ordering,
such as awake, drowsy, asleep, and deep asleep. This is suitable for the
kind of data from this study because the OAA/S scale is ordinal and not
linear. Two models were proposed: model A, where the input variables
are BIS, CePROP, and CeREMI; and model B, where the input variables
are AAI, CePROP, and CeREMI. The composite index is the output
variable that in both models is a prediction of the OAA/S as shown in
ﬁgures 6 and 7. The composite index is therefore ordinal in the 0–5
range as the OAA/S.
An ordinal logistic regression model was calculated by using SPSS
software (SPSS Inc., Chicago, IL), which also provides a more detailed
description of the method. The model is composed of constants, i,
factors, n, and a link function, here the “logit.” The constants are
associated with the ith event, which in the current study refers to the
level of OAA/S.
The factors are obtained from each covariable (input), which here
are BIS, AAI, CePROP, and CeREMI at every jth sample in time. Hence,
the two models are deﬁned in equations 1 and 2
Fig. 6. Model A for calculating the Observer’s Assessment of
Alertness/Sedation Scale (OAA/S) predictor from the combined
information Bispectral Index (BIS)  propofol effect-site con-
centration (CePROP)  remifentanil effect-site concentration
(CeREMI).
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g(OAAS ij) i remiCe Remii  CepropCepropj  BISBISj (1)
g(OAAS ij) i remiCe Remij  CepropCepropj  AIIAAIj. (2)
The accumulated probability of being at or lower than the ith level
of OAA/S at the jth sample in time, ij, is now calculated as
 ij
egOAASi
1eg(OAASi)
(3)
Example: The following state has been recorded: remifentanil 
0 ng/ml, propofol  4 g/ml, AAI  25. When using these data as
input to model B, the corresponding probabilities for OAA/S 0, 1, 2, 3,
4, and 5 are 0.7944, 0.8867, 0.9620, 0.9935, 0.9998, and 1. The model
output is always the OAA/S level, where the accumulated probability
exceeds 0.67. In this example, the predicted OAA/S is 0 because the
ﬁrst probability (0.7944) is larger than 0.67.
Results
Tables 8 and 9 show the parameters of the ordinal logistic regression
for models A and B, with the corresponding levels of signiﬁcance for
each constant and factor as well as the P value for the whole model. A
P value less than 0.05 means that the parameter is signiﬁcant in the
model. Both models were statistically signiﬁcant. The OAA/S values
predicted by the two models were compared with the measured
OAA/S and evaluated using the PK analysis, shown in table 10.
Fig. 7. Model B for calculating the Observer’s Assessment of
Alertness/Sedation Scale (OAA/S) predictor from the combined
information A-Line ARX index (AAI)  propofol effect-site con-
centration (CePROP)  remifentanil effect-site concentration
(CeREMI).
Table 8. Ordinal Logistic Regression of Model A (BIS)
Predictor Value SD Z P
1 3.718 1.851 2.01 0.045
2 2.995 1.850 1.62 0.105
3 1.832 1.853 0.99 0.323
4 0.109 1.868 0.06 0.954
5 3.228 1.896 1.70 0.089
remi 0.9548 0.1163 8.21 0.000
prop 2.6277 0.3395 7.74 0.000
bis 0.10034 0.01779 5.64 0.000
Test that all slopes are zero: P value  0.001.
1–5  constants of the ordinal logistic regression model used in the predic-
tion of the OAA/S levels 1 to 5; remi  coefﬁcient of the ordinal logistic
regression model multiplied with the remifentanil (remi) effect-site concentra-
tion in the prediction equation; prop  coefﬁcient of the ordinal logistic
regression model multiplied with the propofol (prop) effect-site concentration
in the prediction equation; bis  coefﬁcient of the ordinal logistic regression
model multiplied with the BIS in the prediction equation; SD  standard
deviation.
Table 9. Ordinal Logistic Regression of Model B (AAI)
Predictor Value SD Z P
1 9.265 1.117 8.29 0.000
2 8.559 1.094 7.83 0.000
3 7.386 1.057 6.99 0.000
4 5.583 1.009 5.53 0.000
5 1.9793 0.9563 2.07 0.038
remi 1.0143 0.1194 8.50 0.000
prop 3.0479 0.3091 9.86 0.000
AAI 0.064 0.0097 6.61 0.000
Test that all slopes are zero: P value  0.001.
1–5  constants of the ordinal logistic regression model used in the predic-
tion of the OAA/S levels 1 to 5; remi  coefﬁcient of the ordinal logistic
regression model multiplied with the remifentanil (remi) effect-site concentra-
tion in the prediction equation; prop  coefﬁcient of the ordinal logistic
regression model multiplied with the propofol (prop) effect-site concentration
in the predication equation; AAI  coefﬁcient of the ordinal logistic regres-
sion model multiplied with the AAI in the prediction equation; SD  standard
deviation.
Table 10. Prediction Probability (PK of the Indices
Model PK (SE)
Model A (BIS  CePROP  CeREMI) 0.91 (0.01)
Model B (AAI  CePROP  CeREMI) 0.93 (0.01)
AAI  A-Line ARX index; BIS  Bispectral Index; CePROP  calculated
propofol effect-site concentration; CeREMI  calculated remifentanil effect-
site concentration.
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3.2.1 Introduction 
The clinical validation reveals much practical information on the performance of AAI and BIS. 
The prediction probability calculations in study 1 suggest that AAI,BIS and CePROP are equally 
adequate to describe the studied clinical endpoints of anesthesia. However, the methodology 
of our first study did not allow to depict more subtle differences between both cortical (EEG) 
and subcortical (MLAEP) derived indices. One could question if MLAEP derived information 
adds anything supplemental to the indices derived from spontaneous EEG (e.g. BIS, or the 
more recently commercialized “State Entropy” (SE) and “Response Entropy” (RE)). It would 
be very odd that two surrogate indices of hypnotic drug effect, using entirely different 
neurophysiologic principles, perform similarly over a wide range of drug effects. Some studies 
describe a better correlation of MLAEP derived indices with loss and return of consciousness, 
compared to BIS.(1,2) In contrast, BIS would have a better correlation with the hypnotic drug 
concentration.(2-4) As such we had to find a more adequate model for comparing subtle 
differences between monitors. 
We chose to use a continuously available, pharmacologic endpoint as the dependent 
parameter: the predicted effect-site concentration of propofol (CePROP).  In this study, we 
calculated the corresponding CePROP simultaneously with a constant infusion of propofol 1% 
at 300ml/h. AAI, BIS, RE and SE were tested in their ability to detect the gradual transition 
from “fully awake” towards “maximal suppressed EEG”. For the first time, our study 
introduced a specific scientific setting as a benchmark for comparing monitors of the hypnotic 
component of anesthesia. More protocols have been performed in this thesis using the same 
methodology. But more importantly, other research centers have reproduced this 
methodology for validating monitors of the hypnotic component of anesthesia.(5) 
This study includes advanced statistical methods for comparing monitor performance. The 
“baseline variability” depicts the variation in measurements found in the awake patient. 
Baseline variability should be as low as possible.(6) The very deep levels of anesthesia are 
depicted by the correlation between the respective indices and the percentage of 
burstsuppression patterns as measured by every device. The “all round” performance is 
depicted by PK analysis. We also introduced the individualized Spearmann rank correlation, 
as an alternative approach for PK as it depicts the non-linearities in the dataset better. Finally, 
we estimated models of the relationship between every measurement and CePROP using non 
linear mixed effect modeling (NONMEM).(cf. “statistical methods” section in the manuscript 
and chapter 2)  
With these methods, we found some important weaknesses for AAI in comparison with BIS, 
RE and SE. The PK values and Individualized Spearmann Rank Correlations were all within 
acceptable range, indicating high “all round performance”. All indices also correlated 
acceptably with CePROP as described by a sigmoidal Emax relationship using NONMEM. But for 
AAI, baseline variability was excessively high, and AAI is not able to discriminate between 
very deep levels of anesthesia. Conclusion of our study: AAI has a problem at the two 
extremes of the depth of the anesthesia spectrum. 
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Spectral Entropy as an Electroencephalographic Measure
of Anesthetic Drug Effect
A Comparison with Bispectral Index and Processed Midlatency Auditory
Evoked Response
Ann L. G. Vanluchene, M.D.,* Hugo Vereecke, M.D.,† Olivier Thas, M.Sc., Ph.D.,‡ Eric P. Mortier, M.D., D.Sc.,§
Steven L. Shafer, M.D., Michel M. R. F. Struys, M.D., Ph.D.#
Background: The authors compared the behavior of two cal-
culations of electroencephalographic spectral entropy, state en-
tropy (SE) and response entropy (RE), with the A-Line® ARX
Index (AAI) and the Bispectral Index (BIS) and as measures of
anesthetic drug effect. They compared the measures for base-
line variability, burst suppression, and prediction probability.
They also developed pharmacodynamic models relating SE, RE,
AAI, and BIS to the calculated propofol effect-site concentration
(Ceprop).
Methods: With institutional review board approval, the au-
thors studied 10 patients. All patients received 50 mg/min
propofol until either burst suppression greater than 80% or
mean arterial pressure less than 50 mmHg was observed. SE, RE,
AAI, and BIS were continuously recorded. Ceprop was calculated
from the propofol infusion proﬁle. Baseline variability, predic-
tion of burst suppression, prediction probability, and Spear-
man rank correlation were calculated for SE, RE, AAI, and BIS.
The relations between Ceprop and the electroencephalographic
measures of drug effect were estimated using nonlinear mixed
effect modeling.
Results: Baseline variability was lowest when using SE and
RE. Burst suppression was most accurately detected by spectral
entropy. Prediction probability and individualized Spearman
rank correlation were highest for BIS and lowest for SE. Non-
linear mixed effect modeling generated reasonable models re-
lating all four measures to Ceprop.
Conclusions: Compared with BIS and AAI, both SE and RE
seem to be useful electroencephalographic measures of anes-
thetic drug effect, with low baseline variability and accurate
burst suppression prediction. The ability of the measures to
predict Ceprop was best for BIS.
THE regularity of the background electroencephalogram
alters with changing levels of consciousness. Recently,
different entropy concepts have been applied to de-
scribe the “amount of order” in the electroencephalo-
gram.1–3 One of these, Shannon entropy, has been
shown to be a useful measure of anesthetic drug effect.3
Shannon entropy measures the predictability of future
amplitude values of the electroencephalogram based on
the probability distribution of amplitude values already
observed in the signal. Unfortunately, Shannon entropy
as described is not normalized to the total power of the
electroencephalogram. Therefore, its absolute value may
vary between individuals because of interindividual dif-
ferences in signal strength, precluding routine clinical
use. To overcome these shortcomings, spectral entropy
has been developed. The spectral entropy is obtained by
applying the Shannon entropy concept to the power
distribution of the Fourier-transformed signal, which has
been normalized to unit power. Spectral entropy permits
separation of the contributions from different frequency
ranges. For example, using spectral entropy, one can
separate the high-frequency contribution ( 32 Hz,
which is likely electromyographic) from the low-fre-
quency contribution ( 32 Hz, which is likely encepha-
lographic). The detailed spectral entropy algorithm is
published elsewhere.4 Recently, this technology has be-
come commercially availably (M-ENTROPY module; Da-
tex-Ohmeda, Helsinki, Finland). In this device, two spec-
tral entropy indicators are considered, state entropy
(SE), calculated over the frequency range (0.8–32 Hz)
that is likely dominated by the encephalogram, and re-
sponse entropy (RE), calculated over the frequency
range (0.8–47 Hz) that includes both the electroenceph-
alogram and electromyogram. Sudden appearance of the
electromyographic signal data often indicates that the
patient is responding to some external stimulus, such as
a painful stimulus, i.e., nociception, due to some surgical
event.5,6 Such a response may result in arousal if the
level of analgesia is insufﬁcient. In theory, in the non-
paralyzed patient’s electromyogram can provide a rapid
indication of impending arousal.
Processed analysis of the electroencephalogram or
midlatency auditory evoked potential (MLAEP) is increas-
ingly applied as a surrogate endpoint for quantiﬁcation
of anesthetic drug effect. Because of the difﬁculties of
analyzing raw waveforms for both electroencephalo-
gram and MLAEP during anesthesia, extraction and pre-
sentation of this information necessitates computational
analysis of the raw signal. The A-Line® ARX Index (AAI)
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is derived from the MLAEP and has been validated as a
measure of anesthetic drug effect during propofol
administration.7
The most widely adopted electroencephalographic mea-
sure of anesthetic drug effect is the Bispectral Index (BIS).
The BIS has been extensively studied and validated over the
past 10 yr as a measure of anesthetic drug effect.7
We evaluated the four electroencephalographic mea-
sures of drug effect for stability at baseline (minimal
variability in the absence of drug between individuals8),
accurate detection of burst suppression,9 prediction
probability,10,11 and correlation with the propofol effect-
site concentration. We also developed pharmacody-
namic models relating the predicted effect-site propofol
concentration to each measure of drug effect.
Materials and Methods
After institutional ethics committee approval (Ghent
University Hospital, Gent, Belgium), written informed
consent was obtained from 10 patients with American
Society of Anesthesiologists physical status I who were
aged 18–45 yr and scheduled to undergo ambulatory
gynecologic or urologic surgery. Exclusion criteria in-
cluded weight less than 70% or more than 130% of ideal
body weight, neurologic disorder, and recent use of
psychoactive medication, including alcohol.
All patients received a continuous infusion of propofol
at 50 mg/min (Diprivan 1%; AstraZeneca, London,
United Kingdom) using a Fresenius Modular DPS Infu-
sion Pump connected to a Fresenius Base A (Fresenius
Vial Infusion Systems, Brézins, France). To ensure syn-
chronized data recording, all monitor and infusion data
were continuously captured by the computer running
RUGLOOP II** via multiple RS 232 interfaces. By track-
ing the infused propofol volume continuously, RUG-
LOOP II calculated the corresponding effect-site concen-
tration using the three-compartment model enlarged
with an effect compartment previously published by
Schnider et al.12,13 The calculated effect-site propofol
concentration (Ceprop) was computed to yield a time-to-
peak effect of 1.6 min after bolus injection,14 as also
published by Schnider et al.12,13 and clinically conﬁrmed
by Struys et al.15 Propofol was infused via a large left
forearm vein. Every patient received approximately
100 ml crystalloid ﬂuid during the study period. No ﬂuid
load was given before induction. No patient received
preanesthetic medication. No other drugs were given.
All patients maintained spontaneous ventilation via a
facemask delivering 100% O2. Before starting the drug
administration, all patients were asked to close their eyes
and relax for 2 min. Thereafter, baseline measures were
taken. The operating room was kept silent to avoid
noise-related stimulation and artifact.
The propofol infusion was continued until a burst
suppression level of 80% or higher was achieved on the
BIS® monitor (Aspect Medical Systems, Inc., Newton,
MA) or the mean arterial blood pressure decreased be-
low 50 mmHg.
Heart rate, noninvasive blood pressure, oxygen satura-
tion measured by pulse oximetry (SpO2), and capnography
were recorded at 1-min intervals using an S-5 monitor;
Datex-Ohmeda). All data were recorded continuously on
one computer using RUGLOOP software via multiple RS-
232 connections. Averaging of the data was performed
using 10-s intervals.
Electroencephalographic and MLAEP Data
Collection
The SE and RE were calculated using the M-ENTROPY
module. The SE value ranges from 91 to 0, and the RE
value ranges from 100 to 0. Both entropy values were
derived from the frontal electroencephalogram and elec-
tromyogram using three electrodes. SE is computed over
the frequency range from 0.8 to 32 Hz. It includes the
electroencephalogram-dominant part of the spectrum.
The time windows for SE are chosen optimally for each
particular frequency component and range from 60 s to
15 s. RE is computed over a frequency range from 0.8 to
47 Hz. It includes both the electroencephalogram-dom-
inant and the electromyogram-dominant parts of the
spectrum. The time windows for RE are chosen opti-
mally for each frequency, with the longest time window
equal to 15.36 s and the shortest time window, applied
for frequencies between 32 and 47 Hz, equal to 1.92 s.
The RE equals the SE when no electromyographic activ-
ity is detected. The description of the full algorithm is
described elsewhere.4
The AAI (version 1.5) from the MLAEP was calculated
using the A-Line® monitor (Danmeter A/S, Odense, Den-
mark). The AAI value ranges from 100 to 0. The MLAEPs
were elicited with a bilateral click stimulus of 70-dB
intensity and 2-ms duration. Three electrodes (A-Line®
AEP electrodes; Danmeter A/S) were positioned at mid
forehead (), left forehead (reference), and left mastoid
(). The extraction of the MLAEP using a short moving–time
average technique together with an ARX model and the cal-
culations of the AAI have been described previously.16
The BIS (BIS® version 4.0, XP) was derived from the
frontal electroencephalogram and calculated by the A-2000
BIS® monitor using the 4 BIS®-Sensor electrodes (Aspect
Medical Systems). The BIS value ranges from 100 to 0. The
smoothening time of the BIS® monitor was set at 15 s.
All electroencephalographic data were gathered by
computer concurrently with the hemodynamic data and
drug infusion information.
** De Smet T, Struys M: RUGLOOP program. Available at: http://www.
anesthesia-uzgent.be. Accessed February 25, 2004.
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Performance Measures
Baseline Variability. Baseline variability is calculated
by computing the coefﬁcient of variation (CV) on the
electroencephalographic data points obtained during
the ﬁrst 5 s of the protocol, before any drug has been
delivered.
Burst Suppression. The burst suppression ratio
(BSR) of the electroencephalogram is measured by all
three monitors. For the M-ENTROPY module, burst sup-
pression calculation starts by subtracting a local average
from each signal sample to eliminate baseline ﬂuctua-
tions. The signal is then divided into two frequency
bands by elliptic ﬁlters. Cutoff frequencies of the low-
pass and high-pass ﬁlters are 20 and 75 Hz, respectively.
The low-frequency band is used to detect the burst
suppression pattern, and the high-frequency band is
used to detect artifacts. An energy operator is applied to
estimate signal power in both bands in each 0.05-s ep-
och. Suppression is detected if the estimated signal
power is below a ﬁxed threshold at least for 0.5 s and
there is no artifact. The BSR is the percentage of 0.05-s
epochs in the past 60 s that were considered suppressed.
More detailed information on the burst suppression cal-
culation used in the entropy module is described
elsewhere.17
For the A-Line® monitor, the raw signal is passed
though a preprocessing process to reject artifacts. It
then passes through a low-pass ﬁlter with a cutoff fre-
quency of 32 Hz, yielding the electroencephalogram
signal. The ﬁltered signal then is divided in segments of
500 ms, where the mean value is removed to ﬁlter out
low frequencies. If a segment has a determined percent-
age of samples with amplitudes less than 3.4 V, it is
considered as a segment with suppression. The burst
suppression is considered as the percentage of segments
with suppression during 20 s.
For the BIS® monitor, after preprocessing for artifact
detection/correction, the log power of 1-s electroen-
cephalogram epochs in two frequency bands (2–30 and
31–40 Hz) is calculated, and suppression is declared if a
weighted sum of these bands is less than a threshold.
Hereby, the threshold is adaptive (within a narrow
range) based on the statistics of the electroencephalo-
gram. The suppression detection algorithm processes
the electroencephalogram in overlapping 1-s epochs off-
set every 0.5 s. A given 0.5 s of electroencephalogram is
determined to be suppressed if suppression was de-
tected for either of the 2 overlapping 1-s epochs that
contained it. The suppression ratio is the percentage of
0.5-s epochs in the past 63 s that were considered
suppressed.
The relation between the burst suppression and its
related electroencephalographic measure (SE, RE, AAI,
and BIS) was plotted. For each electroencephalographic
measure, a model was ﬁtted to the data using the curve
estimation function from SPSS version 12 (SPSS Inc.,
Chicago, IL). The curve estimation procedure produces
curve estimation regression statistics and related plots
for different curve estimation regression models, includ-
ing linear, logarithmic, inverse, quadratic, cubic, power,
compound, S-curve, logistic, growth, and exponential. A
separate model is produced for each dependent variable
together with its regression coefﬁcients, predicted val-
ues, residuals, and prediction intervals. After this, the
most appropriate regression model can be selected.
Prediction Probability. For each electroencephalo-
graphic measure of anesthetic drug effect, we calculated
the prediction probability (PK) developed by Smith et
al.10,11 PK was calculated as the Somers d statistic using
SPSS version 12, with the electroencephalographic mea-
sure set as the independent variable and the Ceprop as the
dependent variable. (We recognize that this is physiolog-
ically backward in that the propofol effect-site concen-
tration drives the electroencephalographic response.
However, for the purpose of this analysis, the question is
how well the observed measure, which is the electroen-
cephalographic response, predicts the unobserved “un-
derlying” state of the patient, which is the Ceprop). The
Somers d statistic was then rescaled from the 1 to  1
range of the Somers d statistic to the 0 to 1 range of PK,
PK  1  (1  |Somers d|)/2. Then, a PK of 1 for the
electroencephalographic measure means that this mea-
sure always decreases (increases) as the patient reaches
higher (lower) drug concentrations according to the
effect-site propofol concentration. Alternatively, a PK
value of 0.5 means that the measure is useless for pre-
dicting anesthetic drug effect. Individual values were
calculated for each measure, and the average, minimum,
and maximum PK values were then tabulated for each
electroencephalographic measure of anesthetic drug
effect.
Individualized Spearman Rank Correlation. In ad-
dition, a nonparametric alternative was investigated. The
Spearman rank correlations between Ceprop and SE, RE,
AAI, and BIS were individualized in the sense that they
were ﬁrst computed for each patient i separately, say Ri.
The reported Spearman rank correlation, R, is a
weighted average of the Ri (weighted according to the
number of observations for each patient). In this way, R
retained its usual interpretation. The conﬁdence inter-
vals on R were obtained by the bootstrap method18 in
which the hierarchical nature of the data was incorpo-
rated by resampling within patient. Equality of two cor-
relation coefﬁcients was tested at the 5% level of signif-
icance by constructing the 95% conﬁdence intervals of
the difference (conﬁdence intervals were also computed
with the bootstrap technique). All bootstrap calculations
were based on 10,000 simulation runs.
Pharmacodynamic Modeling
The relation between propofol effect-site concentra-
tion and the electroencephalographic measures of anes-
36 VANLUCHENE ET AL.
Anesthesiology, V 101, No 1, Jul 2004
94
thetic drug effect was analyzed using a sigmoid Emax
model:
Effect E0  Emax  E0
Ce
Ce50
  Ce
,
where Effect is the electroencephalographic effect being
measured (SE, RE, AAI, BIS), E0 is the baseline measure-
ment when no drug is present, Emax is the maximum
possible drug effect, Ce is the calculated effect-site con-
centration of propofol, Ce50 is the effect-site concentra-
tion associated with 50% maximal drug effect, and  is
the steepness of the concentration-versus-response rela-
tion. The model parameters were estimated using NON-
MEM V (GloboMax LLC, Hanover, MD). Interindividual
variability was modeled using a log-normal distribution:
Pi PTVe
i ,
where Pi is the parameter value (E0, Emax, , or Ce50) in
the ith patient, PTV is the typical value of the parameter
in the population, and  is a random variable with a
mean of 0 and a variance of 	2. Individual variability is
reported as 	, the SD of  in the log domain, which is
approximately the CV in the standard domain. Residual
intraindividual variability was modeled using a standard
additive error model. Parameters were evaluated by com-
paring the log-likelihood values (the NONMEM objective
function), with improvement of 3.84 in 2LL with the
addition of a single parameter considered statistically
signiﬁcant.19
Results
The population characteristics were as follows:
weight, 62.0 3.8 kg; age, 37.7 16.2 yr; height, 165
6.5 cm; sex, 8 men/2 women. All measured data were
included in the analysis. Figures 1 and 2 show the raw
data over time for the four electroencephalographic
measures of drug effect (SE, RE, AAI, and BIS) and Ceprop.
(In ﬁg. 2, the disruption in the continuous increasing
Ceprop is due to the inevitable change of the 1% propofol
syringe around 600 s.)
Performance Measures
The baseline variability before administration of propo-
fol is shown in table 1. The smallest variability in baseline
values as deﬁned by the CV was found for both spectral
entropy measures (SE and RE), followed by BIS. AAI had
the largest baseline variability.
The correlation between the burst suppression calcu-
lation and its related electroencephalographic measures
of anesthetic drug effect is observed in ﬁgures 3 and 4.
As seen in ﬁgure 3, for both spectral entropy indicators,
a monotonic nonlinear decrease in entropy (quadratic
polygonal curve, goodness-of-ﬁt R2 for SE  0.72 and for
RE  0.71) was observed with increased levels of burst
suppression. Spearman rank correlation coefﬁcients
were 0.62 and 0.63 for SE and RE, respectively.
Figure 4 shows the behavior of the AAI and BIS with
increasing levels of BSR. For AAI, no correlation between
AAI and the AAI burst suppression could be obtained.
For BIS, no accurate correlation could be obtained be-
tween BIS and the BSR when all data were included. At
a BSR greater than 40, a linear correlation was found.
The PK values for SE, RE, AAI, and BIS are shown in
table 2. The individualized Spearman rank correlations
between Ceprop and SE, RE, BIS, and AAI are shown in
table 2.
Pharmacodynamic Modeling
Figure 5 shows the behavior of SE and RE versus Ceprop
for all patients. With increasing Ceprop, both SE and RE
decreased monotonically. Similar ﬁndings were observed
for both AAI and BIS, as seen in ﬁgure 6. For the spectral
entropy, the difference between RE and SE decreased non-
linearly toward 0 with increasing Ceprop (ﬁg. 7).
The relations of Ceprop to SE and RE are plotted in
ﬁgure 8. The relations of Ceprop to BIS and AAI are
shown in ﬁgure 9. The parameter values for each popu-
lation model including the CV (as a measure of interin-
dividual variability in the standard domain) are found in
table 3. The SD for each model (as a measure of the
intraindividual variability in the log domain) was 7.1 for
SE, 6.8 for RE, 4.8 for AAI, and 4.5 for BIS.
Discussion
In this study, we compared two measures of spectral
entropy, SE and RE, with BIS and AAI as a measures of
Fig. 1. Individual raw data for state (SE) and response entropy
(RE) versus time.
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anesthetic drug effect during increasing Ceprop. Also, the
stability at baseline and the correlation of burst suppres-
sion and its related measures of anesthetic drug effect on
the electroencephalogram were tested for the three
devices.
Baseline stability was calculated for all measures as
seen in table 1. Baseline stability and baseline variation
can profoundly affect electroencephalographic-based
pharmacodynamic parameter estimation and the useful-
ness of the processed electroencephalogram or MLAEP
as a measure of the arousal state of the central nervous
system (depth of anesthesia).8 Therefore, variation and
stability at baseline were measured within our study
population by calculating a CV on the data before ad-
ministering any drug in stable conditions. Both spectral
entropy measures showed the highest baseline stability
among patients followed by BIS. High levels of baseline
variation were found for the AAI. Baseline variation
might decrease the predictive ability of the univariate
parameter, as stated by Bruhn et al.8
Burst suppression represents a benign pattern fre-
quently seen in healthy brain at deep levels of the hyp-
notic component of anesthesia. It can be identiﬁed in the
raw electroencephalogram and is composed of episodes
of electrical quiescence (the suppression) alternated
with high-frequency, high-amplitude electrical activity
(the bursts). Increasing anesthetic drug concentration
causes increased duration of the suppression periods.
Burst suppression patterns of the electroencephalogram
are classically quantiﬁed as BSR deﬁned as the percent-
age duration of suppression/duration of the epoch.8,20,21
Fig. 2. Individual raw data for Bispectral Index (BIS) and A-Line®
ARX Index (AAI) and propofol effect-site concentration (Ce
propofol) versus time. (The disruption in the continuous in-
creasing Ce propofol is due to the inevitable change of the 1%
propofol syringe around 600 s.)
Table 1. Baseline Stability Deﬁned as the Coefﬁcient of
Variation of All Measures
SE RE AAI BIS
Mean  SD 89.2  1.4 97.5  1.9 73.0  23.1 95.6  4.6
Coefﬁcient of
variation
1.610 1.955 31.697 4.801
AAI  A-Line ARX Index; BIS  Bispectral Index; RE  response entropy of
the spectral entropy; SE  state entropy of the spectral entropy.
Fig. 3. Behavior of state (SE) (A) and response entropy (RE) (B)
versus the burst suppression (BS) ratio as measured by the
entropy module for all individual patients (dots) and its regres-
sion line (bold line).
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Because the detection of burst suppression represents
an important electroencephalographic component to
measure deep levels of anesthesia, its correlation to its
univariate parameter is important and must be investi-
gated. Figure 3 shows the correlation between SE and RE
and its BSR. As the suppression part of the burst sup-
pression is classiﬁed as highly regular, the spectral en-
tropy algorithm correctly classiﬁes increasing burst sup-
pression as increasing anesthetic drug effect. As a result,
a clear correlation between BSR and SE or RE was found.
For MLAEP, it has been published previously that MLAEP
lacks accuracy in detecting deepening of the hypnotic–
anesthetic level because of a ﬂat MLAEP signal after loss
of consciousness.16 Because AAI is derived from the
MLAEP, no BSR was calculated on the original evoked
potential signal. As a result, no correlation between AAI
and BSR was found. It might be argued that the detection
of electroencephalographic burst suppression beside the
MLAEP-derived AAI might solve the problem of lack of
accuracy at deep levels of anesthesia, which might be
revealed in further studies. For BIS, the onset of burst
suppression was not correctly detected by BIS as long as
BSR was less than 40%, although burst suppression is a
part of the BIS® algorithm. Above a BSR of 40, a linear
correlation was found between BIS and BSR, as seen in
Fig. 4. Behavior of Bispectral Index (BIS) (A) and A-Line® ARX
Index (AAI) (B) versus the burst suppression (BS) ratio as mea-
sured by the BIS® or AAI monitor (A and B, respectively) for all
individual patients (dots).
Table 2. Spearman Rank Correlation Coefﬁcients and Prediction Probability for Each Electroencephalographic Measure of
Anesthetic Drug Effect vs. Propofol Effect-site Concentration
SE RE AAI BIS
PK, median (minimum–maximum) 0.86 0.89 0.87 0.91
(0.60–0.96) (0.67–0.96) (0.81–0.99) (0.72–0.94)
Individualized Spearman rank 0.841  0.014 0.860  0.013 0.869  0.010 0.891  0.011
correlation, mean  SD (95% CI) (0.864, 0.808)* (0.882, 0.831) (0.883, 0.844) (0.907, 0.865)
* P  0.05 between Bispectral Index (BIS) and other measures.
AAI A-Line ARX Index; CI conﬁdence interval; PK prediction probability; RE response entropy of the spectral entropy; SE state entropy of the spectral
entropy.
Fig. 5. Individual raw data for state (SE) and response entropy
(RE) versus propofol effect-site concentration (Ce propofol).
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ﬁgure 8. Others have also found that onset of propofol-
induced burst suppression may be correctly detected as
deepening of anesthesia by approximate entropy, an-
other form of entropy calculation, but not by BIS.22 The
same authors found also that BSR is the only determinant
for BIS values below 30.21
When studying performance accuracy, the question is
how well the observed measure, which is the electroen-
cephalographic response, predicts the unobserved “un-
derlying” state of the patient, which is represented by
the propofol effect-site concentration. Therefore, PK was
calculated for SE, RE, AAI, and BIS. PK, a rescaled variant
of the dy,x measure of association of Kim, generalizes
nonparametric receiver operating characteristics curve
area to a polytomous ordinal patient state. It shows the
correlation between the value of the electroencephalo-
graphic measure of anesthetic drug effect and the calcu-
lated effect-site concentration of propofol, taking into
account both desired performance and the limitations of
the data.10,11 That is, given two randomly selected elec-
troencephalographic-derived data points with distinct
anesthetic drug concentration, PK is the probability that
the indicator describes correctly which of the data
points is the one with the higher (or lower) anesthetic
drug concentration.2 To avoid an overwhelming inﬂu-
Fig. 6. Individual raw data for Bispectral Index (BIS) and A-Line®
ARX Index (AAI) versus propofol effect-site concentration (Ce
propofol).
Fig. 7. Difference between response (RE) and state entropy (SE)
versus the propofol effect-site concentration (Ce propofol) and
its regression analysis.
Fig. 8. The relation between propofol effect-site concentration
and the state (SE) and response entropy (RE) modeled using
nonlinear mixed effect modeling. The individual patients are
represented as dotted lines, and the typical population curve is
plotted as a straight line.
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ence of patient individual variability on the PK calcula-
tion, estimation was performed on an individual patient
basis. Although all four measures tended to have similar
median PK values, the range between the minimum and
maximum observed was more wider for both entropy
measures than for AAI and BIS. Alternatively, a nonpara-
metric approach was used to measure the performance
of SE, RE, AAI, and BIS using the individualized Spearman
rank correlation. The individualized Spearman rank cor-
relation between the four electroencephalographic mea-
sures of drug effect and Ceprop, as shown in table 2,
revealed similar ﬁndings as PK. Even more, a signiﬁcantly
lower value for SE compared with BIS was found.
Figures 5 and 6 show the raw data for each patient for
each electroencephalographic measure of anesthetic
drug effect during increasing Ceprop. Figure 7 shows the
difference between SE and RE in relation to Ceprop.
Previously, using the ABM-2 monitor (Datex-Ohmeda),
Struys et al.6 demonstrated that frontal electromyo-
graphic activity decreases with increasing propofol drug
concentrations and vice versa. However, at higher drug
concentration, the frontal electromyogram disappeared,
making it useless for measuring excessive levels of anes-
thesia. As seen in ﬁgure 7, the difference between RE
and SE approached zero in a concentration-dependent
manner. It has also been reported that electromyo-
graphic activity can be used to detect pending arousal
during anesthesia.5 Because no arousal stimuli were in-
cluded in the study protocol, this must be investigated in
further research.
Figures 8 and 9 show the pharmacodynamic modeling
for all measures versus Ceprop. Previously, the relation
between measures of anesthetic drug effect and Ceprop
was observed following a sigmoid Emax model.
2,3,6,23,24
Therefore, in our study, the relation between the mea-
sures of anesthetic drug effect and Ceprop was also mod-
eled using a sigmoid Emax model, and the model param-
eters were estimated using a population approach. In
NONMEM, the parameters in the individual are weighted
in a Bayesian manner toward the mean for the popula-
tion, based on the variance of the individual parame-
ters.19 The results for each measures of anesthetic drug
effect are shown in ﬁgures 8 and 9. As shown in table 3,
the typical values for each measures of anesthetic drug
effect revealed that for both RE as SE, steeper regression
curves were seen than for both BIS and AAI, indicating a
less graded response in most patients. The measures of
individual variability were smaller for BIS and AAI than
for SE and RE.
Although the use of a sigmoid Emax model is classically
proposed in the literature,2,3,6,23,24 one might criticize
this approach. For the entropy of electroencephalogra-
phy, Steyn-Ross et al.25 discovered that the entropy
might decrease discontinuously at the moment of induc-
tion into unconsciousness. They even concluded that
this discontinuous step change in cortical entropy sug-
gests that the cortical phase transition is analogous to a
ﬁrst-order thermodynamic transition in which the coma-
tose–quiescent state is strongly ordered, whereas the
active cortical state is relatively disordered. Recently,
Bruhn et al.26 found that two successive sigmoidal
curves (instead of one) were useful in describing the
pharmacodynamic behavior of two computerized elec-
troencephalographic measures during isoﬂurane anes-
Fig. 9. The relation between propofol effect-site concentration
and the Bispectral Index (BIS) and A-Line® ARX Index (AAI)
modeled using nonlinear mixed effect modeling. The individual
patients are represented as dotted lines, and the typical popu-
lation curve is plotted as a straight line.
Table 3. Typical Values and Coefﬁcient of Variation for Each
Electroencephalographic Measure of Anesthetic Drug Effect
SE RE AAI BIS
Ce50 4.68 (36%) 4.55 (35%) 4.15 (31%) 4.92 (34%)
E0 89.3 (24%) 97.6 (3%) 70.6 (28%) 95.9 (4%)
Emax 80.6 (28%) 82.9 (11%) 61.8 (31%) 87.5 (11%)
 4.59 (39%) 5.33 (0%) 4.26 (51%) 2.69 (32%)
AAI  A-Line ARX Index; BIS  Bispectral Index; Ce50  the effect site
concentration associated with 50% maximal drug effect; E0  the baseline
measurement when no drug is present; Emax  the maximum possible drug
effect;   the steepness of the concentration-vs.-response relation; SE 
state entropy of the spectral entropy; RE  response entropy of the spectral
entropy.
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thesia. Although examination of our raw data suggests
that a single sigmoidal relation is adequate for the range
of concentrations studied in this experiment, we cannot
rule out the possibility that studies exploring a larger
range of concentrations may necessitate different mod-
els to accurately characterize the relation between ef-
fect-site propofol concentration and electroencephalo-
graphic response.
In conclusion, when comparing the performance of
two spectral entropies, SE and RE, with AAI and BIS as
measures of anesthetic drug effect, it was found that
baseline variability was lowest when using SE and RE,
followed by BIS. AAI showed high baseline variability.
Correlation between the burst suppression calculation
and both RE and SE were observed. For BIS, suppression
ratio values greater than 40% are linearly correlated with
BIS values. For values less than 40%, no correlation with
BIS was found. No correlation was obtained between the
burst suppression calculation and the AAI. Although all
within acceptable range, prediction probability and in-
dividualized Spearman rank correlation were highest for
BIS and lowest for SE. Population pharmacodynamic
modeling of each measure versus Ceprop using a sigmoid
Emax model revealed that for both RE as SE, steeper
curves were seen than for both BIS and AAI, indicating
an less graded response in most patients. The measures
of intraindividual variability were smaller for BIS and AAI
than for SE and RE.
The authors thank the operating room team (Cluster 4, Ghent University
Hospital, Gent, Belgium) for their assistance during the trials.
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3.3.1 Introduction 
Our former study revealed that AAI has problems of large population variability in the awake 
patient. This was confirmed  by Kreuer et al.(1)  Also the lack of descriptive capacity at deep 
levels of anesthesia was confirmed by other studies.(2) This observation re-activated the 
debate on whether mid-latency auditory evoked potentials (MLAEP) as a neurophysiologic 
parameter adds much information to the indices obtained from spontaneous EEG. In an 
editorial of anesthesiology, reflecting on the first AAI validation study by Struys et al,(3) 
Kalkmann et al. suggested that it might be beneficial to combine “the best of both worlds”.(4) 
However, at that time not much scientific foundation was available to underpin this statement. 
In view of this debate, the inventors of AAI addressed the problems by introducing a drastic 
change in the algorithm for AAI calculation. The new AAI (version 1.6) is a composite index 
combining information obtained from MLAEP, spontaneous EEG and the burstsuppression 
percentage. The index was incorporated in a new commercialized model of the A-Line®
monitor. Originally, the new monitor was called A-Line® (version 1.6). More recently, it was 
decided to change the name in AEPmonitor/2. Confusingly, the index is officially called AAI, 
even though it cannot be compared with the former version of AAI, using solitary MLAEP. 
As an additional innovation, the upper scale limit was decreased from 100 to 60, in order to 
decrease baseline variability. This was no rescaling with changed units of measurement, but 
rather an elimination of all data points above 60. The inventors chose this value of 60 based 
on the sensitivity/specificity calculations from our study 1.(3) They concluded from these 
results that values above 60 always indicate “awake” patients with a 100% sensitivity. 
Although the change in scale seems harmless, we wanted to validate this intervention as a 
different index, as the “allround” behavior can be altered by changing scale. 
Additionally, an acoustic stimulus volume controller was implemented as a technical solution 
for electromyographic interferences called “startle response”. This topic will be addressed 
more extensively in a next publication. 
We validated the new version of the AEP monitor/2 by comparing it with the old version of the 
AAI and BIS in a comparable “benchmark” protocol, as used for the second trial.(5) We 
demonstrated a clear improvement on the baseline variability, especially when the upper 
scale limit of 60 was applied. However, bispectral index (BIS) still performed better at 
baseline. The discriminating power at deep levels of anesthesia was significantly improved by 
the inclusion of additional electroencephalographic derived information next to MLAEP. As 
such we proved that “the best of both worlds” indeed increased the descriptive capacity for 
the hypnotic component of anesthesia. Although the improvement is a clinically important 
finding, we couldn’t exclude a potential decreased sensitivity at sedation levels of anesthesia 
when the scale was reduced to 60. In contrast,  other authors have recently successfully used 
the AEP monitor/2 in sedation protocols.(6-8) 
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New Composite Index Based on Midlatency Auditory
Evoked Potential and Electroencephalographic Parameters
to Optimize Correlation with Propofol Effect Site
Concentration
Comparison with Bispectral Index and Solitary Used Fast Extracting Auditory
Evoked Potential Index
Hugo E. M. Vereecke, M.D.,* Pablo Martinez Vasquez, M.Sc.,† Erik Weber Jensen, M.Sc., Ph.D.,†
Olivier Thas, M.Sc., Ph.D.,‡ Rudy Vandenbroecke, M.D., Ph.D.,§ Eric P. Mortier, M.D., D.Sc.,
Michel M. R. F. Struys, M.D., Ph.D.#
Background: This study investigates the accuracy of a com-
posite index, the A-Line® auditory evoked potentials index ver-
sion 1.6 (AAI1.6; Danmeter A/S, Odense, Denmark), as a measure
of cerebral anesthetic drug effect in a model for predicting a
calculated effect site concentration of propofol (CePROP). The
AAI1.6 algorithm extracts information from the midlatency au-
ditory evoked potentials, the spontaneous electroencephalo-
graphic activity, and the detection of burst suppression. The
former version of this monitor, the A-Line® auditory evoked
potential index version 1.5, is only based on fast extracted
midlatency auditory evoked potential information.
Methods: After institutional ethics committee approval (Uni-
versity Hospital, Ghent, Belgium), informed consent was ob-
tained from 13 patients (10 women, 3 men) with an American
Society of Anesthesiologists physical status of I, aged 18–65 yr,
who were scheduled to undergo ambulatory gynecologic or
urologic surgery. The authors evaluated for Bispectral Index,
A-Line® auditory evoked potential index, version 1.5, AAI1.6
scaled from 0 to 100 and AAI1.6 scaled from 0 to 60, the inter-
patient stability at baseline, the detection of burst suppression,
prediction probability, and correlation with CePROP, during a
constant infusion of 1% propofol at 300 ml/h. The authors
developed pharmacodynamic models relating the predicted
CePROP to each measure of cerebral anesthetic drug effect.
Results: Bispectral Index had the lowest interindividual base-
line variability. No signiﬁcant difference was found with pre-
diction probability analysis for all measures. Comparisons for
correlation were performed for all indices. The AAI1.6 scaled to
60 had a signiﬁcantly higher correlation with CePROP compared
with all other measures. The AAI1.6 scaled to 100 had a signiﬁ-
cant higher correlation with CePROP compared with the A-Line
®
auditory evoked potential index version 1.5 (P < 0.05)
Conclusions: The authors found that the application of AAI1.6
has a better correlation with a calculated CePROP compared with
a solitary fast extracting midlatency auditory evoked potential
measure. Whether this improvement in pharmacodynamic
tracing is accompanied by an improved clinical performance
should be investigated using clinical endpoints.
PROCESSED analysis of the electroencephalogram or
midlatency auditory evoked potentials (MLAEPs) is in-
creasingly accepted as surrogate endpoint for quantiﬁca-
tion of anesthetic cerebral drug effect. For the electro-
encephalogram, the Bispectral Index (BIS) incorporated
in the A-2000 BIS® monitor (Aspect Medical Systems,
Newton, MA) has been proven to have a high sensitivity
and speciﬁcity to measure anesthetic drug effect.1–3 For
MLAEPs, Jensen et al.4 developed a new method for
extracting the MLAEP from the electroencephalogram
by using an autoregressive model with an exogenous
input (ARX), allowing fast extraction of the raw MLAEP
signal. A new monitoring variable called the A-Line® ARX
Index, version 1.5 (AAI1.5), is incorporated in a recently
commercialized monitor called the A-Line® (Danmeter
A/S, Odense, Denmark). Various investigators have illus-
trated its clinical usefulness and limitations.2,3,5,6
In previous work, we compared the performance of
both systems and found that the correlation between the
changes in anesthetic drug effect as measured by BIS or
AAI1.5 and the propofol effect site concentration
(CePROP) were accurate, except at baseline and during
excessive levels of anesthetic drug effect, as detected by
the increasing level of burst suppression.7 For BIS, better
baseline stability (minimal variability in the absence of
drugs between individuals) was observed as compared
with AAI1.5.
7 Excessive levels of anesthetic drug effect
remained detectable by the BIS monitor from a burst
suppression ratio of 40%, whereby no changes in AAI1.5
were observed during increasing levels of burst suppres-
sion.7 This lack of information is caused by the fact that
(1) burst suppression ratio does not participate in the
calculation of AAI1.5 and (2) at patient-speciﬁc levels of
anesthetic drug effect, the amplitude (latency) of the
raw MLAEP wave is reduced (increased) in such a way
that it becomes nearly a straight line, limiting its discrim-
inating power.8,9
In a recent editorial in ANESTHESIOLOGY, Kalkman and
Drummond10 stated that it might be proven ultimately, if
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we deem the grail of depth of anesthesia monitoring
worth pursuing, that the optimal monitor of depth of
anesthesia will be one that integrates parameters ex-
tracted from both spontaneous and evoked cerebral elec-
trophysiologic signals. Following this philosophy, the
ﬁrst step is to prove that this monitor has a good corre-
lation with cerebral anesthetic drug effect during the
administration of a hypnotic drug.10 Therefore, we hy-
pothesized that the construction of a composite index
calculated from the combination of a fast extracted
MLAEP, electroencephalogram, and burst suppression
might offer a broader range of information on the calcu-
lated effect site of propofol—as a pharmacodynamic
endpoint of cerebral anesthetic drug effect—compared
with an index based on solitary MLAEP or electroen-
cephalographic input. Recently, an upgrade version of
the A-Line® has been developed, producing such a com-
posite index, called the A-Line® auditory evoked poten-
tial index, version 1.6 (AAI1.6; Danmeter).
This study compares the accuracy of the BIS, AAI1.5,
and AAI1.6 in their ability to predict a progressively
increasing CePROP. Therefore, we evaluated for all mea-
sures the stability at baseline (minimal variability in the
absence of drug between individuals),11 accurate detec-
tion of burst suppression,12 prediction probability,13,14
and correlation with the CePROP. We also developed
pharmacodynamic models relating the predicted CePROP
to each measure of cerebral anesthetic drug effect.
Materials and Methods
Clinical Protocol
After institutional ethics committee approval (Univer-
sity Hospital, Ghent, Belgium), informed consent was
obtained from 13 patients (10 women, 3 men) with an
American Society of Anesthesiologists physical status of
I, aged 18–65 yr, who were scheduled to undergo am-
bulatory gynecologic or urologic surgery. Exclusion cri-
teria included weight less than 70% or more than 130%
of ideal body weight, neurologic disorder, and recent
use of psychoactive medication, including alcohol.
An 18-gauge intravenous line was positioned at a large
left forearm vein. Every patient received approximately
100 ml crystalloid ﬂuid during the study period. No ﬂuid
load was given before induction. No patient received
preoperative medication. No other drugs, including opi-
oids, were given during the study period. All patients
maintained spontaneously ventilating (even at high lev-
els of burst suppression) via a facemask delivering 100%
oxygen at 6 l/min.
Heart rate and noninvasive blood pressure, arterial
oxygen saturation, and capnography were recorded at
1-min intervals using an S-5 monitor (Datex, Helsinki,
Finland). Capnography was monitored by putting the
side stream sample line in the facemask of the patient.
This implies the occurrence of an error for quantiﬁcation
of the partial pressure of carbon dioxide, but it enables
monitoring of respiratory rate and free airway. A silent
operation room was obtained for all patients.
At the start of the study period, 1% propofol was
administered at 300 ml/h via a computer-assisted con-
tinuous infusion device (RUGLOOP**). This system cap-
tures all monitored data while driving a Fresenius Mod-
ular Infusion Pump connected to a Fresenius Base A
(Fresenius Vial Infusion Systems, Bre´zins, France) via an
RS-232 interface. During the propofol infusion, the cor-
responding CePROP is calculated in a time-synchronized
way by RUGLOOP using a three-compartment model
enlarged with an effect site compartment, previously
published by Schnider et al.15,16 The calculated CePROP
was computed to yield a time to peak effect of 1.6 min
after bolus injection,17 as also published by Schnider et
al.15,16 and clinically conﬁrmed by Struys et al. 18 The
propofol infusion was continued at the same speed until
burst suppression levels of 80% or higher were achieved.
However, infusion was stopped earlier if the mean arte-
rial blood pressure became lower than 50 mmHg.
Before the drug administration was started, all patients
were asked to close their eyes and relax for 2 min.
During that time, signal quality, impedance of the elec-
trodes, and the adequate detection of all parameters by
RUGLOOP were veriﬁed. Baseline measures were per-
formed during the ﬁrst 5 s after starting the pumps,
when CePROP was 0 in all patients. Averaging of the data
was performed using a 10-s interval.
Electroencephalographic and MLAEP Data
Collection
BIS-XP (version 4.0) was derived from the frontal elec-
troencephalogram (At-Fpzt) and calculated by the
A-2000 BIS® monitor using four BIS® sensor electrodes
(Aspect Medical Systems, Inc.). The BIS value ranges
from 0 to 100. The smoothening time of the BIS monitor
was set at 15 s.
We recorded raw electroencephalographic data in-
cluding the MLAEP data with a prototype version of the
A-Line® monitor. Three electrodes (A-Line® AEP elec-
trodes; Danmeter A/S) were positioned at mid forehead
(), left forehead (reference), and left mastoid ().
Impedance was always lower than 5 kOhm. In this pro-
tocol, MLAEP was elicited by a bilateral click at 9 Hz,
with a 2-ms duration and an adaptable click intensity set
automatically by the monitor according to the measured
signal-to-noise ratio (SNR) of the raw MLAEP signal.19
Artifact rejection and 25- to 65-Hz band-pass ﬁltering was
conducted previously to the extraction of the MLAEP.
All raw MLAEP data were stored on a compact ﬂash
card (SanDisk, Sunnyvale, CA) connected to the proto-
** RUGLOOP program. Available at: http://www.anesthesia-uzgent.be. Ac-
cessed April 11, 2005.
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type A-Line®. Post hoc, both AAI1.5 and AAI1.6 were
extracted from these data on a time synchronized basis.
The AAI1.5 is calculated using a fast extracting method
called ARX, enabling us to extract information from the
MLAEP within 2–6 s. This protocol has been published
elsewhere.2 The AAI1.5 value ranges from 0 to 100.
The AAI1.6 is a composite index using three sources of
information resulting in an index value ranging between
0 and 100. First, an ARX is used to extract information
from the raw MLAEP wave during periods with high
SNR. The method used is based on the AAI1.5 protocol
and is described elsewhere.4 When the MLAEP is re-
duced to a ﬂat line, the SNR becomes too low to extract
a useful AAI calculation. At that time, the electroen-
cephalographic-based information will determine the
AAI1.6 calculation. Finally, when burst suppression pat-
terns are detected, this information becomes the major
factor in the calculation of the composite index. The
AAI1.6 is mathematically formulated as
AAI1.6  k0AAI1.5  k1 log
E3047 Hz
E1020 Hz
 k2BS
where AAI1.5 is the result of the ARX model. E30–47 Hz
and E10–20 Hz are the results of a power analysis in the
raw electroencephalographic spectrum using higher and
lower frequencies, respectively. BS is the percentage of
burst suppression patterns detected during the last 30 s.
k0, k1, and k2 are functions of the SNR, the detection of
iatrogenic artifacts (translated in a signal quality index),
and the auditory stimulus intensity. The SNR is deter-
mined during the averaging process of the raw signal. It
evaluates the detection quality of the signal under inves-
tigation. For MLAEP, the occurrence of the electroen-
cephalogram, electromyogram, and other artifacts will
induce a lower SNR. For the electroencephalogram, only
electromyographic and iatrogenic artifacts will be taken
into account. The signal quality index is calculated based
on the number (and type) of artifacts during a certain
period of time. If the amount of artifacts per period of
time is higher than a percentage of this time, no AAI1.6 is
calculated because it is not reliable. If the number of
artifacts per period of time is less than this value, an
index is calculated, but the signal quality index bar is
decreased on screen, indicating a lower accuracy of the
calculated index. When this occurs, an artifact code is
transferred to the RUGLOOP program automatically.
These data were deleted post hoc from further analysis.
The burst suppression parameter is deﬁned as the
percentage of time where the power of the electroen-
cephalogram is smaller than 5 V over a period of time.
However, the calculation of burst suppression differs
between monitors. For BIS and AAI1.5, the burst suppres-
sion algorithm details are published previously.7
In the AAI1.6, the burst suppression detection algo-
rithm is based on a maximum likelihood cumsum algo-
rithm, with variable probability functions, using a pre-
processed signal after artifact detection and ﬁltering. The
main property of this method is that low-amplitude sig-
nal criteria are based on probabilities and not on a ﬁxed
number. Second, the signal has no ﬁxed segmentation,
allowing a higher time resolution for detecting changes
in comparison with other methods as applied in AAI1.5
and BIS. Finally, burst suppression is evaluated over a
window of 30 s in AAI1.6, instead of 22 s in the former
version.
Because it might be hypothesized that no additional
information on loss of consciousness is revealed for
AAI1.6 values between 60 and 100,
3 the A-Line® monitor
offers the possibility to adjust the range of the index
toward a 0–60 scale (deﬁned as AAI1.660). However, by
setting all values higher than 60 to 60, it has to be proven
that no information on cerebral anesthetic drug effect is
lost, which is crucial when using the monitor in a phar-
macodynamic protocol or in a clinical setting. Therefore,
applicable performance measurements (baseline vari-
ability, individualized Spearman rank correlation, predic-
tion probability analysis) were calculated on both scales.
Performance Measures
The signiﬁcance level was set at 5% unless otherwise
reported.
Baseline Variability. The baseline variability is calcu-
lated by computing the coefﬁcient of variance on the
electroencephalographic data points obtained during
the ﬁrst 5 s of the protocol, before any drug has been
delivered. In this setting, the baseline variability will
mainly reﬂect interpatient variability because of the
short duration of measurement.
Comparison between AAI1.5 and AAI1.6. A Pearson
correlation was calculated between AAI1.5 and AAI1.6.
Burst Suppression Detection and Parameter Cor-
relation. The relations between the burst suppression
and each measure of anesthetic drug effect are plotted. A
Spearman rank correlation was calculated. For each scat-
terplot, a model was ﬁtted to the data using curve esti-
mation function from Sigmaplot2000® for Windows®
(SPSS Inc., Chicago, IL). The curve estimation function
produces curve estimation regression statistics and re-
lated plots for different curve estimation regression mod-
els including linear, logarithmic, inverse, quadratic, cu-
bic, power, compound, S-curve, logistic, growth, and
exponential. A separate model is produced for each
dependent variable, together with its regression coefﬁ-
cients, predicted values, residuals, and predictive inter-
vals. After this, the most appropriate regression model
can be selected.
Prediction Probability. The ability of the different
indicators to describe the anesthetic drug effect was
evaluated using prediction probability (PK), which com-
pares the performance of indicators having different
units of measurements. PK was calculated using a custom
502 VEREECKE ET AL.
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spreadsheet macro PKMACRO, developed by Smith et
al.13,14 The PK value was calculated for every individual
patient and for all parameters studied. We evaluated the
predictive capacity of BIS, AAI1.5, and AAI1.6 for detect-
ing the calculated CePROP, which has a known correla-
tion with the anesthetic drug effect.18 The calculated
CePROP reached at every 5 s was used as an endpoint for
PK calculation. CePROP was calculated with a precision of
two decimals. A PK of 1 for BIS, AAI1.5, or AAI1.6 would
mean that BIS, AAI1.5, or AAI1.6 always decreases (in-
creases) as the patient reaches higher (lower) drug con-
centrations according to the CePROP. Such an indicator
can perfectly predict the anesthetic drug concentration.
Alternatively, a PK value of 0.5 would mean that the
indicator is useless for predicting anesthetic drug con-
centration. The jackknife method was used to compute
the SE of the estimate, based on the assumption that all
assessments were independent.13,14 After having evalu-
ated normal distribution, a Student t test with Bonferroni
correction was used to evaluate signiﬁcant difference
between PK means.
Individualized Spearman Rank Correlation. As an
additional nonparametric approach, the Spearman rank
correlations between CePROP and BIS, AAI1.5, or AAI1.6
(both scales) were individualized by computing the cor-
relation ﬁrst for every patient i separately, deﬁned as Ri.
The reported Spearman rank correlation, R, is a
weighted average of the Ri (weighted according to the
number of observations for each patient). In this way, R
retained its usual interpretation. The conﬁdence inter-
vals on R were obtained by the bootstrap method in
which the hierarchical nature of the data were incorpo-
rated by resampling within patients. Equality of two
correlation coefﬁcients was tested at the 5% level of
signiﬁcance by constructing the 95% conﬁdence inter-
vals of the difference (conﬁdence intervals were also
computed with the bootstrap technique). All bootstrap
calculations were based on 10,000 simulation runs.
Pharmacodynamic Modeling
The relation between CePROP and the electroencepha-
lographic measures of anesthetic drug effect were ana-
lyzed using a sigmoid Emax model,
Effect  E0
Emax E0 
 Ce
Ce50Ce
where Effect is the electroencephalographic effect being
measured (BIS, AAI1.5, or AAI1.6 [both scales]), E0 is the
baseline measurement when no drug is present, Emax is
the maximum possible drug effect, Ce is the calculated
effect site concentration of propofol, Ce50 is the effect
site concentration associated with 50% maximal drug
effect, and  is the steepness of the concentration–
response relation curve. The model parameters were
estimated using NONMEM V (Globomax LLC, Hanover,
MD). Interindividual variability was modeled using a log-
normal distribution,
Pi  Ptve
i
where Pi is the parameter value (E0, Emax, y or Ce50) in
the ith patient, Ptv is the typical value of the parameter in
the population, and  is a random variable with a mean
of 0 and a variance of 	.2 Individual variability is re-
ported as 	, the SD of  in the log domain, which is
approximately the coefﬁcient of variance in the standard
domain. Residual intraindividual variability was modeled
using a standard additive error model.20
Results
The population characteristics were as follows:
weight, 64.0  3.8 kg; age, 38  6.0; height, 168 
7.8 cm; sex, 10 women and 3 men. All patients remained
within a safe hemodynamic and respiratory clinical state.
All measured data were included in the analysis. Figure
1 shows the raw data over time for the four electroen-
cephalographic measures (BIS, AAI1.5, AAI1.6, AAI1.660)
and CePROP. All patients remained in a hemodynamic and
respiratory safe condition during the study period.
Fig. 1. Raw data of all patients versus time. AAI1.5 A-Line
® ARX
Index version 1.5; AAI1.6  A-Line
® ARX Index version 1.6
(scaled to 100); AAI1.660  A-Line
® ARX Index version 1.6
(scaled to 60); BIS  Bispectral Index; CePROP  effect site
concentration of propofol (the disruption in the continuously
increasing CePROP is due to the inevitable change of the 1%
propofol syringe around 600 s.)
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Performance Measures
The interpatient baseline variability was calculated for
all studied electroencephalographic measures (BIS,
AAI1.5, AAI1.6, AAI1.660). The coefﬁcient of variance on
the ﬁrst 5 s of measurement before administration of
propofol is shown in table 1.
AAI1.5 and AAI1.6 (both scaled between 0 and 100)
were compared as shown in ﬁgure 2. This shows a
strong correlation between both AAI versions (Pearson
correlation R  0.91209833, P  0.001). We notice a
large variability at high values of both parameters and a
tendency for AAI1.5 to remain on a higher value at higher
levels of CePROP in comparison with AAI1.6. For AAI1.5,
no data lower than 7 are observed in contrast to AAI1.6.
The relations between the percentage of burst sup-
pression and BIS, AAI1.5, and AAI1.6 are plotted in ﬁgure
3 together with the most appropriate curve estimation.
For BIS, a cubic polynomial regression curve was con-
sidered to be the best ﬁt. For AAI1.5 and AAI1.6, a sigmoid
regression curve with three parameters was selected as
the best ﬁt. For AAI1.660, identical results to AAI1.6 were
found. Therefore, no graph is presented. The Spearman
rank correlations between burst suppression and BIS,
AAI1.5, and AAI1.6 are 0.728, 0.551, and 0.871,
respectively.
The PK values for BIS, AAI1.5, AAI1.6, and AAI1.660 are
shown in table 2. The individualized Spearman rank
correlations between CePROP and BIS, AAI1.5, AAI1.6, and
AAI1.660 are also included in table 2.
Pharmacodynamic Modeling
Figure 4 shows the behavior of the four electroen-
cephalographic measures versus CePROP for all patients.
With increasing CePROP, all measures decreased. The
relations of CePROP to BIS, AAI1.5, AAI1.6, and AAI1.660
are modeled and shown in ﬁgure 5. The typical param-
eter values for each population model including the
coefﬁcient of variance (as a measure for interindividual
variability in the standard domain) are found in table 3.
The SD for each model (as a measure of the intraindi-
vidual variability in the log domain) was 5.63 for BIS,
13.67 for AAI1.5, 7.24 for AAI1.6, and 4.02 for AAI1.660.
Discussion
This study shows that the application of a composite
index (AAI1.6) based on MLAEPs and spontaneous elec-
troencephalography optimizes the prediction of CePROP
as compared with a solitary fast extracting MLAEP mea-
sure (AAI1.5). Comparing several monitors for cerebral
hypnotic drug effect demands a systematic approach.
The methodology used in this trial is based on a former
Table 1. Baseline Stability Deﬁned as the Coefﬁcient of Variation of All Measures
BIS AAI1.5 AAI1.6 (Scaled 0–100) AAI1.6 (Scaled 0–60)
Mean  SD 96.12  2.40 90.06  21.16 87.00  20.60 58.69  8.58
Coefﬁcient of variation 0.02 0.23 0.24 0.15
AAI1.5  A-Line
® ARX Index version 1.5; AAI1.6  A-Line
® Composite Index (both scales); BIS  Bispectral Index.
Fig. 2. Correlation between the A-Line® ARX Index version 1.5
(AAI1.5) versus A-Line
® ARX Index version 1.6 (AAI1.6). The
black line shows the most appropriate linear correlation.
Fig. 3. Correlation between burst suppression and the A-Line®
ARX Index are shown for the versions 1.5 (AAI1.5) and 1.6
(AAI1.6), respectively. The lower ﬁgure shows the correlation
between the suppression ratio versus the Bispectral Index
(BIS). The black line is the most appropriate ﬁtted regression.
The regression curve formula is printed in the right upper
corner of every ﬁgure. R 2  the goodness of ﬁt of the regres-
sion curve.
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publication from Vanluchene et al.,7 where spectral en-
tropy is compared with BIS and AAI1.5.
The A-Line® monitor offers the possibility to reduce
the upper scale limit to 60, based on the rationale that
values between 60 and 100 suffer from a high interpa-
tient variability and offer no additional information on
loss of consciousness.2 Although this adjustment might
be interesting on a clinical level, it is crucial to prove
whether this scale is applicable to pharmacodynamic
studies investigating subhypnotic levels of anesthesia
(when consciousness is not lost), without losing any
information on the propofol drug concentration. There-
fore, we also investigated the performance accuracy of
the AAI1.660 as an individual index.
High baseline variation, as deﬁned by the coefﬁcient of
variance, might decrease the predictive ability of the
electroencephalogram-derived measures when used to
detect cerebral drug effect, as stated by Bruhn et al. 11
BIS showed the lowest baseline variability. In contrast,
AAI1.5 and AAI1.6 showed a high but comparable coefﬁ-
cient of variance. We found a major improvement in
baseline variability in AAI1.660 in comparison to AAI1.5
and AAI1.6. Although it is potentially interesting when
applying the A-Line® monitor clinically to monitor loss of
consciousness, one might question that it does not make
sense to reduce baseline variability by cutting of data
higher than 60, if this new scale causes a decreased
sensitivity for the detection of subhypnotic levels of
anesthetic drug effect. This reduced upper limit only
makes sense if the other performance measures reveal a
beneﬁcial effect.
Burst suppression is a benign electroencephalographic
pattern frequently seen in healthy brain at deep levels of
anesthesia. Because the detection of burst suppression
represents an important component to the level of hyp-
notic effect, it might be helpful to take into account
burst suppression analysis when measuring deep levels
of anesthetic drug effect because it might optimize the
discriminating power of the investigated index at these
levels. For BIS, burst suppression is included in the
Fig. 4. Raw data of all anesthetic drug effect measures versus
calculated effect site of propofol (CePROP). AAI1.5  A-Line
® ARX
Index version 1.5; AAI1.6  A-Line
® ARX Index version 1.6
(scaled to 100), AAI1.660  A-Line
® ARX Index version 1.6
(scaled to 60).
Fig. 5. NONMEM regression of the population data. AAI1.5 
A-Line® ARX Index version 1.5; AAI1.6  A-Line
® ARX Index
version 1.6; BIS  Bispectral Index; Ce propofol  effect site
concentration of propofol.
Table 2. Individualized Spearman Rank Correlation Coefﬁcients and Prediction Probability for Each Electroencephalographic
Measure of Anesthetic Drug Effect versus Propofol Effect Site Concentration
BIS AAI1.5 AAI1.6 AAI1.660
PK, median (minimum–maximum) 0.91 (0.70–0.98) 0.90 (0.73–0.94) 0.92 (0.75–0.98) 0.89 (0.75–0.97)
Individualized Spearman rank
correlation, mean  SD (95% CI)
0.686  0.033
(0.748, 0.618)†
0.661  0.032
(0.721, 0.597)*†
0.753  0.031
(0.813, 0.691)*†
0.959  0.005
(0.967, 0.949)†
* P  0.05 between AAI1.5 and AAI1.6. † P  0.05 between AAI1.660 and all other measures.
AAI1.5  A-Line
® ARX Index version 1.5; AAI1.6  A-Line
® ARX Index version 1.6 (scaled to 100); AAI1.660  A-Line
® ARX Index version 1.6 (scaled to 60);
BIS  Bispectral Index; CI  conﬁdence interval; PK  prediction probability.
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algorithm. Various authors have found that above a burst
suppression ratio of 40%, a linear correlation exists be-
tween BIS and burst suppression ratio, indicating that
the burst suppression ratio is the only determinant factor
for BIS values below 30.7,21 Our results for BIS, as shown
in ﬁgure 3, are in agreement with these previously pub-
lished ﬁndings. If burst suppression was excluded from
the algorithm, BIS would become very resistant at exces-
sive levels of anesthetic drug effect. In contrast, the
calculation of the AAI1.5 is only based on the MLAEP. As
already observed in previous work, the MLAEP ﬂattens at
patient-speciﬁc levels of anesthetic drug effect, thereby
limiting its discriminating power.7–9 This phenomenon
results in a maximum decreased AAI1.5 “plateau” level
higher than 0. As shown in ﬁgures 2 and 4, the lowest
observed AAI1.5 values are ceiled around 7. Beyond this
level, no additional information on cerebral drug effect
can be obtained. When taking in consideration that the
ED95 for loss of consciousness is around 19 for AAI1.5,
the discriminating power might become very low after
loss of consciousness. For AAI1.6, the electroencephalo-
gram and burst suppression are included as a component
of the composite index as described in the Materials and
Methods section. This results in an increased discrimi-
nating power at deep levels of anesthetic drug effect. As
shown in ﬁgure 3, the absolute values of AAI1.6 are able
to decrease to 0 at increasing levels of burst suppression.
This improvement between AAI1.5 and AAI1.6 is also
reﬂected in the statistically signiﬁcant better individual-
ized Spearman rank correlation for AAI1.6 (table 2).
When studying performance accuracy, the question is
how well the observed measure, which is the electroen-
cephalographic response, predicts the unobserved “un-
derlying” state of the patient, which is represented by
the CePROP. Therefore, PK was calculated for BIS, AAI1.5,
AAI1.6, and AAI1.660. The underlying theoretical back-
ground of PK calculations has been published else-
where.7 In our study, we did not obtain any signiﬁcant
difference between PK values, although AAI1.6 tended to
have the highest median value.
As an additional analysis for correlation between pa-
rameters and CePROP, we calculated the Individualized
Spearman rank correlation coefﬁcients for each measure.
This weighted nonparametric statistical approach de-
picts the nonlinearity in the system much more accu-
rately as compared with PK analyses. Results conﬁrm the
signiﬁcant increase in correlation between AAI1.6 versus
CePROP in comparison to AAI1.5, thereby proving that the
combination of MLAEP and derived measures from the
spontaneous electroencephalogram (power spectrum
analysis and burst suppression calculation) increases the
accuracy to measure cerebral anesthetic drug effect.
Initially, no difference was found between BIS and AAI1.5
or between BIS and AAI1.6 when scaled to 100. However,
when the upper limit of the scale was reduced to 60,
remarkable results were observed. Figure 4 shows that a
high variability and a high amount of nonlinearity are
observed in all measures when scaled to 100. For AAI1.6,
one can say that the signal between 60 and 100 nearly
behaves as “random noise.” By eliminating this part of
the AAI1.6 range, the high variability resulting in a high
level of nonlinearity is drastically reduced. This results in
a very high individualized Spearman rank correlation as
shown in table 2. However, one can raise the question of
whether a constant number around 60 offers more in-
formation compared with the complete scale, both
when predicting propofol anesthetic drug effect and
when evaluating a clinical level of sedation before loss of
consciousness is obtained. This must be studied in fur-
ther research. We were not able to evaluate the clinical
level of sedation in this population because we wanted
to avoid any stimulation during induction.
Figure 5 shows the pharmacodynamic modeling for all
measures versus CePROP. Previously, the relation be-
tween measures of anesthetic drug effect and CePROP
was observed following a sigmoid Emax model. There-
fore, in our study, the relation between the measures of
anesthetic drug effect and CePROP was also modeled
using a sigmoid Emax model, and the model parameters
were estimated using a population approach. In
NONMEM, the parameters in the individual are weighted
in a Bayesian manner toward the mean for the popula-
tion, based on the variance of the individual parameters.
Examining our raw data, we found for all parameters a
single sigmoid regression to be adequate for describing
the range of concentrations used in this study. When
looking at ﬁgure 5, one can conclude that the smoothest
regression is found in AAI1.660. This is reﬂected in an
optimization of both the interindividual and the intrain-
dividual variability in the population. In table 3, the
coefﬁcients of variation of the typical values of the ce-
rebral drug effect measures reveal a major decrease in
Table 3. Typical Values and Coefﬁcients of Variation for Each Electroencephalographic Measure of Anesthetic Drug Effect.
BIS AAI1.5 AAI1.6 (Scaled 0–100) AAI1.6 (Scaled 0–60)
Ce50 6.25 (210%) 6.28 (50%) 5.71 (36%) 6.78 (36%)
E0 92.90 (66%) 74.00 (50%) 79.20 (59%) 57.40 (4%)
Emax 83.60 (127%) 65.70 (36%) 87.50 (31%) 60.00 (31%)
 2.59 (45%) 5.09 (0%) 1.98 (57%) 2.61 (38%)
AAI1.5  A-Line
® ARX Index version 1.5; AAI1.6  A-Line
® ARX Index version 1.6; BIS  Bispectral Index; Ce50  the effect site concentration associated with
50% maximal drug effect; E0  the baseline measurement when no drug is present; Emax  the maximum possible drug effect;   the steepness of the
concentration–response relation.
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the interindividual variability of the slope () when
AAI1.660 is compared to AAI1.6. Simultaneously, a de-
crease in intraindividual variability at baseline is ob-
served for AAI1.660, reﬂected by the lower SD compared
with AAI1.6. However, we want to stress the fact that the
regression analysis for AAI1.660 should be interpreted
cautiously because of the effect of rejection of data on
the NONMEM analysis. It might cause a distortion on the
data input in such a way that the behavior of the popu-
lation regression is closer to the a priori chosen Emax
model. Further research is needed to clarify whether this
result is an artiﬁcial overestimation of the performance
parameters or whether AAI1.660 is indeed able to maintain
a high performance as a hypnotic drug effect monitor.
We conclude that the use of the composite index
AAI1.6, which combines information from the MLAEP,
spontaneous electroencephalogram, and burst suppres-
sion, increases the correlation with the cerebral drug
effect of propofol as compared with the AAI1.5, which is
a solitary fast extracted MLAEP index. By adjusting the
upper scale limit to 60, the performance measures are
optimized even more. However, the implications of this
newly chosen upper scale limit should be further
explored on both the clinical and the pharmacodynamic
level.
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3.4.1 Introduction 
As an additional validation, we investigated the performance of A-Line® auditory evoked 
potential Index (AAI) for measuring the hypnotic component of “difficult anesthetic molecules”. 
Generally, anesthetic cerebral drug effects are considered to be mediated by the gamma 
amino butyric acid (GABA) receptor (e.g. this is the case for propofol). However, a secondary 
pathway, mediated by the N-methyl D-Aspartate (NMDA) receptor can also produce clinical 
anesthesia. A typical NMDA dependent molecule that is used in clinical practice is ketamine.  
 
Ketamine is a dissociative anesthetic drug that disrupts the transfer of sensory input to the 
association areas in the brain. In other words, the patient remains capable to receive sensory 
input, but the brain is not able to organize this in a comprehensive way. Therefore, the patient 
will be “unconscious” of his sensory experiences. An interesting side-effect for anesthesia 
practice is that the patients keep breathing spontaneously, and that the hemodynamic impact 
of ketamine is low. As ketamine evokes EEG changes resembling to epileptic insults, all EEG 
derived indices become distorted.(1) Schwender had studied the effect of ketamine on raw 
MLAEP, but no information was available on the performance of AAI during ketamine 
administration.(2,3) 
 
We studied the effects of ketamine on the first version of the A-Line® auditory evoked 
potential Index (AAI), during a steady state propofol anesthesia that was obtained by TCI 
technology. We compared AAI with simultaneous measurements of BIS. 
 
We found that ketamine had no effect on the mean AAI in the population, although it has a 
known clinical potentiating effect on propofol. Therefore, a perfect measure of the cerebral 
hypnotic drug effect should decrease due to this interaction.(4) Mean BIS was increased, 
which confirmed results of other authors.(4) As an additional finding we found an increase in 
variability of AAI after ketamine administration. We hypothesized that this could be caused by 
an increase in electromyographic interference. 
 
We conclude that neither AAI nor BIS were able to detect the potentiating hypnotic effects of 
ketamine during propofol anesthesia. As the mean AAI remains constant, one might consider 
that AAI is safer to use during anesthesia involving ketamine, as it has a potentially lower 
incidence of false high “awareness” detection in this setting, compared to BIS. 
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Summary
We evaluated the effects of a bolus (0.4 mg.kg)1) and continuous infusion (1 mg.kg)1.h)1) of
ketamine on Bispectral Index (BIS) and A-Line ARX Index (AAI) during propofol anaesthesia.
We included 15 ASA I patients scheduled for general anaesthesia. Induction was performed by
infusion of propofol at 100 ml.h)1 until loss of consciousness. Both BIS and AAI monitors
responded appropriately at that time. The calculated effect site concentration of propofol at loss of
consciousness was maintained by means of a computer controlled infusion system. A ‘pseudo’
steady-state effect site concentration was reached after 4 min. After 1 min of baseline measure-
ments, ketamine was administered. BIS values increased from the 3rd to the 8th min after the
administration of ketamine. The AAI showed no signiﬁcant increase or decrease, but between-
patient variability increased.
Keywords Monitoring: Auditory evoked potentials. Bispectral index. Anaesthetic drugs: Ketamine.
Propofol.
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Ketamine used as an adjuvant during propofol anaesthesia
has potentiating effects on clinical signs like ‘unrespon-
siveness to verbal command’ and ‘loss of eyelash reﬂex’ [1].
However, the dissociative state of anaesthesia evoked by
ketamine is characterised by confusing effects on both the
electroencephalographic (EEG) and auditory evoked
potential monitors [2–4]. For the EEG, bispectral index
(BIS) incorporated in the A-2000 BIS monitor (Aspect
Medical Systems Inc., Newton, MA) has been proven to
have a high sensitivity and speciﬁcity to measure anaes-
thetic drug effect, compared with other processed EEG
variables [5, 6]. With respect to auditory evoked poten-
tials, Jensen et al. developed a new method for extracting
the middle latency auditory evoked potentials (MLAEP)
from the EEG signal by employing an autoregressive
model with an exogenous input (ARX) adaptive model.
This method allows extraction of the MLAEP signal
within 15–25 sweeps of 110 ms duration each, resulting in
only a 6–15-s response delay time [7, 8]. A new
monitoring variable, called the AAI (A-Line ARX-
Index), is then calculated from this fast extracted MLAEP
wave. The calculations of the AAI are described elsewhere
[9, 10]. This new technology is incorporated in a recently
commercialised system, called A-Line. (Developed and
distributed by Danmeter A ⁄ S, Odense, Denmark).
As the clinical signs of the hypnotic state seem to be
potentiated by ketamine, one might hypothesise a
reduction in the measured BIS value or a decrease in
amplitude and latency of the MLAEP curves, resulting in
a lower AAI. However, several authors have described an
apparently contradictory rise in BIS values when ket-
amine is administered as an adjuvant to anaesthesia
[1, 11, 12]. Schwender et al. investigated the effects of
ketamine induction on the MLAEP and concluded that
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ketamine had no inﬂuence on amplitudes or latencies of
the peaks of MLAEP [2]. However, no data are available
for the AAI. Therefore, we determined to investigate the
effects of ketamine administration on the AAI during
steady-state propofol anaesthesia.
Methods
After local Ethics Committee approval and written
informed consent, 15 ASA I patients, aged 18–60 years,
scheduled for general surgery were included. Exclusion
criteria included weight less than 70% or more than 130%
of ideal body weight, neurological disorders, and recent
use of psycho-active medication, including alcohol.
For induction, a continuous infusion of propofol was
started at 100 ml.h)1 until loss of consciousness (LOC)
using a Fresenius Modular DPS Infusion Pump connected
to a Fresenius Base 1 (Fresenius Vial Infusion Systems,
Bre´zins, France). As this pump was controlled using a
computer-assisted infusion device (RUGLOOP**) we
were able to track the calculated plasma and effect-site
propofol concentration. Both concentrations of propofol
were computed using a three-compartment pharmaco-
kinetic-dynamic model enlarged with an effect-site com-
partment, previously published by Schnider et al. [13].
Effect site concentration was computed to yield a time to
peak effect of 1.6 min after bolus injection [13]. At loss of
consciousness (LOC), deﬁned by the clinical signs of ‘loss
of eye-lash reﬂex’ and ‘loss of response to name calling’,
the calculated effect site concentration was recorded and
the propofol infusion system was adjusted to an effect
compartment controlled infusion device using the same
pharmacological model [13]. The target effect site con-
centration was set at the same effect site concentration as
recorded at LOC. This infusion proﬁle was continued
throughout the study period. Using this method, we were
able to reach and maintain a stable (‘pseudo steady-state’)
and comparable hypnotic level between and within
patients at 4 min after LOC (2.5 times ‘time to peak
effect’). We refer to this as a ‘pseudo’ steady-state as it is
the best approximation of a real pharmacodynamic steady
state available at this time. The time between the 4th and
5th min after LOC was used as baseline registration. At the
5th minute after LOC, a bolus of ketamine (0.4 mg.kg)1)
was administered over 5 s followed by a continuous
infusion of 1 mg.kg)1.h)1 for 17 min. Ketamine was
administered as described previously by Hirota et al. [4].
Heart rate and non-invasive blood pressure, SpO2 and
capnography were recorded at 1-min intervals using an
AS3 monitor (Datex, Helsinki, Finland). BIS (version 3.4)
was derived from the frontal EEG (At-Fpzt) and
calculated by the A-2000 BIS monitor using a BIS sensor
(Aspect Medical Systems, Inc., Newton, MA). The
smoothening time of the BIS monitor was set at 15 s.
The AAI from the MLAEP was calculated using the
A-Line monitor (version 1.5; Danmeter A ⁄ S, Odense
Denmark). TheMLAEPwere elicited with a bilateral click
stimulus of 70 dB intensity and 2 ms duration. Three
electrodes (A-Line AEP electrodes, Danmeter A ⁄ S,
Odense Denmark) were positioned at mid forehead (+),
left forehead (reference) and left mastoid (–). The extrac-
tion of the MLAEP using a short Moving Time Average
(MTA) technique together with an ARX model and the
calculations of the AAI are described else where [9].
All haemodynamic data together with BIS and AAI
indices were logged automatically. RUGLOOP recorded
the BIS every 10 s, and the A-Line monitor recorded
AAI values nominally each second. The AAI was
averaged afterwards within 10-s intervals.
Statistical analysis
Signiﬁcance level was set at 5% unless otherwise reported.
For statistical comparison with baseline values, all recor-
ded BIS and AAI values were averaged every minute. As a
baseline, we calculated the average AAI and BIS during
the last minute of steady state before the administration of
ketamine. Normality of all data was tested with the
Kolmogorov–Smirnov test. Mean and standard deviation
(SD) of all the minute-by-minute data was calculated. A
paired t-test with Bonferroni correction was performed to
evaluate any signiﬁcant difference between the baseline
BIS and AAI and the consecutive minute-by-minute
values, with signiﬁcance level set at 0.003. For BIS and
AAI, coefﬁcient of variance (CV) between baseline and
each consecutive minute-by-minute data point was
compared. To evaluate the stability of depth of anaes-
thesia at baseline we compared the ﬁrst and last datapoint
during the 4th min of ‘pseudo’ steady-state with a paired
t-test for both AAI and BIS.
Results
Demographic data are shown in Table 1.
Figure 1A,B shows the raw data, respectively, for BIS
and AAI vs. time. Whereas BIS appears to increase for a
period after the ketamine bolus, this is not true for AAI.
Both the within- and between-individual variability
appear to be smaller for BIS than for AAI.
Table 1 Patients’ demographic data.
Variable Mean (SD)
Age; years 40.63 (15.66)
Height; cm 172.25 (7.89)
Weight; kg 67.81 (16.20)
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Figure 2A,B shows the minute-by-minute calculations
of the mean (SD) for BIS and AAI. For the mean BIS, a
signiﬁcant increase is observed after the start of ketamine
administration from 3 min to 8 min, as shown in Fig. 2A.
However, from 9 min until the end of the procedure, a
constant decrease in mean is observed. The minute-
by-minute mean AAI reveals no systematic pattern and
there is no statistically signiﬁcant difference with respect
to baseline (Fig. 2B).
For both BIS and AAI, the corresponding coefﬁcient of
variance (CV) is indicated above every SD bar in Fig. 2A,
B. The CV for BIS did not change after the start of the
ketamine administration compared to baseline. In con-
trast, the CV for AAI revealed a stable increase after
ketamine.
The ﬁrst and last value of the AAI and BIS during
baseline measurements did not differ signiﬁcantly for any
of the study patients.
Discussion
Ketamine has unique features within the spectrum of
anaesthetic drugs. It has both hypnotic and analgesic effects
which, in combination with steady-state propofol anaes-
thesia, have an additive effect on the clinical signs of the
hypnotic component of anaesthesia [1, 3, 4]. In contrast to
other drugs used in anaesthesia, the hypnotic effect of
ketamine is based on a dissociative mechanism. This term
refers to the original suggestion that ketamine does not
block the sensory input at spinal or brainstem levels, but
interrupts afferent impulses in the diencephalon and in the
association area of the cortex (limbic system) [14]. Previ-
ously, various authors have studied the electroencephalo-
graphic behaviour of ketamine. Corssen et al. showed that
ketamine 1 mg.kg)1 i.v. caused heightened theta activity
on the EEG [14]. Schwender et al. found no effect of a
ketamine induction (2 mg.kg)1 i.v.) on the MLAEP [1].
Figure 1 Raw data of the individual
proﬁles of BIS (1A) and AAI (1B) vs.
time. Baseline (B) is calculated from the
data during pseudo steady-state anaes-
thesia, 4 min after loss of consciousness.
At 1 min, a bolus of ketamine was
administered and a continuous infusion
started.
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Recently, processed EEG and MLAEP derived indica-
tors such as BIS and AAI have been applied in clinical
practice as a measure of anaesthetic depth [9]. Therefore,
we studied the behaviour of both indices during ketamine
administration. It was observed that BIS values increased
signiﬁcantly from the 3rd min until the 8th min after the
administration of ketamine, followed by a subsequent
decrease for the rest of the study period. This increase was
consistent in all patients, reﬂected by a stable CV compared
to baseline, as shown in Fig. 2A. The initial increase in BIS
values might be related to the temporary high ketamine
concentration after the bolus injection. Our dosage scheme
was used previously to investigate the behaviour of
ketamine on BIS [4]. The pharmacokinetic proﬁle of this
scheme does not evoke stable plasma concentrations in the
patient. This might explain the secondary decrease after the
initial increase in BIS. Our results are in agreement with
Hirota et al. [4], who concluded that ketamine increased
BIS during propofol–fentanyl anaesthesia despite a deep-
ening level of hypnosis.
In contrast with the BIS, the mean AAI showed no
signiﬁcant change after ketamine administration. Altho-
ugh this is in agreement with previous reports using raw
MLAEP [2], the increase in CV suggests an enlarged
interindividual variability and less stability in the AAI
trends. This makes interpretation of the individual AAI
more difﬁcult. In previous reports, an increased instability
of the MLAEP during ketamine administration was not
observed. However, in these studies a long average time
of 2 min was required to obtain one clinically usable AEP
signal, possibly resulting in less ﬂuctuating data [2]. Our
AAI data were recorded using a fast extracted MLAEP
signal, resulting in only a 6-s delay and continuous data
generation.
Figure 2 Plots of mean (SD) BIS (2A)
and AAI (2B) vs. time. The coefﬁcient
of variance (CV) is noted above every
SD bar. Baseline (B) is calculated from
the data during pseudo steady-state
anaesthesia, 4 min after loss of con-
sciousness. At 1 min a bolus of ketamine
was administered and a continuous
infusion started. *Signiﬁcant difference
with respect to baseline.
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The results of BIS and AAI might be caused by
instability in the propofol plasma and effect site concen-
trations due to a hypothetical interaction of ketamine on
the pharmacokinetic characteristics of propofol. This
protocol was not designed to demonstrate such an
interaction. Moreover, we put every effort into avoiding
disequilibrium in the effect site concentration of propofol
before and during the delivery of ketamine. We took care
to deliver the best approximation of a pharmacodynamic
steady state by using effect compartment controlled
target-controlled infusions as described previously. By
comparing the ﬁrst and the last baseline BIS and AAI
values, we have additional conﬁrmation of a clinically
comparable depth of anaesthesia during the study period.
The variety of mechanisms and sites of action of
hypnotic drugs can partly explain some of the phenomena
that we have demonstrated. BIS and AAI were developed
as monitors for the mechanisms that create a hypnotic
state, but the question remains as to whether they are
capable of evaluating all sites of action of the different
hypnotics. BIS evaluates the raw EEG signal. A moderate
dose of ketamine produces dominant frontal rhythmic
theta activity with increases in amplitude [3, 15]. This
may evoke an increase in BIS that is not compatible with
the clinical signs.
The methods applied in this study demand the
simultaneous use of both BIS and A-Line monitoring.
Other studies have demonstrated that the auditory stimuli
provoked by the A-line monitor do not inﬂuence the BIS
or the clinical signs of depth of anaesthesia [16,9].
Our study could not demonstrate a signiﬁcant change
in mean AAI after ketamine administration. This does not
prove that ketamine does not inﬂuence the primary
processing of the AEP. As an increase in CV was detected
after ketamine injection, we suspect a ﬂuctuation in the
primary sensory cortex or at a lower level. As the cause of
this phenomenon remains unclear, further investigations
are mandatory.
We conclude that, in our study, BIS and AAI failed to
describe the clinical interaction between ketamine and
propofol anaesthesia. Mean BIS values were increased
consistently and mean AAI showed no signiﬁcant change
after the administration of ketamine. The variability of
BIS remained stable. In contrast, the coefﬁcient of
variance of AAI increased signiﬁcantly, making interpret-
ation of the individual AAI more difﬁcult.
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3.5.1 Introduction 
This study expands the problem of “difficult molecules” to a more general predicament for 
AAI, BIS or Spectral Entropy (SE and RE). The problematic conditions for EEG and MLAEP 
derived monitors are characterized by “high-frequency” interferences in the raw EEG. These 
conditions can be both drug induced (e.g. by ketamine, cf. study 5) or by 
electrophysiological  interferences (e.g. by the EMG).(1-7) 
 
Neuro-muscular blocking agents (NMBA), such as rocuronium, are commonly used to obtain 
immobility during surgery. As NMBA abolish all electrical signal transition from the neurons 
to the muscles, a general muscular paresis sets in, characterized by a complete inhibition of 
the EMG. It has been shown that both the EMG activity as well as the administration of 
NMBA can interfere with electroencephalographic or mid-latency auditory evoked potentials 
monitoring.(5,7-9) Mostly, EMG and NMBA respectively cause an increase/decrease in the 
EEG and MLAEP derived index calculations. Apparently, there is always some EMG activity 
included in the index algorithm calculations. It remains a challenge to filter this EMG 
interference more accurate. 
 
Our main study goal was to exclude whether the increased variability for AAI, after ketamine 
administration, as demonstrated by Vereecke et al,(1) could be partially caused by an 
electromyographic alteration. Our hypothesis was based on the clinical impression that the 
administration of ketamine in a spontaneously breathing patient activated the EMG. 
Additionally, we found in the scientific literature that the basic locomotor rhythmicity in cats 
was N-Methyl D-Aspartate (NMDA) receptor dependent.(10) We felt these observations 
were sufficiently important for performing a new study combining the effects of ketamine and 
rocuronium.  
 
After implementing a “steady-state” anesthesia with remifentanil and propofol, we 
randomized 42 patients in four groups. In a time synchronized way, the patients received 
ketamine (Group Ket), rocuronium (Group Roc) or both (Group Roc+Ket). The fourth group 
was a control group that received no additional medication. This setup allowed conclusions 
on several additional research questions that had not yet been answered: 
 
 1 What is the effect of ketamine on the new composite index AAI1.6? 
 2 What is the effect of ketamine on the SE and RE? 
 3 What is the effect of solitary rocuronium on the new AAI1.6? 
 4 What is the effect of solitary rocuronium on SE and RE? 
 
We performed a within and between group analysis. From this, we concluded that the 
effects of ketamine are independent of the changes in EMG. Rocuronium does not abolish 
or reduce the effects of ketamine on any monitor. Therefore or primary hypothesis was 
rejected. We also found that rocuronium decreases all indices except SE, indicating the 
inclusion of EMG information in most index calculations. The increasing effect of solitary 
ketamine on BIS, RE and SE has been confirmed in our study. Monitoring the hypnotic 
component of anesthesia remains a challenge for NMDA dependent anesthesia. 
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The Effects of Ketamine and Rocuronium on the A-Line®
Auditory Evoked Potential Index, Bispectral Index, and
Spectral Entropy Monitor during Steady State Propofol and
Remifentanil Anesthesia
Hugo E. M. Vereecke, M.D.,* Ann L. Vanluchene, M.D.,* Eric P. Mortier, M.D., D.Sc.,† Karel Everaert, M.D., Ph.D.,‡
Michel M. R. F. Struys, M.D., Ph.D.§
Background: The authors studied the effects of ketamine and
rocuronium on the Bispectral Index, A-Line® auditory evoked po-
tential index, state entropy, and response entropy during a calcu-
lated steady state anesthesia with propofol and remifentanil.
Methods: After ethics committee approval, 42 patients were
allocated to four groups. Baseline measurements were per-
formed after implementing a calculated steady state anesthesia
with propofol and remifentanil. The control group received no
additional medication. The ketamine group received a bolus
and continuous infusion of ketamine. The rocuronium group
received a bolus of rocuronium. The rocuronium–ketamine
group received both. All data were stored during 15 min after
baseline. After inspection of the raw data, the authors con-
ducted an explorative statistical analysis.
Results: No signiﬁcant changes were found in the control group
for any of themonitors. Mean values decreased in the rocuronium
group for the A-Line® auditory evoked potential index, Bispectral
Index, and response entropy, but not for state entropy. In the
ketamine group, the A-Line® auditory evoked potential index and
Bispectral Index did not change signiﬁcantly, but state and re-
sponse entropy increased. In the rocuronium–ketamine group,
the A-Line® auditory evoked potential index and Bispectral Index
did not decrease as found in the rocuronium group. Response and
state entropy increased signiﬁcantly.
Conclusions: The response of all monitors after ketamine
administration is not affected by simultaneous administration
of rocuronium. Interpretation of all studied indices must be
done cautiously while taking into account the clinical setting
during measurement.
THE Bispectral Index (BIS), response entropy (RE), state
entropy (SE), and a recent version of the A-Line® audi-
tory evoked potential index (AAI1.6) have all been in-
vestigated as surrogate endpoints of hypnotic drug ef-
fect. Previously, their behavior during propofol and
remifentanil infusion was studied.1–4 However, little lit-
erature is available on the behavior of the new AAI1.6 in
combined anesthesia conditions.
Several reports have been published on the behavior of
indices derived from electroencephalography and midla-
tency auditory evoked potentials (MLAEPs) during clinical
conditions characterized by an increased high-frequency
electrical activity in the power spectrum of the electroen-
cephalogram.5–11 These conditions can be both drug in-
duced (e.g., by ketamine) or caused by electrophysiologic
interference (e.g., by electromyography).5–12
Ketamine is a dissociative anesthetic drug, inhibiting
the N-methyl-D-aspartate receptor. On the raw electroen-
cephalogram, ketamine evokes an epileptiform activa-
tion with high-frequency features.13 This distortion in-
terferes with the fast extracting index calculations as
demonstrated by an increase in mean BIS, RE, and SE.14
The mean values of the former version of the A-Line®
auditory evoked potential index, which is based solely
on MLAEP, is not affected by ketamine administration.5
The effects of ketamine have not yet been studied for the
new version of the A-Line® monitor (Danmeter A/S,
Odense, Denmark), which calculates a composite index
(AAI1.6) extracted from the electroencephalogram,
MLAEP, and burst suppression.
Because the N-methyl-D-aspartate receptor modulates
the basic locomotor rhythmicity in cats, one could hy-
pothesize that the change in the electroencephalo-
graphic spectrum evoked by ketamine might be partially
derived from altered muscular activity.15 Few data are
available in current literature on the spectral character-
istics of the frontal and retroauricular electromyographic
activity in both the awake and anesthetized conditions.
However, because other facial muscle groups are able to
evoke an electrical activity with a power spectrum rang-
ing from 0.4 to 512 Hz, we can expect a potential
overlap of electromyographic activity with the fre-
quency domains used for any of the investigated index
calculations.16 Because the detection of the electromyo-
gram is not standardized between monitors, electromyo-
graphic activity might be present while going unnoticed
by any of the monitors under investigation. Only the
administration of a neuromuscular blocking agent
(NMBA) is able to exclude all electromyographic inter-
ferences, in both the high- and low-frequency bands of
the power spectrum analysis.
The aim of this study was to investigate whether the
effects of ketamine on BIS, AAI1.6, SE, and RE are inﬂu-
enced by the simultaneous administration of rocuronium
during propofol and remifentanil pseudo–steady state
anesthesia. To answer this question, we performed a
two-step analysis on one control group and three study
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groups receiving rocuronium, ketamine, or both. For
each group, we compared the changes of the studied
indices over time versus their respectively baseline val-
ues. Second, we performed a time-synchronized analysis
between groups to ﬁnd signiﬁcant differences between
the control group and the respective study groups.
Materials and Methods
This study was evaluated and approved by the institu-
tional ethics committee (University Hospital, Ghent, Bel-
gium). After obtaining written informed consent, 42 pa-
tients, all with American Society of Anesthesiologists
physical status I or II, aged 18–65 yr, and scheduled to
undergo gynecologic, urologic, or plastic surgery, were
included. Premedication with benzodiazepines or anxi-
olytic drugs was not allowed. Exclusion criteria were
anxiety necessitating benzodiazepines, the use of psy-
choactive drugs, a history of hearing disorders, or a
neuromuscular disease.
A silent operation room was obtained for all patients.
Electroencephalographic and MLAEP-derived measures,
hemodynamic and ventilation parameters, and acceler-
ometry were monitored as described in a later section.
Induction was performed through an 18-gauge intrave-
nous line, placed in a forearm vein. We took care not to
infuse more than 200 ml of crystalloids before and dur-
ing the study period to avoid excessive hemodynamic
interference.
Anesthetic Drug Administration
Propofol and remifentanil administration was per-
formed by a Fresenius Base A modular infusion pump
(Fresenius Vial Infusion Systems, Bre´zins, France) con-
nected via an RS-232 interface to a computer running
RUGLOOPII. This computer-assisted continuous infu-
sion device captured all monitored data while driving
the pumps and calculating all pharmacokinetic–pharma-
codynamic parameters in a time-synchronized way. Av-
eraging of the data was performed using a 10-s interval.
After appropriate preoxygenation, remifentanil was
targeted to a 2-ng/ml effect site concentration using the
pharmacokinetic–pharmacodynamic model published
by Minto et al.17,18 After 2 min of remifentanil infusion,
1% propofol was started at a constant speed of 300 ml/h
until loss of consciousness was detected, evaluated by
the clinical signs of “loss of eye lash reﬂex” and “loss of
response to name calling.” At that point, the calculated
effect site concentration of propofol, using the pharma-
cokinetic–pharmacodynamic model published by
Schnider et al.,19,20 was locked and maintained in RUG-
LOOPII as published previously.
5
After insertion of a laryngeal mask and implementation
of volume-controlled ventilation with the Datex ADU
ventilator (Datex, Helsinki, Finland), ventilation param-
eters were adjusted to target an end-tidal carbon dioxide
tension between 35 and 38 mmHg. After controlled
ventilation was commenced, a 10-min equilibration pe-
riod was maintained (more than three times the time to
peak effect for propofol and remifentanil) to reach and
maintain a pharmacokinetic–pharmacodynamic pseudo–
steady state for both propofol and remifentanil calcu-
lated effect site concentrations. We carefully selected
this level of anesthetic drug effect because it is a relevant
situation for clinical anesthetic practice compatible with
a surgical level of anesthesia.
Group Randomization
Baseline measurements were registered during 1 min
after the equilibration period, and randomization was
performed. The patients were allocated to one of four
groups. The ﬁrst group was the control group (CON-
TROL), meaning that no additional medication was ad-
ministered during the study period. The second group
(KET) received a bolus of ketamine (0.4 mg/kg) followed
by a continuous infusion of ketamine (1 mg  kg1  h1).
The third group (ROC) received a single bolus of rocu-
ronium (0.9 mg/kg), and the fourth group (ROC  KET)
received both rocuronium and ketamine simultaneously
in the same dose as mentioned above. After administra-
tion of the study drug according to randomization, all
measurements were logged into the computer for a
15-min study period. After this study period, the laryn-
geal mask was replaced by an endotracheal tube if nec-
essary, and surgery was commenced.
Electroencephalographic Measures
The BIS XP® (Aspect Medical Systems, Newton, MA),
spectral entropy (Datex-Ohmeda, Helsinki, Finland), and
A-Line® monitors (Danmeter A/S) were attached to the
patients. For BIS, a BIS® sensor (Aspect Medical Systems)
was attached to the right side of the patient’s forehead.
For A-Line®, three electrodes (A-Line® auditory evoked
potential electrodes; Danmeter A/S) were positioned at
the mid-forehead (), left forehead (reference), and left
mastoid (). For RE and SE, we used an Entropy Sensor®
(Datex-Ohmeda) attached to the left side of the head.
The Entropy Sensor® was always attached closest to the
eyebrow, the BIS® electrode was attached higher on the
forehead, and the A-Line® auditory evoked potential
electrodes were attached in between both.
The BIS was derived from the frontal electroencepha-
logram (At-Fpzt) and calculated by the BIS XP® monitor
(Aspect Medical Systems). The smoothing time of the
BIS® monitor was set at 15 s.
The AAI1.6 was calculated using version 1.6 of the
A-Line® auditory evoked potential index monitor (Dan-
meter). The algorithm extracts information from the
 RUGLOOPII, written by Tom De Smet, M.Sc., and Michel M. R. F. Struys,
M.D., Ph.D. More information available at: http://www.anesthesia-uzgent.be.
Accessed January 5, 2006.
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electroencephalogram, burst suppression, and MLAEP as
described elsewhere.1 MLAEPs were elicited with head-
phones producing a bilateral click stimulus of variable
click intensity and 2-ms duration. The click intensity is
automatically adjusted according to the measured signal-
to-noise ratio to avoid interfering startle responses. By
using an autoregression method with exogenous input,
the AAI1.6 can be calculated within a short delay time of
approximately 6 s.
Response entropy and SE are calculated using the Da-
tex M-Entropy® module (Datex). The algorithm has been
published elsewhere.21
Hemodynamic and NMBA Monitoring
Electrocardiogram, capnography, oxygen saturation,
and noninvasive blood pressure measurements were
monitored by the Datex S5® monitor (Datex) and auto-
matically logged into RUGLOOPII. The hemodynamic
data were averaged every minute.
An accelerometry monitor (S5® module; Datex) was
positioned at the nervus ulnaris on the contralateral side
of the intravenous line to detect the train-of-four percent-
age on the musculus adductor pollicis. After the patient
had lost consciousness, a train-of-four percentage calcu-
lation was performed every 10 s to evaluate the curari-
zation level during the study period. The accelerometry
was calibrated in all patients according to the manufac-
turer’s guidelines before any NMBA was administered.
Statistical Analysis
The signiﬁcance level was set at 5% unless otherwise
reported. Signiﬁcant difference in demographic charac-
teristics was tested using an analysis of variance with a
Dunnett multiple comparisons test if appropriate. Statis-
tical analysis was performed in an exploratory setting.
This means we decided which statistical test to use after
having inspected the raw data ﬁrst.
There is no statistical accepted standard for analysis of
trend data. All regression models become very complex,
without any assumption about the development of data
over time. In our case, such a model would need 16
parameters (16 time points), 3 parameters per group
(with one reference group), and 15 times 3 parameters
for all possible interactions between time and groups.
Moreover, one could argue that the correlation between
values within each patient would also have to be con-
sidered.
For these reasons, we chose to analyze the data in two
steps. In the ﬁrst step, we analyzed differences within
each group (or, more precisely, if there were differences
with respect to baseline). In a second analysis, we inves-
tigated whether there were differences between groups,
without taking into account the time points.
For every individual patient, the raw data obtained
from the studied monitors were averaged on a minute-
by-minute basis starting with the baseline measurements
resulting in one mean BIS, AAI1.6, RE, and SE per
minute. By using an individual mean per minute, the
natural ﬂuctuation of the raw data obtained from all
tested monitors is included in the analysis. Moreover, a
change in response of a studied monitor must be con-
sistent during the main part of every minute before it
will trigger the statistical test to indicate signiﬁcant dif-
ference. These individual means were averaged within
every study group (CONTROL, ROC, KET, and ROC 
KET), resulting in a group mean of means and SD for
every studied minute. The statistical tests for the within-
and between-group analyses were chosen after inspec-
tion of the raw data and after testing of normality using
the Kolmogorov-Smirnov test.
For the within-group analysis, we performed a repeat-
ed-measures analysis of variance with Dunnett post hoc
test for multiple comparisons to be able to detect signif-
icant differences between the baseline means of AAI1.6,
BIS, SE, and RE and the consecutive minute-by-minute
means within the CONTROL, ROC, KET, and ROC 
KET groups (P  0.05).
In a second analysis (the between-group analysis), we
compared the results of the control group with the
respective study groups in a time-synchronized way. We
compared all study groups versus CONTROL, ROC ver-
sus ROC  KET, and KET versus ROC  KET. All of the
baseline values were subtracted from the respective
mean value of every consecutive minute to better reﬂect
the amount of change versus baseline and to avoid the
drawback of large baseline variability in the data set. For
every comparison, the absolute difference of the means
with the corresponding 95% conﬁdence interval, based
on the t distribution, was calculated. When the conﬁ-
dence interval of the difference of the means includes
zero, the measured difference of means between the
studied groups is based on coincidence. When zero is
not included in the interval, the measured difference
between means is statistical signiﬁcant (P  0.05).
The detection of electromyographic activity is not
comparable between devices because a different deﬁni-
tion is used in every monitor. Moreover, in some pa-
tients, conﬂicting results in detection of electromyo-
graphic activity were seen between monitors. Therefore,
we only present electromyographic measurements re-
sults in a descriptive manner.
Results
Forty-two patients were included in this study. One
patient was excluded post hoc because of a failure in the
train-of-four measurement. Demographic data are shown
in table 1. No signiﬁcant differences were found be-
tween groups considering age, weight, height, lean body
mass, body surface area, ideal body weight, and the
proportion of males versus females.
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Hemodynamic parameters did not change in a clini-
cally signiﬁcant way for any group. The train-of-four
percent was 0 for all patients receiving rocuronium from
minute 3 until the end of the study period, indicating a
clinical comparable drug effect of rocuronium during
measurements.
The results for the within-group analysis are depicted
in ﬁgures 1–4 for AAI1.6, BIS, RE, and SE, respectively. In
CONTROL, no signiﬁcant differences were found for all
monitors when comparing baseline values with the con-
secutive minute means. In ROC, a signiﬁcant decrease
was seen for AAI1.6, BIS, and RE but not for SE. In KET,
a signiﬁcant increase was seen for RE and SE but not for
AAI1.6 and BIS. Although the mean BIS showed an in-
creasing trend after administration of ketamine, this
trend never reached signiﬁcance because of a wide
range of BIS responses within our population. In ROC 
KET, the mean RE and SE increased signiﬁcantly. In ROC
 KET, AAI1.6 decreased, but the decreasing response
of RE and BIS seen after monoadministration of rocuro-
nium disappeared after ketamine was associated. BIS did
not increase signiﬁcantly in the ROC  KET group.
Again, this was probably caused by the large SDs reﬂect-
ing major differences in response between patients in
this study group.
Figures 5–8 show the results for the comparison of the
absolute change from baseline between all study groups
for AAI1.6, BIS, RE, and SE, respectively. Five compari-
sons were made: CONTROL versus KET, CONTROL ver-
sus ROC, CONTROL versus ROC  KET, ROC versus
ROC  KET, and KET versus ROC  KET.
When comparing CONTROL versus KET, the absolute
change from baseline of the AAI1.6 was comparable at
all times. For BIS, RE, and SE, the absolute change from
baseline was signiﬁcantly larger for KET compared with
CONTROL, during a considerable duration of time.
When comparing CONTROL versus ROC, AAI1.6, RE,
and SE did not change signiﬁcantly from baseline in ROC
compared with CONTROL. For BIS, only on minute 6
was the absolute change from baseline signiﬁcantly
larger in ROC compared with CONTROL.
The comparison between CONTROL versus ROC 
KET showed no difference in changes from baseline for
AAI1.6 and BIS. RE and SE had a signiﬁcantly larger
change from baseline in ROC  KET compared with
CONTROL during several minutes.
When comparing ROC versus ROC  KET, AAI1.6 and
BIS did not show a signiﬁcant change from baseline. RE and
SE had a signiﬁcantly larger change from baseline in ROC
KET compared with ROC during several minutes.
When comparing KET versus ROC  KET, no differ-
ences were found in the absolute changes from baseline
for AAI1.6, RE, and SE between groups. For BIS, the
changes from baseline were signiﬁcantly larger in KET
compared with ROC  KET from minute 3 to minute 8.
Persistent electromyographic activity was detected
throughout the study period in two patients of the CON-
TROL group. One case was detected by the A-Line®, and
one was detected by the entropy monitor. For the KET
group, no major electromyographic activity was de-
tected by any monitor; however, the difference between
RE and SE gradually increased during the study period
from a mean difference of 1.3 to 2.2. For the ROC KET
group, no electromyogram was registered by the A-Line®
or BIS®, but on the entropy monitor, a comparable
gradual increase in mean difference between RE and SE
was seen (from 1.13 at baseline to 2.26 at minute 15).
For the ROC group, both the A-Line® and the entropy
monitor detected electromyography in the same patient
from baseline to minute 2 of the study period. The BIS®
monitor did not detect any electromyographic activity in
any of the studied patients.
One patient of the ROC group kept showing electro-
myographic activity throughout the study period on the
A-Line® monitor, even after the administration of rocu-
ronium. This electromyographic activity was not de-
tected by BIS® or entropy. Unfortunately, a failure in the
train-of-four monitor made it impossible to evaluate the
intensity of the NMBA effect in this particular patient.
Therefore, we excluded this patient from the analysis.
Discussion
In this study, the response of four electroencephalo-
graphic and MLAEP-derived depth of anesthesia moni-
tors have been investigated in clinical anesthetic condi-
tions, during which ketamine and rocuronium were
administered in a solitary or combined way. The re-
sponse of all monitors was compared with baseline val-
ues (within-group analysis) and with a control group,
receiving a comparable calculated steady state anesthe-
sia as given in all study groups (between-group analysis).
Table 1. Demographic Data
n Age  SD, yr Weight  SD, kg Length  SD, cm BMI  SD, kg/m2 Sex, M/F
CONTROL 10 38  10.1 78.3  12.4 173.7  13.2 25.9  3.1 6/4
ROC 11 34.7  7.3 70.4  16.7 176  7.8 22.6  4.1 7/5
KET 10 37.8  11.2 75.3  19.2 174.6  13.2 24.3  3.2 5/5
ROC  KET 10 36.9  10.8 72.4  15.3 171.5  6.5 24.4  3.8 4/6
BMI  body mass index; CONTROL  control group; KET  ketamine group; n  total number of patients; ROC  rocuronium group; ROC  KET 
rocuronium–ketamine group.
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For the CONTROL group, all monitors remained unal-
tered after baseline measurements, indicating a compa-
rable clinical and pharmacologic calculated steady state
anesthesia between patients during the study period.
In the KET group, the within-group analysis suggested
that AAI1.6 and BIS were not affected signiﬁcantly by
ketamine. In contrast, RE and SE showed an increasing
response after solitary ketamine administration.
One could speculate that the addition of electroen-
cephalogram-extracted information to the MLAEP-de-
rived information, as done for AAI1.6, does not alter the
index behavior compared with the former version of the
A-Line® monitor, which was based on MLAEP alone.5
However, it is inherent in the new algorithm that the
electroencephalogram-derived information only be-
comes an important covariate for index calculations in
conditions with low signal-to-noise ratios for MLAEP de-
tection.1 In our setting, all environmental interference
was avoided, causing a high signal-to-noise ratio, which
might have been sufﬁcient to avoid the use of electro-
encephalogram-derived information. As such, we can
not exclude the occurrence of a more pronounced effect
Fig. 1. Mean A-Line® auditory evoked potential index, version 1.6 (AAI1.6), is depicted for every study group, calculated on a
minute-by-minute basis with respective SDs, from minute 1 (baseline) to minute 16. CONTROL, KET, ROC, ROC  KET  results of
the control, ketamine, rocuronium, and combined rocuronium–ketamine groups, respectively. * P < 0.05.
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of ketamine during more challenging conditions for
MLAEP extraction (e.g., during surgery).
For BIS, the result of the within-group analysis of KET
is in contrast with older publications indicating an in-
crease in BIS after ketamine administration.5,14 Although
ﬁgure 2 shows a clear increasing trend for BIS in KET,
this trend is not signiﬁcant because of the large SDs,
which are a reﬂection of the large variability in BIS
responses within our population. In contrast, the be-
tween-group analysis has more power to detect signiﬁ-
cant differences compared with the within-group analy-
sis, due to the elimination of the baseline variability in
the data set. This was done by subtracting the baseline
mean from the mean of every studied minute. As such,
this new data set reﬂects the absolute change from
baseline. In ﬁgure 6, this resulted in a signiﬁcantly larger
change from baseline for BIS in KET compared with
CONTROL during several minutes. The less pronounced
effects of ketamine on BIS in our study compared with
the known literature are probably related to the deeper
level of anesthesia chosen in our study. Because no
surgical stimulation was present during measurement,
Fig. 2. Mean Bispectral Index (BIS) is depicted for every study group, calculated on a minute-by-minute basis with respective SDs,
from minute 1 (baseline) to minute 16. CONTROL, KET, ROC, ROC  KET  results of the control, ketamine, rocuronium, and
combined rocuronium–ketamine groups, respectively. * P < 0.05.
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the combination of remifentanil and propofol evoked a
moderate level of burst suppression patterns in some
patients during the study period. The number of patients
with burst suppression was comparable between
groups, being 3, 4, 4, and 3 patients for CONTROL, ROC,
KET, and ROC  KET, respectively. It has been shown
before that BIS loses monotonicity when a suppression
rate is detected between 0 and 40%.1 At that time, an
increased interindividual variability in BIS calculations is
present compared with lighter levels of anesthesia.1 This
increased variability, which does not occur for the other
studied monitors, might explain the limited response of
mean BIS after ketamine administration in our study
population.
In the ROC group, rocuronium decreased the AAI1.6
and the RE compared with baseline in the within-group
analysis, but this effect could not be conﬁrmed by the
between-group analysis. When comparing CONTROL
versus ROC, AAI1.6, RE, and SE did not change signiﬁ-
cantly from baseline in ROC compared with CONTROL.
Fig. 3. Mean response entropy (RE) is depicted for every study group, calculated on a minute-by-minute basis with respective SDs,
from minute 1 (baseline) to minute 16. CONTROL, KET, ROC, ROC  KET  results of the control, ketamine, rocuronium, and
combined rocuronium–ketamine groups, respectively. * P < 0.05.
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This was in contrast to our ﬁndings in the within-group
analysis for AAI1.6, BIS, and RE. Apparently, the electro-
myogram is a main portion of the baseline interindi-
vidual variability of AAI1.6, BIS, and RE. By eliminating
the baseline variability in our between-group analysis,
the test does not detect any difference anymore between
CONTROL and ROC. These ﬁndings suggest that the
effect of rocuronium on the mean values of AAI1.6, RE,
and BIS is mainly caused by a drastic reduction in inter-
individual variability. For BIS, the decreasing effect in
ROC is more pronounced compared with the other mon-
itors. Therefore, it is reﬂected in both the within- and
between-group analyses. These results are in agreement
with the literature.7,9,12
In the ROC  KET group, the AAI1.6 remained sensi-
tive for the decreasing effects of rocuronium in the
within-group analysis. For RE and SE, rocuronium was
not able to abolish or dampen the effects of ketamine.
These results suggest that the distortions in the RE and
SE calculations evoked by ketamine are independent of
the electromyographic activity.
For BIS, the within-group analysis was not able to
Fig. 4. Mean state entropy (SE) is depicted for every study group, calculated on a minute-by-minute basis with respective SDs, from
minute 1 (baseline) to minute 16. CONTROL, KET, ROC, ROC  KET  results of the control, ketamine, rocuronium, and combined
rocuronium–ketamine groups, respectively. * P < 0.05.
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detect any change in ROC  KET. Again, this is probably
due to the wide variety in BIS responses in our population.
However, the comparison between KET and ROC  KET
indicated a larger change from baseline in KET compared
with ROC  KET at the beginning of the study period.
From minute 9 through minute 15, no differences were
found between KET and ROC  KET. Although not signif-
icantly different from baseline, a progressive higher trend
was seen near the end of the study period for ROC  KET
compared with CONTROL. By combining these ﬁndings,
we conclude that ketamine still has an increasing effect on
BIS calculations; however, this effect is much smaller at
Fig. 5. Between-group comparison for the A-Line® auditory evoked potential index, version 1.6 (AAI1.6). Minute 1 is the baseline
measurement. The axis shows the absolute difference of the mean change from baseline between the compared groups for every
studied minute, together with the corresponding 95% conﬁdence interval (CI). CONTROL  control group; KET  ketamine group;
ROC  rocuronium group; ROC  KET  combined rocuronium–ketamine group.
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deep levels of anesthesia compared with the known effects
from the literature.5
All electroencephalographic and MLAEP-derived depth
of anesthesia monitors are characterized by a large inter-
individual and intraindividual variability. A major reason
for this variability is the occurrence of electromyo-
graphic activity. In our study, electromyographic activity
was detected only by the A-Line® and entropy monitor in
a limited number of patients. This was probably caused
by a lower electromyographic activity at deep levels of
anesthesia compared with other studies performed at
lighter levels of anesthesia, during an ongoing surgical
Fig. 6. Between-group comparison for the Bispectral Index (BIS). Minute 1 is the baseline measurement. The axis shows the absolute
difference of the mean change from baseline between the compared groups for every studied minute, together with the correspond-
ing 95% conﬁdence interval (CI). CONTROL control group; KET ketamine group; ROC rocuronium group; ROCKET combined
rocuronium–ketamine group. * P < 0.05.
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procedure or in the awake patient.8 However, anesthe-
siologists should also be aware of the fact that all studied
monitors deﬁne the electromyogram in a different fre-
quency band of the power spectrum, ranging from 70 to
110 Hz, 65 to 85 Hz, and 32 to 47 Hz for BIS, AAI1.6, and
the entropy monitor, respectively. Although a limited
number of data are available in the current literature, one
can speculate that electromyographic activity occurs in a
much wider range and still can distort index calculations
at times where no electromyogram detection is present.
Fig. 7. Between-group comparison for the response entropy (RE). Minute 1 is the baseline measurement. The axis shows the absolute
difference of the mean change from baseline between the compared groups for every studied minute, together with the correspond-
ing 95% conﬁdence interval (CI). CONTROL control group; KET ketamine group; ROC rocuronium group; ROCKET combined
rocuronium–ketamine group. * P < 0.05.
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The entropy monitor deﬁnes the electromyogram be-
tween 32 and 47 Hz in the power spectrum. This fre-
quency domain is included in the algorithm for the
calculation of RE, which is propagated by the company
commercializing the monitor, as a fast-responding depth
of hypnosis index or even as an indicator of arousal. By
including a part of the electromyogram in the algorithm,
the decreasing RE after solitary rocuronium administra-
tion is to be expected. However, if a depth of hypnosis
monitor detects the administration of a nonhypnotic
NMBA, this drawback might cause a need for redeﬁning
cutoff values of the depth of hypnosis indices, whether
a NMBA is in use or not. At this time, no commercially
available electroencephalogram or MLAEP-derived mon-
Fig. 8. Between-group comparison for the state entropy (SE). Minute 1 is the baseline measurement. The axis shows the absolute
difference of the mean change from baseline between the compared groups for every studied minute, together with the correspond-
ing 95% conﬁdence interval (CI). CONTROL control group; KET ketamine group; ROC rocuronium group; ROCKET combined
rocuronium–ketamine group. * P < 0.05.
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itor is able to detect or ﬁlter all of the interfering elec-
tromyographic activity in a sufﬁciently accurate way. As
such, it is our opinion that the electromyogram should
be considered as noise in the data until more evidence is
available to support the use of the electromyogram as an
indicator of arousal or the hypnotic component of anes-
thesia. At this time, no evidence exists to support the 32-
to 47-Hz frequency band as superior to the other fre-
quency bands, as an indicator of arousal.
Because the effects of ketamine were larger on RE
compared with SE, a progressive increase in the differ-
ence between RE and SE was seen over time in both KET
and ROC  KET. This gives the impression of an in-
creased electromyographic activity. Because rocuronium
is not able to reduce the increasing RE in ROC  KET,
we consider this progressive increasing difference be-
tween RE and SE to be a result of the electroencephalo-
graphic alterations evoked by ketamine, not by electro-
myographic activation.
As a general remark on the results of this study, we
must consider the fact that the inconsistent signiﬁcant
levels over time, which are seen in several comparisons,
can be related to the limitations in group size combined
with the large biologic variability of the studied indices.
The fact that the difference in a comparison is not
considered to be signiﬁcant does not always mean that
there is no difference. We might have simply missed it.
Statistical analysis for this study was performed in an
exploratory, rather than a conﬁrmatory, setting. This
means that we decided which statistical test to use after
inspecting the raw data ﬁrst. Although this methodology
might be prone to bias, we preferred to do so because
we could not be sure how the model would behave in
advance. Moreover, because the biologic variability of
electroencephalographic and MLAEP-derived indices is
large, we preferred to proceed with statistical analysis
only after we found a meaningful trend in the raw data.
The interpretation of our results should be considered
with this drawback in mind.
In conclusion, we investigated the effects of ketamine
and rocuronium on four electroencephalographic and
MLAEP-derived parameters. Ketamine has no effect on
AAI1.6 calculations during anesthetic conditions with a
high signal-to-noise ratio for MLAEP extraction. AAI1.6,
BIS, and RE decrease after rocuronium administration.
RE and SE increase after ketamine administration, inde-
pendent of the effects of rocuronium. In our population,
BIS has a less pronounced response compared with the
known literature, after the administration of ketamine.
We hypothesize that this is caused by the higher vari-
ability of BIS calculations at deep levels of anesthesia
compatible with burst suppression patterns.
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3.6.1 Introduction 
In comparison with EEG derived hypnotic drug effect monitors, the additional value of 
MLAEP as an endpoint of hypnotic drug effect, remains debatable.(1-4) The AAI technology 
has reached a high level of performance, although remaining practical issues might hamper 
commercial success, compared to the EEG indices. The use of headphones disrupts the 
verbal communication between the patient and the anesthesiologist, which is indicated by  
many users to be an important drawback. Secondly, MLAEP can not be used in patients with 
important hearing deficits. Additionally, loud acoustic stimuli applied for a long time might 
appear harmful for the patient’s hearing. Therefore, MLAEP derived indices should be used 
with caution during long procedures, or for monitoring sedation at the intensive care. Finnally, 
As long as no high quality outcome and macro-economical studies are performed, it remains 
difficult to evaluate the balance between costs and gain of the AAI. 
After a thorough evaluation of our study results, and discussing the formerly mentioned 
practical issues within the consortium,,Danmeter has chosen to abandon the MLAEP as a 
source of information, and developed a new EEG based index, called the cerebral state 
index (CSI). The CSI has been developed using raw binary files registered with the AEP 
monitor/2, containing all electroencephalographic data of one of our studies.(5) The CSI 
algorithm is based on a combination of “neural networking” and “fuzzy logic” technology.(cf. 
appendix of the manuscript) Due to the development process, CSI is the first 
electroencephalographic monitor using the same electrode position as the AEP monitor/2. 
Theoretically, with this parameter, we will be able to perform trials that compare AAI, with a 
simultaneously extracted EEG derived index using identical electrode positions. This creates 
possibilities for the future, to investigating the additional value of MLAEP versus EEG, as a 
measure of cerebral hypnotic drug effect. Of course, CSI needs to be validated first, both at a 
clinical and pharmacological level. 
We validated CSI in a retrospective database of raw EEG samples. We reused all the raw 
data files containing EEG and MLAEP, obtained during our former validation studies, 
published by Struys et al.(6) and by Vereecke et al.(7) By doing so, the CSI algorithm has 
been validated, both on a clinical level (detecting the level of OAA/S SCALE), as on a 
pharmacological level (detecting the CePROP). Moreover, in this study, we used the composite 
index AAI as a validated pharmacodynamic reflection of cerebral hypnotic drug effect. 
Therefore, this study is an example of how AAI can be applied for further pharmacologic and 
neurophysiologic developments. 
Within the limitations of the retrospective methodology, we concluded that CSI is a promising 
index, performing adequately for detecting both clinical and pharmacological endpoints of 
hypnotic drug effect. More prospective clinical validation is mandatory, as our methodology 
excludes the evaluation of potential shortfalls of hardware and software of the 
commercialized “cerebral state monitor” (Danmeter, Odense, Denmark). In fact we only 
validated the “CSI algorithm”. 
The CSI validation study has won the “best clinical trial” award 2006 of the Belgian Society of 
Anesthesia and Resuscitation (BSAR). 
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Cerebral State Index during Propofol Anesthesia
A Comparison with the Bispectral Index and the A-Line ARX Index
Erik W. Jensen, Ph.D.,* Hector Litvan, M.D., Ph.D.,† Miren Revuelta, M.D.,‡ Bernardo E. Rodriguez, M.Sc.,§
Pere Caminal, Ph.D., Pablo Martinez, M.Sc.,§ Hugo Vereecke, M.D.,# Michel M. R. F. Struys, M.D., Ph.D.**
Background: The objective of this study was to prospectively
test the Cerebral State Index designed for measuring the depth
of anesthesia. The Cerebral State Index is calculated using a
fuzzy logic combination of four subparameters of the electro-
encephalographic signal. The performance of the Cerebral State
Index was compared with that of the Bispectral Index and the
A-Line ARX Index.
Methods: This study applied raw data from two previously
published clinical protocols. The patients in protocol 1 were
given a continuous propofol infusion, 300 ml/h, until 80% of
burst suppression occurred. In protocol 2, a stepwise increased
target-controlled infusion of propofol was administered to pa-
tients until loss of response to noxious stimuli while the Ob-
server’s Assessment of Alertness and Sedation was registered
every 4 min. The Cerebral State Index was calculated off-line
from the recorded electroencephalographic data. The Spear-
man rank correlation coefﬁcient between electronic indices
and the effect site concentration of propofol was calculated
along with the prediction probability of each index to predict
the Observer’s Assessment of Alertness and Sedation level.
Results: The Spearman rank correlation coefﬁcients between
the Cerebral State Index, Bispectral Index, and A-Line ARX In-
dex and the propofol effect site concentration were 0.94,
0.89, and 0.82, respectively, in protocol 1, whereas the pre-
diction probability values between the Cerebral State Index,
Bispectral Index, and A-Line ARX Index and the Observer’s
Assessment of Alertness and Sedation score in protocol 2 were
0.92, 0.93, and 0.91, respectively.
Conclusion: The Cerebral State Index detects well the gradu-
ated levels of propofol anesthesia when compared with the
propofol effect site concentration and the Observer’s Assess-
ment of Alertness and Sedation score.
MONITORING depth of anesthesia is gaining increased
importance. A number of methods have been suggested,
most of them based on the analysis of the electroen-
cephalographic signal. These methods can in general be
classiﬁed into those that analyze the spontaneous elec-
troencephalographic activity and those that measure the
response of the electroencephalographic signal to acous-
tic stimuli, auditory evoked potentials (AEPs).
In spontaneous electroencephalogram analysis, initial
methods analyzed one single computerized parameter,
such as the spectral edge frequency,1 but during the past
decade, a multiparametric approach has been favored in
some methods, such as the clustering analysis of subpa-
rameters of the electroencephalogram proposed by
Thomsen and Prior2 or the Bispectral Index (BIS®; As-
pect Medical Systems, Inc., Newton, MA) validated in
numerous publications and calculated by using four sub-
parameters of the electroencephalographic signal.3–5
For the AEP, the particular component that correlates
to the depth of anesthesia is the midlatency auditory
evoked potential (MLAEP). The MLAEP is allegedly supe-
rior to the spontaneous electroencephalographic meth-
ods, at least in the early works where the AEP was
compared with single parametric analysis of the electro-
encephalograph.6 However, the multiparametric analy-
ses have been shown to have as good a correlation to
depth of anesthesia as the MLAEP.7–9 Recently, Jensen et
al.10 developed a composite index, the A-Line ARX In-
dex, version 1.6 (AAI1.6), based on a combination of
MLAEP and spontaneous electroencephalographic data.
For the MLAEP part of this algorithm, a previously vali-
dated method for fast extraction based on an autoregres-
sive model with an exogenous input adaptive model was
used.10 If the MLAEP quality is too low, spontaneous
electroencephalographic components are used. The
AAI1.6 is commercially implemented in the AEP Moni-
tor/2 (Danmeter A/S, Odense, Denmark).11
All mentioned derived electroencephalographic and
MLAEP indices assume an underlying mathematical func-
tion governing the relation between the electroenceph-
alogram and the clinical state of the patient. This might
possibly result in less accurate functioning at speciﬁc
anesthetic states, e.g., causing plateau levels or other less
reactive periods in the index at speciﬁc levels of the
hypnotic component of anesthesia.12,13
A different method for system identiﬁcation using neu-
ral networks and fuzzy logic has been applied increas-
ingly in medical technology, where it provides decision
support and expert systems with powerful reasoning
capabilities.14,15 Fuzzy reasoning allows the implemen-
tation of very complex processes, where a simple math-
ematical model cannot be obtained. Fuzzy logic can also
be successfully applied to highly nonlinear processes,
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where it is observed to greatly simplify the modeling.
The advantage of this approach is that it does not assume
any underlying mathematical function governing the re-
lation between the electroencephalogram and the clini-
cal state of the patient. It might be hypothesized that this
offers modeling advantages because it rather uses clini-
cal data to determine the values of the fuzzy rules to
achieve the best ﬁt between the subparameters of the
electroencephalogram and the anesthetic depth.
A new index, the Cerebral State Index (CSI), deﬁned
by two of the authors (E.W.J. and P.M.), is based on the
combination of four subparameters of the electroen-
cephalographic signal. Three of these are derived from
spectral analysis of the electroencephalogram, and the
fourth is the burst suppression ratio (BS%) calculated by
the monitor.
These parameters are used as inputs to an Adaptive
Neuro Fuzzy Inference System (ANFIS),16,17 which opti-
mizes the rules governing the relation between the input
parameters using a least mean squares approach. The
mathematics is described in detail in the accompanying
appendix. Recently, the CSI has been implemented in a
commercially available monitor, the Cerebral State Mon-
itor (Danmeter A/S).
The objective of this study was to prospectively test
the correlation of the CSI with the effect site concentra-
tion of propofol and with patient state of responsiveness
to verbal command as assessed by the Observer’s Assess-
ment of Alertness and Sedation (OAA/S) scale. The per-
formance of the CSI was also compared with that of the
BIS and AAI indexes in the same patient populations.
Materials and Methods
The raw data from two previously published studies
were used. Both patient databases were exclusively ob-
tained at Ghent University Hospital (Gent, Belgium). For
all patients in both protocols, informed consent was
obtained after approval from the institutional ethics
committee.
Protocol 1 studied deep anesthetic levels reaching
high levels of burst suppression during propofol admin-
istration.11 Protocol 2 studied the correlation between
different clinical levels of responsiveness as measured by
the OAA/S scale18 versus the electroencephalogram dur-
ing steady state propofol administration.7 Because the
raw electroencephalographic data, vital signs, and phar-
macologic data were recorded online and stored elec-
tronically in a time-synchronized way, it was possible to
reanalyze the raw electroencephalographic data without
the requirement of including new patients.
Clinical Protocols
In both protocols, exclusion criteria were weight less
than 70% or more than 130% of ideal body weight,
neurologic disorder, and recent use of psychoactive
medication, including alcohol.
Protocol 1 (Deep Anesthesia Reaching High Lev-
els of Burst Suppression). The population for this
study protocol was formed by 13 patients (10 women, 3
men; American Society of Anesthesiologists physical sta-
tus I; aged 18–65 yr) scheduled to undergo ambulatory
gynecologic or urologic surgery. Before drug administra-
tion was started, all patients were asked to close their
eyes and relax for 2 min. After this time, baseline mea-
surements were taken. All patients then received a con-
tinuous infusion of propofol at 300 ml/h. Infusion was
continued until a burst suppression level of 80% or
higher was achieved. However, propofol infusion was
stopped earlier if the mean arterial blood pressure be-
came lower than 50 mmHg.
Protocol 2 (OAA/S Levels). The study population
was formed by 20 female patients (American Society of
Anesthesiologists physical status I; aged 18–60 yr)
scheduled to undergo ambulatory gynecologic surgery.
All patients received an effect site compartment target-
controlled infusion of propofol. The initial propofol ef-
fect site concentration (Ce prop) was set at 1.5 g/ml
and increased every 4 min by 0.5 g/ml until an OAA/S
level of 0 was reached. The level of consciousness,
assessed through the OAA/S score, was recorded along
with the electronic indices before each increase in effect
target concentration. Table 1 describes the OAA/S score
levels and their clinical interpretation.
In both protocols, a similar clinical setting was used.
Propofol was administered as the only drug, through a
large left forearm vein, and infusion was conducted via
the computer-assisted continuous-infusion device RUG-
LOOP II (Demed Engineering, Temse, Belgium). This
device drove a Fresenius Modular DPS Infusion Pump
connected to a Fresenius Base A (Fresenius Vial Infusion
Systems, Bre´zins, France) through an RS-232 interface.
To determine Ce prop, the software uses a three-com-
partment model enlarged with an effect site compart-
ment, previously published by Schnider et al.19,20 The
calculated Ce prop was computed to yield a time to peak
effect of 1.6 min after bolus injection,21 as also published
by Schnider et al.19,20 and clinically conﬁrmed by Struys
et al.22 Heart rate and noninvasive blood pressure, pulse
oximetry, and capnography were recorded at 1-min time
Table 1. Responsiveness Scores of the Modiﬁed OAA/S Scale
Score Responsiveness
5 Responds readily to name spoken in normal tone
4 Lethargic response to name spoken in normal tone
3 Response only after name is called loudly and/or repeatedly
2 Response only after mild prodding or shaking
1 Response only after painful trapezius squeeze
0 No response after painful trapezius squeeze
OAA/S  Observer’s Assessment of Alertness and Sedation.
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intervals using an S5® monitor (Datex-Ohmeda, Helsinki,
Finland). All patients maintained spontaneous ventilation
via a facemask delivering 100% oxygen.
Electroencephalographic Measurements
In both protocols, the BIS and the raw electroencepha-
lographic signal with the AEP signal embedded were
simultaneously acquired for all patients. The BIS XP®
(version 4.0) was derived from the frontal electroen-
cephalogram (At-Fpzt) and calculated by the A-2000 BIS®
Monitor using four BIS®-Sensor electrodes (Aspect Med-
ical Systems, Inc.). The smoothening time of the BIS®
monitor was set at 15 s. The raw electroencephalo-
graphic signal corresponding to each patient was re-
corded using the A-Line Monitor (Scientiﬁc Version; Dan-
meter A/S) with three electrodes positioned at
midforehead (), left forehead (reference), and left mas-
toid () along with headphones to deliver a train of
bilateral clicks at a frequency of 9 Hz with a 2-ms dura-
tion and an adaptable intensity set automatically by the
monitor.
The electroencephalographic signal was sampled at
900 Hz and band-pass ﬁltered in the 0.5- to 45-Hz band.
The AAI1.6 was calculated off-line based on the raw
MLAEP data. For all calculations, the AAI has been scaled
to a 0–60 interval (AAI60). This scale provides the best
stability in the awake state, as proven by Vereecke et
al.11 The CSI was calculated off-line from the raw elec-
troencephalographic records. Mathematical details from
this technology are given in the appendix. It has already
been shown that the embedded AEPs resulting from the
click stimuli have no effect on the BIS,23 which includes
the  ratio in its calculation. Although an inﬂuence of the
AEP in the raw signal cannot be excluded, in general, the
signal-to-noise ratio between the AEP and the electroen-
cephalographic signal is less than 1 to 30; therefore, the
inﬂuence of the clicks is assumed to be less than approx-
imately 3% of the ﬁnal value.
The burst suppression values were taken from the
speciﬁc parameters calculated by each monitor: the sup-
pression ratio (SR) provided by the BIS and BS% for the
AAI60 and CSI calculations.
Statistical Analysis
Comparison between CSI, BIS, and AAI. In proto-
col 1, a linear regression and its corresponding correla-
tion coefﬁcient was calculated between CSI and BIS. A
nonparametric approach, the Spearman rank correla-
tion, R, was calculated to study the relation between Ce
prop and CSI, BIS, or AAI. The Spearman rank correla-
tion was calculated on pooled data.
The relation between Ce prop and the electroencepha-
lographic measures of anesthetic drug effect was ana-
lyzed using a sigmoid Emax model,
Effect E0
(Emax  E0)
Ce
(Ce50Ce)
,
where Effect is the electroencephalographic effect being
measured (CSI), E0 is the baseline measurement when no
drug is present, Emax is the maximum possible drug
effect, Ce is the calculated effect site concentration of
propofol, Ce50 is the effect site concentration associated
with 50% maximal drug effect, and  is the steepness of
the concentration–response relation curve. The model
parameters were estimated using NONMEM V (Globo-
max LLC, Hanover, MD). The parameters for the BIS and
AAI60 have already been estimated for this population by
Vereecke et al.11 The relation between Ce prop and CSI
was calculated using the same NONMEM V speciﬁca-
tions as described by Vereecke et al.11
In protocol 2, the ability of the CSI, BIS, and AAI to
predict the response to verbal command, as deﬁned by
the OAA/S scale, was evaluated using prediction proba-
bility (PK). Prediction probability was calculated using a
custom spreadsheet macro, PKMACRO, developed by
Smith et al.24,25 The PK value was calculated as the mean
from pooled data of all patients. A PK of 1 for the CSI
indicator would mean that CSI always decreases (in-
creases) as the patient reaches deeper levels of anesthe-
sia according to the OAA/S scale. Such an indicator can
perfectly predict the anesthetic state. Alternatively, a PK
value of 0.5 would mean that the indicator is useless for
predicting the depth of anesthesia. The jackknife
method was used to compute the SE of the estimate.24,25
After having evaluated normal distribution, a Student t
test with Bonferroni correction was used to evaluate
signiﬁcant difference between the PK means. A Friedman
analysis was conducted, and if P  0.05, a Wilcoxon
signed rank sum test was used to test for signiﬁcance
between the electronic indices at adjacent OAA/S levels
(5 vs. 4, 4 vs. 3 . . .).
Results
Protocol 1
All data from the published study11 were included in
the analysis.
Figure 1 shows a pooled scatter plot of the raw data for
all patients. A relation between Ce prop and the elec-
tronic indices, CSI, BIS, and AAI60, is hereby shown in
plots A, B, and C, respectively. The behavior of the two
spontaneous electroencephalographic indices, CSI and
BIS, were comparable, as shown in ﬁgure 2. The equa-
tion for the regression line was CSI  1.02 BIS (P  0.05
for linearity). Table 2 shows the results of the Spearman
rank correlation between propofol and the three indices.
The CSI showed a signiﬁcantly higher correlation than
the other two indices.
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The high concentrations of propofol caused consider-
able amount of burst suppression, as shown in ﬁgure 3.
Figure 3A shows CSI versus its BS%, where the relation
is almost linear when BS% is larger than 60. The equation
for the regression line, assuming BS%  1, is shown to
have a signiﬁcant (P  0.05) linear ﬁt to the data. Less
linearity is seen for the BIS and AAI60 in ﬁgures 3A and B,
respectively.
The NONMEM analysis (ﬁg. 4) showed that for this
population, the typical values (coefﬁcient of variation)
for the sigmoid Emax model between Ce prop and CSI
were C50  9.85 (65%), E0  94 (4.6%), Emax  100
(110%), and   3.45 (31%). The SD, depicting the
residual intraindividual variability, was 6.79.
Protocol 2
All raw data from the published study were included.7
Figure 5 shows the CSI, BIS, and AAI60 versus OAA/S. To
compare the different adjacent OAA/S levels for all three
indices, a Mann–Whitney U test was applied. The results
are shown in table 3. The table shows that in general the
BIS and AAI were able to distinguish between OAA/S
levels 5 to 2. For the CSI, a smoother drop was observed
between level 3 and 2, whereas at deeper anesthesia, the
CSI was the only parameter that showed signiﬁcant dif-
ferences between OAA/S levels 0 and 1.
Table 4 lists the PK values of the OAA/S for CSI, BIS,
and AAI60. All PK values were above 0.9, and there were
no signiﬁcant differences between the PK values of the
three electronic indices.
Fig. 1. Raw data of all patients for the three electronic indices
(Cerebral State Index [CSI, A]; Bispectral Index [BIS, B]; and
A-Line ARX Index version 1.6, scaled to 60 [AAI60, C]) versus
propofol effect site concentration (Ce propofol) for the data
recorded according to protocol 1.
Fig. 2. Linear regression (thick line) and 95% conﬁdence inter-
val (thin lines) between the Cerebral State Index (CSI) and the
Bispectral Index (BIS) values for the data recorded according to
protocol 1. The regression followed the equation CSI-1.02 BIS.
Table 2. Spearman Rank Correlations for the Three Electronic
Indices vs. Propofol Effect Site Concentration According to
Protocol 1
Index Spearman Rank Correlation
BIS 0.818*
AAI60 0.887*
CSI 0.943*
* Correlation is signiﬁcant at the 0.01 level.
AAI60  A-Line ARX Index scaled to 60; BIS  Bispectral Index; CSI 
Cerebral State Index.
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Discussion
The core of the CSI signal processing algorithm is fuzzy
logic based. The power of fuzzy logic lies in its ability to
perform reasonable and meaningful operations on con-
cepts that cannot be easily codiﬁed using a classic logic
approach. Such modiﬁcations allow for a much more
ﬂexible and widespread use of reliable and consistent
logic in a variety of applications.
Classic logic relies on something being either true or
false. Therefore, either something completely belongs to
a set or it is completely excluded from it. Fuzzy logic
broadens this deﬁnition of membership. The basis of the
logic is fuzzy sets. Unlike in “crisp” sets, where member-
ship is full or none, an object is allowed to belong only
partly to one set. The membership of an object to a
particular set is described by a real value from a range
between 0 and 1. Such logic allows a much easier appli-
cation of many problems that cannot be easily imple-
mented using the classic approach, which only allows a
single object to be a member of two mutually exclu-
sive—in the “crisp” sense—sets.
The most common use of fuzzy logic lies in the ﬁeld of
control systems, although the theory seems to have big
potential in the different ﬁelds of artiﬁcial intelligence.
The large computational burden of fuzzy logic systems is
only justiﬁed if a model describing the relation between
input and output does not exist. This is the case in the
current application, where the relation between the
input parameters ( ratio,  ratio, the difference be-
tween the two, and BS%) and the clinical state is un-
known; therefore, no model is available, which means
that the neuro-fuzzy method offers a fast and robust
alternative to establish the causal relation between in-
puts and output. This causal relation may well incorpo-
rate nonlinear relations between the linear input param-
eters,  and  ratio.
When validating a depth of anesthesia monitor, it can
only be called accurate if it (1) provides an accurate
correlation with cerebral drug effect reﬂected by its
effect site concentration, (2) correlates well with the
clinical state of the patients, and (3) informs the clinician
when excessive levels of anesthesia are present. In this
study, these three aspects were tested using existing
databases. The propofol effect site concentration has
shown a good correlation to anesthetic depth in several
studies, in particular in controlled patient groups; there-
fore, it was used in this study to evaluate the perfor-
mance of the CSI as a cerebral drug effect monitor in
Fig. 3. The relation between the Cerebral State Index (CSI, A);
Bispectral Index (BIS, B); and A-Line ARX Index version 1.6,
scaled to 60 (AAI60, C), and burst suppression, measured as the
burst suppression percentage (BS%) for the CSI and AAI60 and
as the suppression ratio (SR) for the BIS.
Fig. 4. Sigmoid Emax model of the Cerebral State Index (CSI)
versus propofol effect site concentration (Ce propofol). The
thin lines represent individual patient ﬁts, whereas the bold line
represents the typical curve of the population data.
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comparison to BIS and AAI60.
7–9,26 Even more important,
a depth of anesthesia monitor should ﬁrst of all correlate
well with the clinical state of the patient, with minimum
time delay and variation. To investigate this, we selected
the OAA/S score because it provides a good correlation
with a clinical reﬂection of the hypnotic component of
anesthesia and has been tested prospectively,27 although
it has its limitations, as we pointed out in a previous
article.28 Burst suppression represents a benign pattern
frequently seen in a healthy brain at deep levels of the
hypnotic component of anesthesia. It can be identiﬁed
in the raw electroencephalogram and is composed of
episodes of electrical quiescence (the “suppression”)
alternated with high-frequency, high-amplitude electri-
cal activity (the “bursts”). Increasing anesthetic drug
concentration causes increased duration of the suppres-
sion periods. Burst suppression patterns of the electro-
encephalogram are classically quantiﬁed as the percent-
age duration of suppression over a given time period.
Because the detection of burst suppression represents
an important electroencephalogram component to mea-
sure deep levels of anesthesia, its correlation to its uni-
variate parameter is important and must be investigated9
The current study demonstrated that both a continu-
ous (protocol 1) and a stepwise increase (protocol 2) in
Ce prop resulted in a monotonic decrease in the CSI.
These results are comparable with those of our previous
study,7,8 where it was shown that AAI and BIS decrease
during increased Ce prop. In protocol 1, CSI showed the
highest correlation to the effect site concentration of
propofol. The highest concentration of Ce prop was 14
g/ml which resulted in CSI values approximately from
10 to 20. The higher correlation might be because the
Fig. 5. Mean and 95% conﬁdence interval for Cerebral State
Index (CSI, A); Bispectral Index (BIS, B); and A-Line ARX Index
version 1.6, scaled to 60 (AAI60, C) versus the Observer’s Assess-
ment of Alertness and Sedation Scale (OAAS), according to pro-
tocol 2.
Table 3. Mann–Whitney U Test Results (P Values) for
Signiﬁcant Differences between the Values of the Three
Electronic Indices to Predict Adjacent OAA/S Levels from
Protocol 2
OAA/S BIS AAI60 CSI
5 vs. 4  0.05  0.05  0.05
4 vs. 3  0.05  0.05  0.05
3 vs. 2  0.05  0.05 0.101
2 vs. 1 0.186 0.209 0.257
1 vs. 0 0.530 0.956  0.05
All P values are two-tailed. P  0.05: signiﬁcant difference.
AAI60  A-Line ARX Index scaled to 60; BIS  Bispectral Index; CSI 
Cerebral State Index; OAA/S  Observer’s Assessment of Alertness and
Sedation.
Table 4. Prediction Probability (PK) for the Electronic Indices
to Predict OAA/S Levels from Protocol 2
PK for OAA/S Levels
BIS 0.93 (0.01)
AAI60 0.91 (0.01)
CSI 0.92 (0.01)
Results are shown as mean (SD) jackknife estimate.
AAI60  A-Line ARX Index scaled to 60; BIS  Bispectral Index; CSI 
Cerebral State Index; OAA/S  Observer’s Assessment of Alertness and
Sedation.
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CSI system was partially trained with propofol data, so
the pharmacologic relation is already installed in the
system. More research must be done to test the behavior
of the CSI when other drugs and drug combinations are
used. The behaviors of the two indices derived from the
spontaneous electroencephalogram, CSI and BIS, are
shown in ﬁgure 2 to be similar. In this study, a nearly
pure linear relation was found between CSI and BIS.
Although scientiﬁcally not that important, it is interest-
ing from a clinical point of view to have values in the
same range with different monitors when indicating
identical clinical hypnotic–anesthetic states. Although
the overall correlation between CSI and BIS is high,
individual variations were present, e.g., a CSI value of 35
simultaneously with a BIS of 70, or vice versa, a BIS value
of 30 while the CSI was 80. Those individual values are
difﬁcult to account for with the current study design;
however, it could be due to interference from electro-
myography in either device. In the awake state, there
was a high clustering of data with values of both CSI and
BIS above 90. It cannot be ruled out that the CSI has
some inﬂuence of facialis electromyography. This should
be explored in a study where neuromuscular blocking
agents are administered.
As said, the behavior of the index at levels of burst
suppression was studied. The linear regressions between
the indices and their burst suppression shows the high-
est linearity for CSI, also at low values of BS%, than the
corresponding linear regression between BIS and the
suppression ratio calculated by the BIS® monitor. The
relation between BIS and the suppression ratio seems to
be biphasic, as published previously,11 which in turn
may indicate a better detection of the onset of suppres-
sion by the CSI. The AAI60 has less correlation, but
monophasic, to the BS% because the BS% has less weight
in the AAI algorithm. As shown in ﬁgure 5 and table 3, a
decrease in the OAA/S score resulted in a monotonic
decrease in the three indices, CSI, BIS, and AAI60. A
difference between the ability to differentiate the adja-
cent levels of the OAA/S scale was signiﬁcant. As seen in
previous work,11 BIS and AAI revealed relevant informa-
tion until loss of consciousness but did not become
signiﬁcant at deeper levels of anesthesia because of the
wide variability among patients. The CSI was less signif-
icant at the intermediate levels 2 and 3 but was able to
distinguish the lowest levels of the OAA/S scale, indicat-
ing both loss of responsiveness to verbal and tactile
stimuli.
The PK is widely used to investigate the overall relative
performance of the different electroencephalogram-de-
rived indices to measure the hypnotic component of
anesthesia.24,25 Therefore, PK analysis was conducted on
the study data of protocol 2. Table 4 shows that the CSI
has a similar performance to BIS and AAI60 in terms of
predicting the clinical state of the patient assessed by the
OAA/S scale. Interestingly, the PK value for AAI60 (0.91),
hereby using the new composite index based on MLAEP
and electroencephalographic components, performed
somewhat better than the original solitary used fast ex-
tracting AEP index (AAI version 1.4, scaled from 0 to
100) as published in the original article7 using the same
data sets (PK  0.89).
In conclusion, this study shows that the CSI produces
a highly signiﬁcant correlation with the propofol effect
site concentration and has a high PK for the OAA/S.
Further studies are needed to validate the CSI to estab-
lish its reliability in clinical practice applying other types
of anesthetics and other patient groups.
References
1. Lloyd-Thomas AR, Cole PV, Prior PF: Quantitative EEG and brainstem
auditory evoked potentials: Comparison of isoﬂurane with halothane using the
cerebral function analysing monitor. Br J Anaesth 1990; 65:306–12
2. Thomsen CE, Prior PF: Quantitative EEG in assessment of anaesthetic depth:
Comparative study of methodology. Br J Anaesth 1996; 77:172–8
3. Flaishon R, Windsor A, Sigl J, Sebel PS: Recovery of consciousness after
thiopental or propofol: Bispectral index and isolated forearm technique. ANES-
THESIOLOGY 1997; 86:613–9
4. Sigl JC, Chamoun NG: An introduction to bispectral analysis for the elec-
troencephalogram. J Clin Monit 1994; 10:392–404
5. Rampil IJ: A primer for EEG signal processing in anesthesia. ANESTHESIOLOGY
1998; 89:980–1002
6. Thornton C, Konieczko KM, Knight AB, Kaul B, Jones JG, Dore CJ, White
DC: Effect of propofol on the auditory evoked response and oesophageal con-
tractility. Br J Anaesth 1989; 63:411–7
7. Struys MM, Jensen EW, Smith W, Smith NT, Rampil I, Dumortier FJ, Mestach
C, Mortier EP: Performance of the ARX-derived auditory evoked potential index
as an indicator of anesthetic depth: A comparison with Bispectral Index and
hemodynamic measures during propofol administration. ANESTHESIOLOGY 2002;
96:803–16
8. Struys MM, Vereecke H, Moerman A, Jensen EW, Verhaeghen D, De Neve
N, Dumortier FJ, Mortier EP: Ability of the Bispectral Index, autoregressive
modelling with exogenous input-derived auditory evoked potentials, and pre-
dicted propofol concentrations to measure patient responsiveness during anes-
thesia with propofol and remifentanil. ANESTHESIOLOGY 2003; 99:802–12
9. Vanluchene AL, Vereecke H, Thas O, Mortier EP, Shafer SL, Struys MM:
Spectral entropy as an electroencephalographic measure of anesthetic drug
effect: A comparison with Bispectral Index and processed midlatency auditory
evoked response. ANESTHESIOLOGY 2004; 101:34–42
10. Jensen EW, Lindholm P, Henneberg SW: Autoregressive modeling with
exogenous input of middle-latency auditory-evoked potentials to measure rapid
changes in depth of anesthesia. Methods Inf Med 1996; 35:256–60
11. Vereecke HEM, Vasquez PM, Jensen EW, Thas O, Vandenbroecke R,
Mortier EP, Struys MMRF: New composite index based on midlatency auditory
evoked potential and electroencephalographic parameters to optimize correla-
tion with propofol effect site concentration: Comparison with Bispectral Index
and solitary used fast extracting auditory evoked potential index. ANESTHESIOLOGY
2005; 103:500–7
12. Kreuer S, Bruhn J, Larsen R, Grundmann U, Shafer SL, Wilhelm W: Appli-
cation of Bispectral Index and Narcotrend index to the measurement of the
electroencephalographic effects of isoﬂurane with and without burst suppres-
sion. ANESTHESIOLOGY 2004; 101:847–54
13. Kreuer S, Bruhn J, Larsen R, Bauer C, Wilhelm W: Comparison of BIS and
AAI as measures of anaesthetic drug effect during desﬂurane-remifentanil anaes-
thesia. Acta Anaesthesiol Scand 2004; 48:1168–73
14. Grant P, Naesh O: Fuzzy logic and decision-making in anaesthetics. J R Soc
Med 2005; 98:7–9
15. Jensen EW, Nebot A, Caminal P, Henneberg SW: Identiﬁcation of causal
relations between haemodynamic variables, auditory evoked potentials and
isoﬂurane by means of fuzzy logic. Br J Anaesth 1999; 82:25–32
16. Jang JSR: ANFIS: Adaptive-Network-Based Fuzzy Inference System. IEEE
Trans Syst Man Cybernetics 1993; 23:665–85
17. Jensen EW, Nebot A: Comparison of FIR and ANFIS Methodologies for the
Prediction of Physiologic Parameters in Anaesthesiology. The European Congress on
Intelligent Techniques and Soft Computing (EUFIT) 1998; Proceedings, Vol 3, ELITE
Foundation, Aachen, Germany, ELITE Foundation, p 1889
18. Chernik DA, Gillings D, Laine H, Hendler J, Silver JM, Davidson AB,
Schwam EM, Siegel JL: Validity and reliability of the Observer’s Assessment of
Alertness/Sedation Scale: Study with intravenous midazolam. J Clin Psychophar-
macol 1990; 10:244–51
34 JENSEN ET AL.
Anesthesiology, V 105, No 1, Jul 2006
149
19. Schnider TW, Minto CF, Shafer SL, Gambus PL, Andresen C, Goodale DB,
Youngs EJ: The inﬂuence of age on propofol pharmacodynamics. ANESTHESIOLOGY
1999; 90:1502–16
20. Schnider TW, Minto CF, Gambus PL, Andresen C, Goodale DB, Shafer SL,
Youngs EJ: The inﬂuence of method of administration and covariates on the
pharmacokinetics of propofol in adult volunteers. ANESTHESIOLOGY 1998;
88:1170–82
21. Minto CF, Schnider TW, Gregg KM, Henthorn TK, Shafer SL: Using the
time of maximum effect site concentration to combine pharmacokinetics and
pharmacodynamics. ANESTHESIOLOGY 2003; 99:324–33
22. Struys MM, De Smet T, Depoorter B, Versichelen LF, Mortier EP, Dumor-
tier FJ, Shafer SL, Rolly G: Comparison of plasma compartment versus two
methods for effect compartment–controlled target-controlled infusion for propo-
fol. ANESTHESIOLOGY 2000; 92:399–406
23. Kreuer S, Wilhelm W, Bruhn J: The inﬂuence of the click stimulus of the
Alaris AEP monitor on the depth of anesthesia (letter). Anesth Analg 2003; 97:604
24. Smith WD, Dutton RC, Smith NT: A measure of association for assessing
prediction accuracy that is a generalization of non-parametric ROC area. Stat Med
1996; 15:1199–215
25. Smith WD, Dutton RC, Smith NT: Measuring the performance of anes-
thetic depth indicators. ANESTHESIOLOGY 1996; 84:38–51
26. Vanluchene AL, Struys MM, Heyse BE, Mortier EP: Spectral entropy mea-
surement of patient responsiveness during propofol and remifentanil: A compar-
ison with the bispectral index. Br J Anaesth 2004; 93:645–54
27. Glass PS, Bloom M, Kearse L, Rosow C, Sebel P, Manberg P: Bispectral
analysis measures sedation and memory effects of propofol, midazolam, isoﬂu-
rane, and alfentanil in healthy volunteers. ANESTHESIOLOGY 1997; 86:836–47
28. Jensen EW, Litvan H, Struys M, Martinez Vazquez P: Pitfalls and challenges
when assessing the depth of hypnosis during general anaesthesia by clinical signs
and electronic indices. Acta Anaesthesiol Scand 2004; 48:1260–7
Appendix
The CSI
The objective of the Cerebral State Index (CSI) is to monitor the
level of consciousness during general anesthesia. The CSI is a unitless
scale from 0 to 100, where 0 indicates a ﬂat electroencephalographic
signal and 100 indicates the awake state. The range of adequate
anesthesia is designed as the 40–60 range (table A1).
The CSI requires three electrodes positioned at the middle forehead,
left forehead, and left mastoid. Alternatively, the right forehead and
right mastoid can be used.
Methods of the CSI
The CSI is calculated based on four subparameters of the electroen-
cephalogram:  ratio,  ratio,  ratio   ratio, and burst suppression,
deﬁning an index from 0 to 100. The novelty of the CSI is that a fuzzy
inference system was used to deﬁne the index.
The particular method used was the Adaptive Neuro Fuzzy Inference
System (ANFIS). The ANFIS was trained with prerecorded electroen-
cephalographic data, where 20 were from propofol and remifentanil
anesthesia, 15 were from propofol infusion until 80% of burst suppres-
sion occurred, and 15 were from sevoﬂurane anesthesia, giving a total
of 50 patients. The total number of training points was more than
200,000, sufﬁcient to achieve convergence for the 104 parameters in
the 4 input 2 membership ANFIS model. All data were recorded at Gent
University Hospital (Ghent, Belgium).
During burst suppression, the  and  ratios are no longer monot-
onously decreasing as a function of anesthetic depth, and therefore,
they cannot be used in the calculation of the ﬁnal index. Figure A1
shows the power spectrum of the electroencephalographic signal with
the bands of the  ratio marked.
The four subparameters were deﬁned as follows:
ratio log
E3042.5Hz
E1121Hz
ratio log
E3042.5Hz
E612Hz
()ratio log
E612Hz
E1121Hz
Burst suppression (BS%): deﬁned as the percentage of time in a 30-s
window where the amplitude of the electroencephalographic signal
was less than 3.5 V.
ANFIS Model Structure. Each of the three energy ratios corre-
lates individually to the depth of anesthesia. This has been shown in
numerous publications. However, by combining the parameters, a
higher correlation coefﬁcient can be reached. An intuitive explana-
tion to this fact is that the ANFIS system, shown in ﬁgure A2,
automatically uses the best parameter, meaning that when one fails,
another might still be a good correlate. The burst suppression
parameter indicates deep anesthesia; in this case, the weight on the
spectral parameters will be less because they are not good corre-
lates during deep anesthesia with burst suppression due to the
nonstationary nature of the electroencephalogram in this situation.
The structure of the ANFIS systems ensures that each linguistic term
is represented by only one fuzzy set. The parameters of the ANFIS
model were determined by training using 50 patients anesthetized
with propofol, remifentanil, and inhalational agents. The total up-
date delay of the index is approximately 15 s.
Table A1. Deﬁnition of CSI Range
CSI Clinical State
90–100 Awake
80–90 Drowsy
60–80 Light anesthesia or sedation
40–60 Range considered as adequate for surgical anesthesia
10–40 Deep anesthesia, in most cases accompanied by burst
suppression
0–10 The BS% is larger than 75. When CSI is below 3, the
electroencephalograph is practically isoelectric.
BS%  burst suppression ratio; CSI  Cerebral State Index.
Fig. A1. Power spectrum of the electroencephalographic signal
(EEG) showing the bands used for the calculation of the  ratio.
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Fig. A2. The Adaptive Neuro Fuzzy
Inference System (ANFIS) structure.
CSI  Cerebral State Index;
inputmf  input membership func-
tion; outputmf  output member-
ship function.
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Chapter 4 Final discussion and future perspectives 
When Thornton et al, in 1983, first described the dose dependent changes in the auditory 
evoked potentials (AEP), or more specifically, in the mid-latency auditory evoked potentials 
(MLAEP), she suggested this phenomenon could be a useful tool for quantifying the cerebral 
effects of hypnotic drugs.(1-4) It took more than 20 years to overcome the major drawbacks 
and reach this goal. 
At first, multiple methods were developed to improve the extraction speed of MLAEP from the 
raw electroencephalogram. Various mathematical approaches were applied to the raw 
MLAEP wave in order to reduce observers bias and convert the complex and rapid changes 
of MLAEP waves into one single number.(5-11) This single number is much easier to 
interpret  by an anesthesiologist without specific theoretical background on MLAEP behavior. 
If the number goes down, the patient is more asleep, and vice versa.  
   
This thesis is the result of intense collaboration between engineers, developing both hard- 
and software, and anesthesiologists, with an interest in clinical pharmacology and 
neurophysiology. This cooperation started with the original study of Erik Weber Jensen, who 
worked at the Polytechnic University of Catalonia, Centre of Research in Biomedical 
Engineering, Barcelona, Spain. He applied an autoregressive model with exogenous input 
(ARX) on raw MLAEP, to allow a faster detection of changes in MLAEP.(12,13) It allowed 
extraction of MLAEP derived information with a delay of only 6 seconds. No former MLAEP 
derived index or spontaneous electroencephalographic derived index could respond this fast 
to changes in cerebral hypnotic drug effect. Therefore, the new index was a promising tool 
for anesthesia applications. 
At first this technology was only tested on rats. However, for human applications, more 
severe regulations on hardware quality and safety need to be fulfilled, as dictated by 
European regulation authorities. The development of such a device is expensive and 
demands special expertise, which could be provided by the medical industry only. Danmeter, 
located in Odense, Denmark, agreed to support the development of such a hardware device, 
called A-Line®, and aimed to commercialize the technology, after human validation. During 
this validation and optimization process, different names were given to both the monitor, and 
the MLAEP derived A-Line ARX index (AAI). At first, Alaris® (now incorporated in the 
“Cardinal Health” industrial group) was the global distributor of the A-Line® monitor, while 
Danmeter only focused on production. At that time the name of the monitor was: “Alaris® A-
Line Monitor” or “Alaris® AEP monitor”. Since the implementation of the AAI version 1.6, the 
monitor is called “AEP monitor/2”, and is now (again) distributed by Danmeter. AAI has been 
used in many studies as an abbreviation of both “A-Line® ARX Index” and “A-Line® Auditory 
Evoked Potential Index”. The algorithms of the consecutive versions AAI1.5 and AAI1.6, are 
completely different. Their behavior as a measure for cerebral drug effect is incomparable. 
Confusingly, the basic name of both versions remained “AAI”. All these changes happened 
over a 6 years period. This might induce confusion for anesthesiologists with less expertise in 
the subject. Nowadays, the AEP monitor/2 becomes more widespread. Therefore, a 
consensus on the exact name will be increasingly important. 
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As an independent partner of the consortium, the department of anesthesia of the University 
of AAI. At the start, no consensus was available on the minimal quality levels that should be 
met by a depth-of-anesthesia monitor to guarantee safety in the general population. This lack 
of regulations has led to an explosive growth of new indices, based on several 
neurophysiologic principles. They all claim to have sufficiently adequate correlation with the 
hypnotic component of anesthesia. However, the “validation processes” of these devices are 
very diverse and often not comparable. Therefore, we aimed to construct a systematic 
methodology, for validating and comparing different indices of the hypnotic component of 
anesthesia, independent of their neurophysiologic background. This methodology had to be 
sufficiently reproducible, in order to allow other researchers to compare future indices in the 
same way. 
Our strategy includes several steps: 
1) The AAI must be able to discriminate several clinical endpoints of anesthesia 
that are routinely used in anesthesia practice. The sensitivity for this measurement 
must be maintained, both in mono-anesthetic conditions, as during combined 
effects of hypnotics and analgesics. This validation step was the target of our first 
study. 
2) As neurophysiologic measures are also indicated as pharmacodynamic endpoints 
of cerebral drug effect, new indices of the hypnotic component of anesthesia, 
should have a close correlation with the effect-site concentrations of anesthetic 
hypnotic drugs. As the detection of clinical endpoints of anesthesia is susceptible 
to observers bias, the pharmacological validation allows a more objective 
comparison of different monitors of cerebral hypnotic drug effect. This step in the 
validation process was the target of our second publication. 
3) The effects of difficult molecules, such as ketamine, nitrous oxide and xenon, 
should be explored. The classic hypnotic drugs use a molecular mechanism based 
on the gamma-amino butyric acid (GABA) receptor action. However, some 
molecules evoke clinical anesthetic effects by means of an alternative pathway. 
For these molecules, the N-Methyl-D-Aspartate (NMDA) receptor appears to be a 
key player in the effectuation of anesthesia. In our research group, we chose to 
test the effects of ketamine, a clinically relevant NMDA inhibitor, on the first 
version of AAI and bispectral index. The results are found in our fourth publication. 
We found that no EEG or MLAEP derived index is able to detect the potentiating 
interaction between propofol and ketamine adequately.  
4) The potential mechanical or physiologic interferences must be depicted as 
thoroughly as possible. Many of these problems only arise once a monitor is 
implemented in clinical practice. It was already published in the scientific literature, 
that electromyographic (EMG) interference is a general problem for all EEG and 
by vecuronium, a neuro-muscular blocking agent. This study strongly suggests 
Hospital Ghent, has become involved in the clinical validation process for human applications 
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MLAEP derived measurements. For AAI, Ge et al. confirmed that AAI was reduced 
that EMG interferences determines part of the AAI calculation. We obtained much 
information on the interference of EMG on AAI in our fifth study.(14)  
With these steps, we present a reproducible strategy to compare the behavior of EEG and 
MLAEP derived indices during total intravenous anesthesia. Our methodology has received a 
very positive response at international congresses. Recently, other research centers 
published comparable validation protocols.(15,16) As our protocols have been designed in 
cooperation, and with extensive feedback from international partners, both from the 
academic  and the industrial world, we feel to have made a substantial contribution to the 
construction of an objective benchmark for monitors of the hypnotic component of 
anesthesia. 
Prior to the start of the consortium, its participants agreed to implement a gentleman’s 
agreement. All costs for the studies were covered by institutional funding. Danmeter 
delivered the necessary hardware for AEP monitoring. The results of the studies were 
reported to Danmeter before the date of publication, in order for them to allow adaptations in 
marketing strategy, or to develop improvements on the technology. On the other hand, the 
rights of publishing the results and the ownership of the data remained with the independent 
researcher. In order to avoid conflicts of interest, the company that has a commercial interest 
in the device could not interfere with the format or the content of the publication. 
During the first validation session, we observed some drawbacks for AAI, in comparison with 
other EEG derived indices. Our results suggest that MLAEP derived information depicts a 
rather “limited” range of hypnotic drug effect compared to EEG derived indices. The 
consortium generated several suggestions that could help to improve the performance of the 
ARX technology. Some of these suggestions were addressed by the manufacturer, and 
implemented in a new monitor, called the AEP monitor/2. This new device contains both 
hard- and software improvements. 
The most apparent adaptation in the AEP monitor/2 was the use of a new algorithm for AAI 
calculation, called AAI version1.6 (AAI1.6). The source of information on cerebral drug effect 
was expanded from solitary MLAEP to a composite index that combines both MLAEP and 
EEG derived information.  This drastic change was also supported by additional findings of 
other authors. It has been stated in literature that MLAEP derived indices appear to correlate 
better with loss and return of consciousness, rather than with the effect-site concentration of 
a hypnotic drug.(17-20) Although these statements are not fully confirmed yet, it suggests 
that combining information from MLAEP and EEG might result in a high performance index 
that combines the best of both worlds.  
At deep levels of anesthesia, MLAEP is reduced to a flat line that does not contain 
information anymore. By including EEG in the AAI calculation, the lack of descriptive capacity 
at deep levels of anesthesia might be resolved. In our third study we used the same 
validation method as described for the first validation to compare the old version of AAI 
(AAI1.5) with the new version (AAI1.6) and with bispectral index (BIS). This study revealed a 
marked improvement of the descriptive capacity of AAI at deep levels of anesthesia. By 
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reducing the upper scale limit from 100 to 60, the baseline variability was also reduced 
drastically. However, in the awake patients BIS remained the more constant parameter. Due 
to the proven improvements in the new system, it was decided to continue the validation 
process with the new index AAI1.6.
In our fifth trial we combined ketamine and rocuronium to explore the interacting effect of 
both molecules on AAI1.6. Apart from the main investigation question, whether the effect of 
ketamine on EEG registration was partially mediated by EMG interference, we 
simultaneously could explore the effects of solitary administered rocuronium and the effects 
of solitary ketamine on the AAI1.6. The results of this study indicate that the new version of 
AAI has not resolved the problem for measuring the effects of NMDA dependent hypnotic 
drug effects. Moreover, the effects of rocuronium suggest a persistent interfering effect of 
EMG, but this interference was comparable to the EEG derived indices.  
After our experimental validation process, the question whether MLAEP is able to extract 
different information on cerebral hypnotic drug effect compared to EEG is not yet answered. 
However, the performance of the AAI1.6 has reached a comparably high performance level as 
found for BIS and Spectral Entropy. Still, many pharmacologic and physiologic factors 
determine the behavior of the measurement of raw EEG and MLAEP. Some of the potential 
causes for unexpected behavior have been studied in this thesis. The main message to the 
clinical anesthesiologist remains to be vigilant when using a monitor for the hypnotic 
component of anesthesia. One must always be aware that unexpected values of an EEG or 
MLAEP derived index do not always mean “unexpected changes in drug effect”. Therefore, 
the interpretation of EEG and MLAEP derived parameters must always be correlated to the 
patients’ condition at the time of measurement. 
Meanwhile, additional clinical validation and outcome studies remain mandatory in order to 
decide whether measuring the hypnotic component of anesthesia is worth the effort. In this 
view, for AAI, several important questions are yet to be answered.  
1) The AAI must be sensitive for all commonly used anesthetics. In our validation 
process, we only focused on intravenous anesthesia with propofol, or the 
combination of propofol and remifentanil. Eventually, it will be mandatory to 
develop a comparable strategy for the effects of inhalation anesthesia. However, 
some practical problems of inhalation anesthesia might limit the methodological 
possibilities. It appears problematic to evoke a gradual transition from “fully awake” 
to “deep sedation”, by means of inhalation anesthetics. Not all inhalation 
anesthetics are advised for mask induction, due to irritating bronchial effects. 
Moreover, we have to cope with the safety issue concerning excitatory symptoms 
in the patients, at light levels of anesthesia. Additionally, it is not easy to evoke 
excessive burstsuppression levels using inhalation anesthetics alone, without 
important hemodynamic or respiratory side effects. Therefore, we will never be 
able to evaluate such a wide range of hypnotic drug effects in one pharmacological 
validation study. The validation of effects of inhalational hypnotics on EEG and 
MLAEP derived indices will need a different approach compared to the validation 
process described in this thesis. 
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2) Once AAI is validated in a controlled scientific setting, the performance in clinical 
anesthesia conditions must be confirmed. The clinical practice of anesthesia has 
much more confounding variables compared to a scientific setting. A scientific 
experiment aims to limit the “unknown” covariates that might interfere with the 
measurement. Therefore, it is not guaranteed that a device will have a comparable 
efficacy in clinical practice compared to the results in a controlled scientific 
experiment. 
3) Although a measurement might have a high performance in the above test phase, 
eventually, it must be studied whether the new technology improves the outcome
of the patient. During this validation, it should be determined whether the use of 
AAI improves quality of anesthesia or if it decreases recovery times. Is it possible 
to avoid awareness by using AAI? To answer such questions, large numbers of 
patients are needed. Therefore, it is often necessary to perform this validation in 
multicentre trials. 
4) Every measurement costs money to the patient and to society. Therefore the costs 
must be balanced to the gains. In my personal opinion, outcome and macro-
economic cost-effectiveness studies for AAI must be considered in a broader 
context. Do we improve the outcome by quantifying the hypnotic component of 
anesthesia? How much do we want to pay for that improvement? Until today, this 
remains a topic of debate and further study, both for EEG as well as MLAEP 
derived indices. 
Why use the AAI today? The value of using any monitor of hypnotic drug effect results 
probably from the additional vigilance provided to the anesthesiologist. Although “false 
positive” and “false negative” measurements can occur, an alarm will prompt the 
anesthesiologist to check all parameters of the patient. This additional check might just make 
the difference between “awareness” or “no awareness”. Perhaps this mechanism partially 
explains the large decrease of awareness in a high risk population monitored by BIS.(21) 
Both EEG and MLAEP derived indices are prone for measurement errors, but apparently, 
this does not exclude a spectacular result on the clinical endpoint of “awareness”. Therefore, 
it remains interesting to proceed with the research on outcome. 
At an academic level, the search for new indications for AAI in anesthesia has already 
began. Bonhomme et al have studied the potential use of AAI, as a quantification of 
“nociception”, in addition to a BIS guided anesthesia.(22) Although our studies indicate a low 
accuracy for predicting response to a painful stimulus, we did not investigate the magnitude 
in change of AAI at the onset of a sustained painful stimulus (such as surgery). Bonhomme 
states that this might contain additional information on the degree of nociception versus 
antinociception. Much work still needs to be done in order to confirm this theory. 
Why not using the A-Line® machine today? The AAI technology has reached a high level of 
performance. But some practical issues might hamper commercial success. The use of a 
headphone disrupts the verbal communication between the patient and the anesthesiologist 
at the time of anesthesia induction. Although the time of personal contact in anesthesia 
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practice is often limited, many anesthesiologists indicate that this is an important drawback. 
Indeed, during the induction most patients have a certain degree of fear. It can be very 
therapeutic, if the anesthesiologist verbally reassures his patient. A potential solution for this 
problem is the use of bone conduction to transduce the acoustic stimulus towards the nervus 
acousticus. In that way the headphones might become unnecessary. This technology 
deserves further exploration. 
The application of loud acoustic stimuli for a long duration might appear harmful. Although 
this is not yet a proven fact, MLAEP derived indices should be used with caution during long 
procedures, or for monitoring sedation at the intensive care. 
Until now the A-line® is only available as a “stand-alone” machine. This might be unpractical 
for ergonomics in the operation theatre. A module version that can be combined with the 
other monitoring parameters might decrease the resistance for using a monitor for the 
hypnotic component of anesthesia. 
For now, the cost of any monitor of the hypnotic component of anesthesia remains high. This 
is an important limitation for more general use of these devices, as many hospitals question 
the cost-benefit ratio. 
These practical issues have been discussed within the consortium, after a thorough 
evaluation of our study results. As a response, Danmeter has chosen to abandon the MLAEP 
as a source of information, and developed a new EEG based index, called the cerebral state 
index (CSI). It was developed, using raw EEG data that was gathered during our A-Line®
validation process. Therefore, it must be measured by using the same electrode positions as 
the AAI. Moreover, the manufacturer chose to make this device as small as possible 
(handheld device) to cope with ergonomics. The price is also much lower compared to BIS 
and Spectral Entropy, thus better coping with the economical issues.  
In view of this (commercially driven) decision of Danmeter, one could wonder if there is any 
future in MLAEP? I think there is. On an academic level, the CSI opens additional 
perspectives for exploring the additional value of MLAEP versus EEG. As CSI (a cortically 
derived index) can be extracted post hoc from the raw AEP monitor/2 registrations (including 
subcortical MLAEP), researchers now have a strong tool for quantifying both cortical and 
subcortical responses in a time and location synchronized way. In order to optimize the 
output of a solitary MLAEP derived index, we had to combine both cortical (EEG + 
burstsuppression) and subcortical (MLAEP) derived information. However, it can not be 
excluded that both entities enclose a different kind of information on the patients’ anesthetic 
state. One important difference of maintaining MLAEP as a monitor of cerebral hypnotic drug 
effect could be the faster response time for detecting changes in the clinical condition of the 
patient? Moreover, if the “nociception” theory of Bonhomme et al appears feasible, one might 
wonder if we could combine both cortical and subcortical derived information into a single 
monitoring device, correlating respectively to the “hypnotic” level of anesthesia (the cortical 
component), as well as the “analgesic” component of anesthesia (the subcortical 
component). Probably, these fundamental questions can only be fully explored, once the 
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correlation between the respective neurophysiological measurements and the clinical 
phenomenon of consciousness are better understood (e.g. with neuro-imaging techniques?).   
This future perspective depends on many unknown factors. But every technological 
achievement of today at one point started as a sci-fi idea. For now, we can only keep on 
measuring, and finish what we started in the first place. Isn’t that the secret to all success? 
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Summary 
The exact physiologic and anatomical mechanism of “consciousness” is yet insufficiently 
understood. However, in anesthesia, empirical methods were able to optimize many 
techniques for interfering with “consciousness”. One goal of an adequate anesthesia is to 
maintain a sufficient level of hypnotic drug effect. In order to avoid insufficient or excessive 
drug administration, indirect or “surrogate” measures of the hypnotic component of 
anesthesia have been developed, based on alterations in spontaneous 
electroencephalogram (EEG) or mid-latency auditory evoked potentials (MLAEP).  
The MLAEP are elicited by headphones, producing repetitive auditory stimuli. The electrical 
activity evoked by these stimuli can be measured by means of three electrodes on the 
patients forehead. This thesis investigates the performance of a new fast extracting MLAEP 
technology (called ARX) to monitor the hypnotic component of anesthesia. The fast 
extraction time is a major advantage for monitoring sudden changes in pharmacological 
condition during anesthesia. A commercialized index, using ARX technology, is called the 
A-Line® auditory evoked potential index (AAI). The AAI is a single numerical quantification 
of the changes in the main components of MLAEP with a minimal processing delay of 6 
seconds. 
This thesis includes a search for reproducible ways to compare EEG or MLAEP derived 
indices of hypnotic drug effect. In two separate trials, we compared the ability of AAI to 
detect both clinical and pharmacological endpoints of cerebral hypnotic drug effect, with 
other surrogate measures of hypnotic drug effect. Secondly, we evaluated the ability of AAI 
to detect “difficult molecules” such as ketamine, that has a specific effect on EEG. The 
result of this first validation phase, showed serious drawbacks for AAI at baseline and at 
very deep levels of anesthesia. Therefore, we participated in the development of a new 
algorithm for AAI, combining both EEG and MLAEP derived information in a composite 
index (AAI1.6). 
 
The AAI1.6 was evaluated in a second validation process, which showed a major 
improvement in comparison with the old version of AAI (version 1.5), based on solitary 
MLAEP. The effects of difficult molecules on AAI1.6 was reevaluated, in a trial combining 
ketamine, with a neuromuscular blocking agent (rocuronium). 
 
Although the use of MLAEP for clinical anesthesia goals is optimized significantly, practical 
issues remain, such as the need for a normal hearing threshold. Therefore, commercial 
success might be limited. A new EEG derived index, called the cerebral state index (CSI), 
is developed using raw EEG datasets from our AAI validation studies. We validated CSI, 
both on clinical and pharmacological level, as it might be a helpful tool for exploring the 
additional value of evoked potentials versus spontaneous EEG. 
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Samenvatting 
De exacte fysiologische en anatomische achtergrond van “bewustzijn” is onvoldoende 
gekend. Nochtans zijn op empirische basis meerdere anesthesie technieken ontwikkeld, 
die gericht inwerken op “bewustzijn”. Een belangrijk doel van anesthesie, is het 
onderhouden van een adequaat niveau van hypnotisch effect. Om insufficiënte of 
excessieve hypnotische effecten te vermijden, zijn indirecte of “surrogaat” metingen van de 
hypnotische component van anesthesie ontwikkeld, gebaseerd op veranderingen in het 
spontane elektro-encefalogram (EEG) en de mid-latente akoestisch uitgelokte 
hersenpotentialen (MLAEP). 
  
De MLAEP worden uitgelokt door het toedienen van repetitieve akoestische stimuli via een 
hoofdtelefoon. De daardoor verwekte elektrische hersenpotentialen, kunnen gemeten 
worden via drie elektroden op het hoofd van de patiënt. Wij onderzochten de prestaties van 
een nieuwe techniek voor snelle MLAEP extractie (ARX genaamd), om de hypnotische 
component van anesthesie te meten. De korte berekeningstijd is een groot voordeel in snel 
veranderende farmacologische condities zoals anesthesie. Een gecommercialiseerde 
index, gebruik makend van ARX, is beschikbaar onder de naam, “A-Line® auditory evoked 
potential Index” (AAI). AAI is een numerieke vereenvoudiging van de veranderingen in de 
componenten van MLAEP, met een berekeningsvertraging van slechts 6 seconden. 
 
Deze thesis omvat een zoektocht naar reproduceerbare vergelijkingsmethodes, om EEG 
en MLAEP afgeleide monitors aan elkaar te toetsen. In twee studies vergeleken we AAI 
met andere metingen van hypnotisch effect, in hun capaciteit om zowel klinische, als 
farmacologische eindpunten van anesthesie te detecteren. Vervolgens bestudeerden we 
de effecten van “moeilijke molecules”, zoals ketamine, op AAI. Ketamine heeft een gekend 
verstorend effect op EEG. Deze validatie onthulde enige zwakheden voor AAI. De meting 
van wakkere patiënten was te variabel en de meting van diepe anesthesie was ongevoelig. 
Daarom participeerden wij in de ontwikkeling van een nieuw algoritme voor AAI, waarbij 
EEG en MLAEP afgeleide informatie verenigd werden in een “samengestelde” index AAI1.6.  
 
De AAI1.6 onderging een tweede validatie, welke een duidelijke verbetering toonde ten 
opzichte van de oudere AAI (versie 1.5). Het effect van moeilijke molecules werd 
geëvalueerd voor AAI1.6 in een studie, waar spierverslappers met ketamine gecombineerd 
werden.  
 
Hoewel de toepasbaarheid van MLAEP in de klinische praktijk is verbeterd, blijven 
praktische hinderpalen een commercieel succes in de weg staan. De EEG datasets uit 
onze AAI validatie, werden daarom gebruikt ter ontwikkeling van de Cerebral State Index 
(CSI), een nieuwe EEG afgeleide index. CSI werd zowel klinisch als farmacologisch 
gevalideerd. Het gebruik van CSI kan een nuttig werktuig worden om de additionele 
waarde van MLAEP versus spontaan EEG in anesthesie omstandigheden verder te 
exploreren. 
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List of Abbreviations 
 
AAI A-Line ® auditory evoked potentials index 
AAI1.5 A-Line ® auditory evoked potentials index, version 1.5 
AAI1.6 A-Line ® auditory evoked potentials index, version 1.6 
AEP Auditory evoked potentials 
AEPex Auditory evoked potential index 
ARX Autoregressive Model With Exogenous Input 
ASSR Auditory Steady State Response 
AUC Area under the curve 
BAEP Brainstem Auditory Evoked Potentials 
BIS Bispectral Index 
CePROP Effect-site concentration of propofol 
CeREMI Effect-site concentration of remifentanil 
CI Confidence interval 
CMRR Common Mode Rejection Ratio 
CpPROP Plasmaconcentration of propofol 
CpREMI Plasmaconcentration of remifentanil 
CSI Cerebral State Index 
CUN Canonical Univariate  
ED50 Effective dose to obtain drug effect in 50% of the population 
ED95 Effective dose to obtain drug effect in 95% of the population 
EEG Electroencephalogram 
Emax Model of drug effect that describes a sigmoidal relationship between concentration 
and effect with a maximum limit  
EMG Electromyogram 
f Frequency 
FFT Fast Fourier Analysis 
Hz Hertz 
ke0 Equilibration constant reflecting the elimination speed of a drug out of the effect-site 
LLAEP Long-latency auditory evoked potentials 
LOE Loss of eyelash reflex 
LORNOXIOUS Loss of response to noxious stimulus 
LORVERBAL Loss of response to a verbal command 
LORLash Loss of response to eyelash reflex 
LORN Loss of response to noxious stimulus 
MAC Minimal Alveolar Concentration 
MF Median Frequency 
MLAEP Mid-latency auditory evoked potentials 
MTA Moving Time Average 
MTA15 Moving Time Average, extracted from 15 sweeps 
MTA256 Moving Time Average, extracted from 256 sweeps 
N20 Nitrous Oxide (Laughing Gas) 
NMBA Neuro Muscular Blocking Agent 
NMDA N-Methyl D-Aspartate 
NONMEM Non Linear Mixed Effects Modeling 
OAA/S Observers Assesment of Alertness and Sedation Scale  
P Probability 
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PD Pharmacodynamics 
Pk Prediction Probability  
PK Pharmacokinetics 
pKa Ionization Constant (kinetics, chemistry) 
PKPD Pharmacokinetic-pharmacodynamic 
ș Phase 
RE Response Entropy 
SD Standard deviation 
SE State Entropy 
SEF95% Spectral edge frequency 95% 
SNR Signal-to-noise ratio 
SR Suppression Ratio 
SSEP Somato-sensory evoked potential 
TCI Target controlled infusion 
VEP Visual evoked potential 
WT Wavelet transformation 
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